

## SEARCH REQUEST FORM

Scientific and Technical Information Center

Requester's Full Name: Sabiha Qazi Examiner # 74141 Date: 12/1/05  
 Art Unit: 1616 Phone Number 28622 Serial Number 09/913,403  
 Mail Box and Bldg/Room Location: \_\_\_\_\_ Results Format Preferred (circle): PAPER DISK E-MAIL

4C70, Rev. 4A45  
 if more than one search is submitted, please prioritize searches in order of need.

\*\*\*\*\*  
 Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc., if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of invention: Epoxy-steroidal  
 Inventors (please provide full names): J. C. Alexander et al.

Earliest Priority Filing Date: 7/27/00

\*For Sequence Searches Only\* Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number. Elected → eplerenone + metoprolol combination

Please search for the combination of eplerenone and Beta adrenergic antagonist as in cl 1.  
 pharmaceutical composition and method of treating Cardiovascular disorder by said combination

- ① Cls 48 - 51, <sup>63+64</sup> → method of treating  
 ② Composition → Cls 53 - 61 + 42  
 ③ Combination → Cls 1, 9 - 20

Please see attached sheets  
 Thank you

## STAFF USE ONLY

	Type of Search	Vendors and cost where applicable
Searcher: <u>an</u>	NA Sequence (#) _____	STN <u>✓</u>
Searcher Phone: <u>22504</u>	AA Sequence (#) _____	Dialog _____
Searcher Location _____	Structure (#) _____	Questel/Orbit _____
Date Searcher Picked Up <u>1/17/05</u>	Bibliographic <u>✓</u>	Dr Link _____
Date Completed <u>1/17/05</u>	Language _____	Lexis/Novis _____
Searcher Prep & Review Time _____	Fulltext _____	Sequence Systems _____
Searcher Prep Time <u>20</u>	Patent Family _____	WWW/Internet _____
Search Time <u>165</u>	Other _____	Other (specify) _____

H/entx see 10/343,166

=> d his

(FILE 'HOME' ENTERED AT 07:29:42 ON 19 JAN 2005)  
SET COST OFF

FILE 'REGISTRY' ENTERED AT 07:29:51 ON 19 JAN 2005

L1 1 S EPLERENONE/CN  
L2 62 S 107724-20-9/CRN  
L3 26 S L2 AND MXS/CI  
L4 26 S L2 AND MIX?  
L5 26 S L3,L4  
L6 36 S L2 NOT L5  
L7 1 S 51384-51-1  
L8 33 S 51384-51-1/CRN  
L9 14 S L8 AND (MXS/CI OR MIX?)  
L10 19 S L8 NOT L9  
E C15H25NO3/MF  
L11 10 S E3 AND 46.150.18/RID AND 1/NR AND 2 PROPANOL AND 4 2 METHOXYE  
L12 4 S L11 AND METHYLETHYL  
L13 3 S L12 NOT 11C  
SEL RN  
L14 47 S E1-E3/CRN  
L15 14 S L14 NOT L8  
L16 1 S L15 AND (MXS/CI OR MIX?)  
L17 13 S L15 NOT L16  
L18 11 S L17 NOT C20H18O8  
L19 30 S L18,L10  
L20 17 S L8,L14 NOT L19  
L21 21 S 29122-68-7 OR 66722-44-9 OR 36894-69-6 OR 37517-30-9 OR 62658  
SEL RN  
L22 376 S E4-24/CRN  
L23 153 S L22 AND (MXS/CI OR MIX?)  
L24 223 S L22 NOT L23  
L25 83 S L24 NOT SALT  
L26 79 S L25 NOT PMS/CI  
L27 140 S L24 NOT L25  
L28 219 S L26,L27  
L29 157 S L22 NOT L28  
L30 0 S L6 AND L14  
L31 0 S L6 AND L22  
L32 5 S C24H30O6/MF AND OC2-OC4-C5-C6-C6-C6/ES  
SEL RN 1 3  
L33 2 S E25-E26  
L34 0 S E25-E26/CRN  
L35 3 S L1,L33

FILE 'HCAPLUS' ENTERED AT 07:58:57 ON 19 JAN 2005

L36 173 S L35  
L37 196 S EPLERENONE  
L38 19 S CGP30083 OR CGP() (30083 OR 30 083) OR EPOXYMEXRENONE  
L39 8 S L6  
L40 1 S L5  
L41 213 S L36-L40  
L42 2799 S L13  
L43 3747 S METOPROLOL  
L44 5 S BEATROLOL OR MEIJOPROLOL OR METOHEXAL OR SEROKEN OR SPESICOR  
L45 18326 S L21  
L46 605 S L19  
L47 16 S L20  
L48 20312 S L42-L47  
L49 18326 S L21  
L50 4320 S L28  
L51 93 S L29

L52 15065 S ACEBUTOLOL OR ATENOLOL OR BISOPROLOL OR BOPINDOLOL OR BUCINDO  
L53 26224 S L49-L52  
L54 2038 S BETA ADRENERGIC ANTAGONIST  
E ADRENOCEPTOR/CT  
L55 3381 S E17-E20  
L56 137 S E32-E35 (L) ANTAGONIST  
L57 15 S L41 AND L48  
L58 14 S L41 AND L53  
L59 17 S L41 AND L54-L56  
L60 24 S L57-L59  
L61 6 S L60 AND (PD<=20010727 OR PRD<=20010727 OR AD<=20010727)  
L62 7 S L60 AND PHARMACIA?/PA,CS  
L63 1 S L60 AND (ALEXANDER ? OR SCHUH ?)/AU  
L64 12 S L61-L63  
L65 6 S L61 AND L64

FILE 'REGISTRY' ENTERED AT 08:13:26 ON 19 JAN 2005

L66 1 S 30236-31-8  
L67 1 S "(S)-SOTALOL"/CN

FILE 'HCAPLUS' ENTERED AT 08:14:33 ON 19 JAN 2005

L68 242 S L66,L67  
L69 27097 S PROPRANOLOL  
L70 39578 S L53,L68,L69  
L71 14 S L41 AND L70  
L72 0 S L71 NOT L60  
L73 24 S L60,L71  
L74 6 S L73 AND L61  
L75 7 S L73 AND L62,L63  
L76 12 S L74,L75  
L77 7 S L76 AND (PY<=2001 OR PRY<=2001 OR AY<=2001)  
L78 5 S L76 NOT L77  
L79 12 S L73 NOT L76

FILE 'MEDLINE' ENTERED AT 08:17:39 ON 19 JAN 2005

L80 2 S L35  
L81 200 S L37 OR L38  
L82 200 S L80,L81  
L83 3527 S L13  
L84 4790 S L43 OR L44  
L85 42726 S L21 OR L19 OR L20  
L86 171 S L28 OR L29 OR L66 OR L67  
L87 54921 S L52 OR L69  
L88 1512 S L54  
E BETA ADRENERGIC ANTAGONIST/CT  
E E8+ALL  
E E2+ALL  
L89 62846 S E14+NT  
L90 8 S L82 AND L83-L89  
L91 1 S L90 AND PY<=2001  
L92 7 S L90 NOT L91

FILE 'EMBASE' ENTERED AT 08:22:33 ON 19 JAN 2005

L93 430 S L82  
L94 106403 S L83-L88  
L95 9 S ADRENERGIC BETA ANTAGONIST  
E BETA ADRENERGIC ANTAGONIST/CT  
E E3+ALL  
E E2+ALL  
L96 134943 S E6+NT  
L97 190 S L93 AND L94-L96  
L98 9 S L97 AND PY<=2001  
L99 0 S EPLERENONE(L)CB/CT AND L98

FILE 'BIOSIS' ENTERED AT 08:26:04 ON 19 JAN 2005

L100 182 S L82  
L101 11 S L100 AND P/DT  
L102 37 S L100 AND PY<=2001  
L103 3 S L101,L102 AND (ALEXANDER ? OR SCHUH ?)/AU  
L104 44 S L101,L102  
L105 0 S L104 AND L83-L88,L95

=> fil biosis

FILE 'BIOSIS' ENTERED AT 08:28:33 ON 19 JAN 2005

Copyright (c) 2005 The Thomson Corporation.

FILE COVERS 1969 TO DATE.

CAS REGISTRY NUMBERS AND CHEMICAL NAMES (CNs) PRESENT  
FROM JANUARY 1969 TO DATE.

RECORDS LAST ADDED: 12 January 2005 (20050112/ED)

FILE RELOADED: 19 October 2003.

=> d l103 all tot

L103 ANSWER 1 OF 3 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation. on STN  
AN 2004:299139 BIOSIS  
DN PREV200400303820  
TI Methods of treating heart failure and hypertension using combinations of  
**eplerenone** and an angiotensin converting enzyme inhibitor.  
AU Perez, Alfonso T. [Inventor, Reprint Author]; Asner, Debra J. [Inventor];  
LaChapelle, Richard J. [Inventor]; **Alexander, John C.**  
[Inventor]; Roniker, Barbara [Inventor]  
CS Princeton, NJ, USA  
ASSIGNEE: Pharmacia Corporation  
PI US 6747020 June 08, 2004  
SO Official Gazette of the United States Patent and Trademark Office Patents,  
(June 8 2004) Vol. 1283, No. 2. <http://www.uspto.gov/web/menu/patdata.html>  
. e-file.  
ISSN: 0098-1133 (ISSN print).  
DT **Patent**  
LA English  
ED Entered STN: 30 Jun 2004  
Last Updated on STN: 30 Jun 2004  
AB Methods of using **eplerenone**, an angiotensin converting enzyme  
inhibitor and optionally a diuretic are described for treatment of heart  
failure and hypertension.  
NCL 514175000  
CC Pathology - Therapy 12512  
Cardiovascular system - Heart pathology 14506  
Cardiovascular system - Blood vessel pathology 14508  
Pharmacology - General 22002  
Pharmacology - Cardiovascular system 22010  
Allergy 35500  
IT Major Concepts  
Pharmacology  
IT Diseases  
heart failure: heart disease  
Heart Failure, Congestive (MeSH)  
IT Diseases  
hypertension: vascular disease  
Hypertension (MeSH)  
IT Chemicals & Biochemicals  
**eplerenone**: angiotensin-converting enzyme inhibitor-drug,  
cardiovascular-drug, enzyme inhibitor-drug

RN 107724-20-9 (eplerenone)

L103 ANSWER 2 OF 3 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation. on STN  
AN 1999:520742 BIOSIS  
DN PREV199900520742  
TI **Eplerenone**, a novel and selective aldosterone receptor  
antagonist: Efficacy in patients with mild to moderate hypertension.  
AU Epstein, Murray [Reprint author]; Menard, Joel; **Alexander, John C.**  
; Roniker, Barbara  
CS University Miami, Miami, FL, USA  
SO Circulation, (Oct. 27, 1998) Vol. 98, No. 17 SUPPL., pp. I98-I99. print.  
Meeting Info.: 71st Scientific Sessions of the American Heart Association.  
Dallas, Texas, USA. November 8-11, 1998. The American Heart Association.  
CODEN: CIRCAZ. ISSN: 0009-7322.  
DT Conference; (Meeting)  
Conference; Abstract; (Meeting Abstract)  
LA English  
ED Entered STN: 3 Dec 1999  
Last Updated on STN: 3 Dec 1999  
CC Pharmacology - General 22002  
Biochemistry studies - General 10060  
Cardiovascular system - General and methods 14501  
General biology - Symposia, transactions and proceedings 00520  
IT Major Concepts  
Cardiovascular Medicine (Human Medicine, Medical Sciences);  
Pharmacology  
IT Diseases  
hypertension: vascular disease  
Hypertension (MeSH)  
IT Chemicals & Biochemicals  
aldosterone; **eplerenone**: antihypertensive-drug, aldosterone  
receptor antagonist, efficacy  
IT Miscellaneous Descriptors  
adverse events; blood pressure; target organ damage; Meeting Abstract  
ORGN Classifier  
Hominidae 86215  
Super Taxa  
Primates; Mammalia; Vertebrata; Chordata; Animalia  
Organism Name  
human: patient  
Taxa Notes  
Animals, Chordates, Humans, Mammals, Primates, Vertebrates  
RN 52-39-1 (aldosterone)  
107724-20-9 (eplerenone)

L103 ANSWER 3 OF 3 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation. on STN  
AN 1999:25079 BIOSIS  
DN PREV199900025079  
TI **Eplerenone**, a new selective aldosterone receptor antagonist  
(SARA): Efficacy in patients with mild to moderate hypertension.  
AU Epstein, M. [Reprint author]; **Alexander, J. C.**; Roniker, B.  
CS Dep. Med., Univ. Miami Sch. Med., Miami, FL, USA  
SO Journal of the American Society of Nephrology, (Sept., 1998) Vol. 9, No.  
PROGRAM AND ABSTR. ISSUE, pp. 322A-323A. print.  
Meeting Info.: 31st Annual Meeting of the American Society of Nephrology.  
Philadelphia, Pennsylvania, USA. October 25-28, 1998. American Society of  
Nephrology.  
CODEN: JASNEU. ISSN: 1046-6673.  
DT Conference; (Meeting)  
Conference; Abstract; (Meeting Abstract)  
Conference; (Meeting Poster)  
LA English  
ED Entered STN: 20 Jan 1999

Last Updated on STN: 20 Jan 1999

CC Pharmacology - Cardiovascular system 22010  
 Biochemistry studies - General 10060  
 Pathology - Therapy 12512  
 Cardiovascular system - Blood vessel pathology 14508  
 Pharmacology - Clinical pharmacology 22005  
 General biology - Symposia, transactions and proceedings 00520

IT Major Concepts  
 Cardiovascular Medicine (Human Medicine, Medical Sciences);  
 Pharmacology

IT Diseases  
 hypertension: vascular disease  
 Hypertension (MeSH)

IT Chemicals & Biochemicals  
**eplerenone**: antihypertensive-drug, selective aldosterone  
 receptor antagonist

IT Miscellaneous Descriptors  
 Meeting Abstract; Meeting Poster

ORGN Classifier  
 Hominidae 86215  
 Super Taxa  
 Primates; Mammalia; Vertebrata; Chordata; Animalia  
 Organism Name  
 human: patient  
 Taxa Notes  
 Animals, Chordates, Humans, Mammals, Primates, Vertebrates

RN 107724-20-9 (**eplerenone**)  
 52-39-1 (ALDOSTERONE)

=> fil hcaplus

FILE 'HCAPLUS' ENTERED AT 08:28:39 ON 19 JAN 2005  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 19 Jan 2005 VOL 142 ISS 4  
 FILE LAST UPDATED: 18 Jan 2005 (20050118/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d 177 all hitstr tot

L77 ANSWER 1 OF 7 HCAPLUS COPYRIGHT 2005 ACS on STN  
 AN 2003:492701 HCAPLUS  
 DN 139:57968  
 ED Entered STN: 29 Jun 2003  
 TI Bretylium compositions and kits in preventing and treating cardiovascular conditions  
 IN Bacaner, Marvin B.; Kreevoy, Maurice M.

PA USA  
 SO U.S. Pat. Appl. Publ., 51 pp., Cont.-in-part of U.S. Ser. No. 869,940.  
 CODEN: USXXCO  
 DT Patent  
 LA English  
 IC ICM A61K031-606  
 NCL 514161000  
 CC 63-6 (Pharmaceuticals)  
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003119794	A1	20030626	US 2002-271044	20021015 <--
	WO 2000040232	A2	20000713	WO 2000-US350	20000106 <--
	WO 2000040232	A3	20001123		
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	ZA 2001005931	A	20030311	ZA 2001-5931	20010718 <--
	US 6482811	B1	20021119	US 2001-869940	20011127 <--
PRAI	US 1999-115143P	P	19990108	<--	
	US 1999-116567P	P	19990121	<--	
	WO 2000-US350	W	20000106	<--	
	US 2001-329447P	P	20011015	<--	
	US 2001-869940	A2	20011127	<--	
	US 2002-394953P	P	20020710		

## CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 2003119794	ICM	A61K031-606
	NCL	514161000
US 2003119794	ECLA	A61K009/48H2; A61K045/06 <--
US 6482811	ECLA	A61K009/48H2; A61K045/06 <--

OS MARPAT 139:57968

AB The present invention is directed to pharmaceutical combinations and kits comprising bretylium as the active ingredient, as well as methods for preventing and/or treating conditions related to the cardiovascular system using such novel pharmaceutical combinations. A resuscitation solution is prepared by dissolving bretylium tosylate 15, acetylsalicylic acid 7.5, and **esmolol** 0.25 mg, meglumine 0.3 mmol/kg, and potassium gluconate 2 mmol/dose in an aqueous solution of 5% glucose 70 mL. For producing a resuscitation solution suitable for administration to an average 70-kg human,

the

solution contains bretylium tosylate 1.05 g, acetylsalicylic acid 525, **esmolol** 17.5, meglumine 4095 and potassium gluconate 468 mg in 70 mL an aqueous solution of 5% glucose.

ST bretylium formulation cardiovascular disorder

IT Heart

(Purkinje system; bretylium compns. and kits in preventing and treating cardiovascular conditions)

IT Disaccharides

Monosaccharides

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (amino; bretylium compns. and kits in preventing and treating cardiovascular conditions)

IT Polysaccharides, biological studies

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (aminodeoxy; bretylium compns. and kits in preventing and treating

cardiovascular conditions)  
IT Heart, disease  
(angina pectoris; bretylium compns. and kits in preventing and treating  
cardiovascular conditions)  
IT Shock (circulatory collapse)  
(antidefibrillatory; bretylium compns. and kits in preventing and  
treating cardiovascular conditions)  
IT Heart, disease  
(arrhythmia; bretylium compns. and kits in preventing and treating  
cardiovascular conditions)  
IT Heart, disease  
(atrial fibrillation; bretylium compns. and kits in preventing and  
treating cardiovascular conditions)  
IT Antihypotensives  
Buffers  
Cardiovascular agents  
Heart, disease  
Heart rate  
Human  
Partition  
(bretylium compns. and kits in preventing and treating cardiovascular  
conditions)  
IT Drug delivery systems  
(capsules; bretylium compns. and kits in preventing and treating  
cardiovascular conditions)  
IT Shock (circulatory collapse)  
(cardiogenic; bretylium compns. and kits in preventing and treating  
cardiovascular conditions)  
IT Artery, disease  
(coronary, spasm; bretylium compns. and kits in preventing and treating  
cardiovascular conditions)  
IT Heart, disease  
(failure; bretylium compns. and kits in preventing and treating  
cardiovascular conditions)  
IT Shock (circulatory collapse)  
(hemorrhagic; bretylium compns. and kits in preventing and treating  
cardiovascular conditions)  
IT Shock (circulatory collapse)  
(hypovolemic; bretylium compns. and kits in preventing and treating  
cardiovascular conditions)  
IT Heart, disease  
(infarction; bretylium compns. and kits in preventing and treating  
cardiovascular conditions)  
IT Drug delivery systems  
(injections, i.m.; bretylium compns. and kits in preventing and  
treating cardiovascular conditions)  
IT Drug delivery systems  
(injections, i.v.; bretylium compns. and kits in preventing and  
treating cardiovascular conditions)  
IT Drug delivery systems  
(injections; bretylium compns. and kits in preventing and treating  
cardiovascular conditions)  
IT Drug delivery systems  
(oral; bretylium compns. and kits in preventing and treating  
cardiovascular conditions)  
IT Shock (circulatory collapse)  
(septic; bretylium compns. and kits in preventing and treating  
cardiovascular conditions)  
IT Drug delivery systems  
(solns.; bretylium compns. and kits in preventing and treating  
cardiovascular conditions)  
IT Drug delivery systems  
(suspensions; bretylium compns. and kits in preventing and treating



- cardiovascular conditions)
- IT Ganglion  
(sympathetic, blockade; bretylium compns. and kits in preventing and treating cardiovascular conditions)
- IT Heart, disease  
(systole dysfunction; bretylium compns. and kits in preventing and treating cardiovascular conditions)
- IT Drug delivery systems  
(tablets; bretylium compns. and kits in preventing and treating cardiovascular conditions)
- IT Heart, disease  
(tachycardia, atrial; bretylium compns. and kits in preventing and treating cardiovascular conditions)
- IT Antidepressants  
(tricyclic; bretylium compns. and kits in preventing and treating cardiovascular conditions)
- IT Heart, disease  
(ventricular arrhythmia; bretylium compns. and kits in preventing and treating cardiovascular conditions)
- IT Heart, disease  
(ventricular fibrillation; bretylium compns. and kits in preventing and treating cardiovascular conditions)
- IT Heart, disease  
(ventricular tachycardia; bretylium compns. and kits in preventing and treating cardiovascular conditions)
- IT **Adrenoceptor antagonists**  
( $\beta$  -; bretylium compns. and kits in preventing and treating cardiovascular conditions)
- IT 50-78-2, Acetylsalicylic acid 50-78-2D, Acetylsalicylic acid, salts  
59-41-6, Bretylium 61-75-6, Bretylium tosylate 525-66-6,  
**Propranolol**  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(bretylium compns. and kits in preventing and treating cardiovascular conditions)
- IT 3170-72-7P, Bretylium bromide  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(bretylium compns. and kits in preventing and treating cardiovascular conditions)
- IT 148794-29-0P, Bretylium dodecyl sulfate  
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(bretylium compns. and kits in preventing and treating cardiovascular conditions)
- IT 50-47-5, Desipramine 50-48-6, Amitriptyline 51-43-4, Epinephrine  
54-21-7, Sodium salicylate 68-04-2, Sodium citrate 72-69-5,  
Nortriptyline 77-92-9, Citric acid, biological studies 144-55-8,  
Sodium bicarbonate, biological studies 438-60-8, Protriptyline  
577-11-7, Sodium di(2-ethyl hexyl)sulfosuccinate 6284-40-8, Methyl  
glucamine 22232-71-9, Mazindol 26839-75-8, **Timolol**  
29122-68-7, **Atenolol** 36894-69-6,  
**Labetalol** 37517-30-9, **Acebutolol**  
51384-51-1, **Metoprolol** 57460-41-0, **Talinolol**  
72956-09-3, **Carvedilol** 81147-92-4,  
**Esmolol** 107724-20-9, **Eplerenone** 282095-85-6  
282095-86-7, biological studies  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(bretylium compns. and kits in preventing and treating cardiovascular conditions)
- IT 151-21-3, SDS, reactions 598-56-1 3433-80-5, 2-Bromobenzyl bromide  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(in bretylium salt preparation; bretylium compns. and kits in preventing and

treating cardiovascular conditions)

IT 525-66-6, **Propranolol**


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)

(bretylium compns. and kits in preventing and treating cardiovascular conditions)

RN 525-66-6 HCAPLUS

CN 2-Propanol, 1-[(1-methylethyl)amino]-3-(1-naphthalenyloxy)- (9CI) (CA INDEX NAME)



IT 26839-75-8, **Timolol** 29122-68-7,  
**Atenolol** 36894-69-6, **Labetalol**  
 37517-30-9, **Acebutolol** 51384-51-1,  
**Metoprolol** 72956-09-3, **Carvedilol**  
 81147-92-4, **Esmolol** 107724-20-9,  
**Eplerenone**


RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(bretylium compns. and kits in preventing and treating cardiovascular conditions)

RN 26839-75-8 HCAPLUS


CN 2-Propanol, 1-[(1,1-dimethylethyl)amino]-3-[[4-(4-morpholinyl)-1,2,5-thiadiazol-3-yl]oxy]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 29122-68-7 HCAPLUS

CN Benzeneacetamide, 4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]- (9CI) (CA INDEX NAME)




RN 36894-69-6 HCAPLUS

CN Benzamide, 2-hydroxy-5-[1-hydroxy-2-[(1-methyl-3-phenylpropyl)amino]ethyl]-  
(9CI) (CA INDEX NAME)




RN 37517-30-9 HCAPLUS

CN Butanamide, N-[3-acetyl-4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]phenyl]-  
(9CI) (CA INDEX NAME)



RN 51384-51-1 HCAPLUS


CN 2-Propanol, 1-[4-(2-methoxyethyl)phenoxy]-3-[(1-methylethyl)amino]- (9CI)  
(CA INDEX NAME)




RN 72956-09-3 HCAPLUS

CN 2-Propanol, 1-(9H-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]-  
(9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 81147-92-4 HCAPLUS  
 CN Benzenepropanoic acid, 4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 107724-20-9 HCAPLUS  
 CN Pregn-4-ene-7,21-dicarboxylic acid, 9,11-epoxy-17-hydroxy-3-oxo-,  $\gamma$ -lactone, methyl ester, (7 $\alpha$ ,11 $\alpha$ ,17 $\alpha$ )- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L77 ANSWER 2 OF 7 HCAPLUS COPYRIGHT 2005 ACS on STN  
 AN 2003:472394 HCAPLUS  
 DN 139:31256  
 ED Entered STN: 20 Jun 2003  
 TI Methods and compositions for treating ophthalmic disorders with  
 epoxy-steroidal aldosterone receptor antagonists  
 IN Aiken, James W.  
 PA **Pharmacia Corporation, USA**  
 SO PCT Int. Appl., 68 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 IC ICM A61K031-58  
 ICS A61K045-06; A61P027-02; A61P027-06  
 CC 2-4 (Mammalian Hormones)  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003049745	A1	20030619	WO 2002-US39807	20021212 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2003158162	A1	20030821	US 2002-317650	20021212 <--
	EP 1455795	A1	20040915	EP 2002-784791	20021212 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	BR 2002014924	A	20041130	BR 2002-14924	20021212 <--
PRAI	US 2001-341033P	P	20011212	<--	
	WO 2002-US39807	W	20021212		

## CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2003049745	ICM	A61K031-58
	ICS	A61K045-06; A61P027-02; A61P027-06
US 2003158162	ECLA	A61K031/164+M; A61K031/5575+M; A61K031/58; A61K031/58+M; A61K031/585; A61K031/585+M; A61K045/06<--
AB		A method for treating or preventing ophthalmic disorders comprising the

administration of one or more aldosterone receptor antagonists that contain a 9,11-epoxy moiety, such as **eplerenone** is disclosed. The method results in a reduction of intraocular pressure which treats or prevents the ophthalmic disorders. The epoxysteroid compds. can be co-administered with cytoskeletal disruptors, prostaglandin compds. and/or antiglaucoma agents. Among the disorders are intraocular hypertension, glaucoma, low tension glaucoma, age-related macula degeneration (AMD), macular edema, and diabetic retinopathy. As glucocorticoids and mineralocorticoids also cause the retention of ions, such as sodium and potassium, where aldosterone receptors are located, aldosterone receptor antagonists that contain a 9,11-epoxy moiety, such as **eplerenone**, also can be administered to modulate the intraocular concentration of ions. Thus, aldosterone receptor antagonists can be administered to maintain an intraocular ionic environment that is beneficial to intraocular cell survival.

- ST epoxysteroid aldosterone receptor antagonist ophthalmic disorders treatment antiglaucoma
- IT Epoxy group
  - (9,11-epoxy moiety-containing steroids; methods and compns. for treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists)
- IT Prostaglandins
  - RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
  - (A; methods and compns. for treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists in combination with cytoskeletal disrupting agents and/or prostaglandin compds.)
- IT Adenosine receptors
  - RL: BSU (Biological study, unclassified); BIOL (Biological study)
  - (A3, antagonists; methods and compns. for treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists in combination with antiglaucoma agents)
- IT Prostaglandins
  - RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
  - (B; methods and compns. for treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists in combination with cytoskeletal disrupting agents and/or prostaglandin compds.)
- IT Dopamine agonists
  - (D1; methods and compns. for treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists in combination with antiglaucoma agents)
- IT Prostaglandins
  - RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
  - (E; methods and compns. for treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists in combination with cytoskeletal disrupting agents and/or prostaglandin compds.)
- IT Prostaglandins
  - RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
  - (F; methods and compns. for treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists in combination with cytoskeletal disrupting agents and/or prostaglandin compds.)
- IT Muscarinic agonists
  - (M3; methods and compns. for treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists in combination with antiglaucoma agents)
- IT Muscarinic agonists
  - (M1; methods and compns. for treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists in combination with antiglaucoma agents)
- IT Prostaglandins

- RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(PGD; methods and compns. for treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists in combination with cytoskeletal disrupting agents and/or prostaglandin compds.)
- IT Somatostatin receptors  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(SSTR4, agonists; methods and compns. for treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists in combination with antiglaucoma agents)
- IT Tumor necrosis factors  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(agonists; methods and compns. for treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists in combination with antiglaucoma agents)
- IT Corticosteroid receptors  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(antagonists; methods and compns. for treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists in combination with antiglaucoma agents)
- IT Eye  
(anterior chamber, aqueous humor inflow/outflow; methods and compns. for treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists)
- IT Eye  
(aqueous humor, controlled inflow/outflow; methods and compns. for treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists)
- IT Anion exchangers  
(chloride, inhibitors; methods and compns. for treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists in combination with antiglaucoma agents)
- IT Eye, disease  
(diabetic retinopathy; methods and compns. for treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists)
- IT Steroids, biological studies  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(epoxy-; methods and compns. for treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists)
- IT Mineralocorticoid receptors  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(epoxysteroidal antagonist; methods and compns. for treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists)
- IT Transport proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(hydrogen ion-sodium exchanger, inhibitors; methods and compns. for treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists in combination with antiglaucoma agents)
- IT Eye  
(intraocular fluid; methods and compns. for treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists)
- IT Glaucoma (disease)  
(low-tension; methods and compns. for treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists)
- IT Eye, disease  
(macula, senile degeneration; methods and compns. for treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists)
- IT Eye, disease  
(macular edema; methods and compns. for treating ophthalmic disorders

- with epoxy-steroidal aldosterone receptor antagonists)
- IT Glaucoma (disease)  
Human  
(methods and compns. for treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists)
- IT Adrenoceptor agonists  
Antiglaucoma agents  
Cholinergic agonists  
Cholinergic antagonists  
Muscarinic agonists  
(methods and compns. for treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists in combination with antiglaucoma agents)
- IT Cannabinoids  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(methods and compns. for treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists in combination with antiglaucoma agents)
- IT Cytoskeleton  
(methods and compns. for treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists in combination with cytoskeletal disrupting agents and/or prostaglandin compds.)
- IT Prostaglandins  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(methods and compns. for treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists in combination with cytoskeletal disrupting agents and/or prostaglandin compds.)
- IT Prostaglandins  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(prodrugs; methods and compns. for treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists in combination with cytoskeletal disrupting agents and/or prostaglandin compds.)
- IT Prostaglandins  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(prostanoids; methods and compns. for treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists in combination with cytoskeletal disrupting agents and/or prostaglandin compds.)
- IT Drug delivery systems  
(solns., ophthalmic; methods and compns. for treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists in combination with antiglaucoma agents)
- IT Adrenoceptor antagonists  
( $\alpha$ -; methods and compns. for treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists in combination with antiglaucoma agents)
- IT Adrenoceptor antagonists  
( $\beta$  -; methods and compns. for treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists in combination with antiglaucoma agents)
- IT Adrenoceptor antagonists  
( $\beta$  2-; methods and compns. for treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists in combination with antiglaucoma agents)
- IT 9001-03-0, Carbonic anhydrase  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(I, II and IV inhibitors; methods and compns. for treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists in combination with antiglaucoma agents)
- IT 551-11-1, PGF2 $\alpha$



RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (agonists; methods and compns. for treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists in combination with cytoskeletal disrupting agents and/or prostaglandin compds.)

IT 11128-99-7, Angiotensin II  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (antagonists; methods and compns. for treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists in combination with antiglaucoma agents)

IT 26921-17-5, Timolol maleate  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (in solution with dorzolamide hydrochloride; methods and compns. for treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists in combination with antiglaucoma agents)

IT 141436-78-4, Protein kinase C 182372-13-0, Rho kinase  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (inhibitors; methods and compns. for treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists in combination with antiglaucoma agents)

IT 7440-09-7, Potassium, biological studies 7440-23-5, Sodium, biological studies  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (methods and compns. for modulating intraocular ionic levels with epoxy-steroidal aldosterone receptor antagonists for treating ophthalmic disorders)

IT 95716-76-0 95716-78-2 95716-94-2 95716-95-3 95716-96-4  
 95716-97-5 95716-98-6 95716-99-7 95717-02-5 107724-20-9  
 380606-04-2  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (methods and compns. for treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists)

IT 51-43-4, Epinephrine 51-48-9, L-Thyroxine, biological studies 51-83-2, Carbachol 54-71-7, Pilocarpine hydrochloride 59-66-5, Acetazolamide 92-13-7, Pilocarpine 120-97-8, Dichlorophenamide 554-57-4, Methazolamide 4205-90-7, Clonidine 26839-75-8, Timolol 27912-14-7, Betagan 51781-21-6, Carteolol hydrochloride 59803-98-4, Brimonidine 63659-18-7, Betaxolol 63659-19-8, Betaxolol hydrochloride 66711-21-5, Apraclonidine 94421-68-8, Anandamide 120279-96-1, Dorzolamide 130693-82-2, Dorzolamide hydrochloride 138890-62-7, Brinzolamide 150937-43-2 151499-39-7, Bafilomycin  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (methods and compns. for treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists in combination with antiglaucoma agents)

IT 120373-36-6, Unoprostone 130209-82-4, Latanoprost 155206-00-1, Lumigan 157283-68-6, Travoprost  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (methods and compns. for treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists in combination with cytoskeletal disrupting agents and/or prostaglandin compds.)

IT 9000-83-3, ATPase  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (vacuolar proton, inhibitors; methods and compns. for treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists in combination with antiglaucoma agents)

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 RE

- (1) Funder, J; WO 0195893 A 2001 HCAPLUS
- (2) Grob, J; US 4559332 A 1985 HCAPLUS
- (3) Mathur, L; WO 0187284 A 2001 HCAPLUS
- (4) Olins, G; WO 9640255 A 1996 HCAPLUS
- (5) Pharmacia Corp; WO 0209760 A 2002 HCAPLUS
- (6) Rabasseda, X; DRUGS OF THE FUTURE 1999, V24(5), P488 HCAPLUS

IT 26921-17-5, **Timolol** maleate  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
 (Biological study); USES (Uses)  
 (in solution with dorzolamide hydrochloride; methods and compns. for  
 treating ophthalmic disorders with epoxy-steroidal aldosterone receptor  
 antagonists in combination with antiglaucoma agents)

RN 26921-17-5 HCAPLUS


CN 2-Propanol, 1-[(1,1-dimethylethyl)amino]-3-[[4-(4-morpholinyl)-1,2,5-  
 thiadiazol-3-yl]oxy]-, (2S)-, (2Z)-2-butenedioate (1:1) (salt) (9CI) (CA  
 INDEX NAME)

CM 1

CRN 26839-75-8

CMF C13 H24 N4 O3 S

Absolute stereochemistry. Rotation (-).




CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.




IT 107724-20-9

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
 (Biological study); USES (Uses)  
 (methods and compns. for treating ophthalmic disorders with  
 epoxy-steroidal aldosterone receptor antagonists)

RN 107724-20-9 HCAPLUS


CN Pregn-4-ene-7,21-dicarboxylic acid, 9,11-epoxy-17-hydroxy-3-oxo-,  
 $\gamma$ -lactone, methyl ester, (7 $\alpha$ ,11 $\alpha$ ,17 $\alpha$ )- (9CI) (CA  
 INDEX NAME)

Absolute stereochemistry.




IT 26839-75-8, Timolol 27912-14-7, Betagan  
 51781-21-6, Carteolol hydrochloride 63659-18-7  
 , Betaxolol 63659-19-8, Betaxolol  
 hydrochloride  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
 (Biological study); USES (Uses)  
 (methods and compns. for treating ophthalmic disorders with  
 epoxy-steroidal aldosterone receptor antagonists in combination with  
 antiglaucoma agents)  
 RN 26839-75-8 HCAPLUS  
 CN 2-Propanol, 1-[(1,1-dimethylethyl)amino]-3-[[4-(4-morpholinyl)-1,2,5-  
 thiadiazol-3-yl]oxy]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 27912-14-7 HCAPLUS  
 CN 1(2H)-Naphthalenone, 5-[(2S)-3-[(1,1-dimethylethyl)amino]-2-  
 hydroxypropoxy]-3,4-dihydro-, hydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 51781-21-6 HCAPLUS


CN 2(1H)-Quinolinone, 5-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-3,4-dihydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 63659-18-7 HCAPLUS

CN 2-Propanol, 1-[4-[2-(cyclopropylmethoxy)ethyl]phenoxy]-3-[(1-methylethyl)amino]- (9CI) (CA INDEX NAME)



RN 63659-19-8 HCAPLUS

CN 2-Propanol, 1-[4-[2-(cyclopropylmethoxy)ethyl]phenoxy]-3-[(1-methylethyl)amino]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

L77 ANSWER 3 OF 7 HCAPLUS COPYRIGHT 2005 ACS on STN  
 AN 2003:396452 HCAPLUS  
 DN 138:363210  
 ED Entered STN: 23 May 2003  
 TI Methods for the treatment or prophylaxis of aldosterone-mediated  
 pathogenic effects in a subject using an epoxy-steroidal aldosterone  
 antagonist  
 IN Williams, Gordon H.; Funder, John W.; Garthwaite, Susan M.; Roniker,  
 Barbara; Fedde, Kenton N.; Rocha, Ricardo  
 PA USA  
 SO U.S. Pat. Appl. Publ., 242 pp., Cont.-in-part of U.S. Ser. No. 713,348.  
 CODEN: USXXCO  
 DT Patent  
 LA English  
 IC ICM A61K031-58  
 NCL 514172000  
 CC 2-4 (Mammalian Hormones)  
 Section cross-reference(s): 1, 63, 75  
 FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003096798	A1	20030522	US 2001-17288	20011213 <--
	US 2003125312	A1	20030703	US 2001-915784	20010726 <--
	US 6716829	B2	20040406		
	EP 1453522	A1	20040908	EP 2001-998044	20011213 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	US 2003191100	A1	20031009	US 2002-243876	20020913 <--
	US 2003203884	A1	20031030	US 2003-354823	20030130 <--
	US 2004067916	A1	20040408	US 2003-648863	20030826 <--
	US 2004102424	A1	20040527	US 2003-682527	20031009 <--
PRAI	US 1999-164390P	P	19991109	<--	
	US 2000-211064P	P	20000613	<--	
	US 2000-211250P	P	20000613	<--	
	US 2000-211253P	P	20000613	<--	
	US 2000-211264P	P	20000613	<--	
	US 2000-211311P	P	20000613	<--	
	US 2000-211340P	P	20000613	<--	
	US 2000-211451P	P	20000613	<--	
	US 2000-211459P	P	20000613	<--	
	US 2000-221358P	P	20000727	<--	
	US 2000-221364P	P	20000727	<--	
	US 2000-233056P	P	20000914	<--	
	US 2000-709253	A2	20001108	<--	
	US 2000-713348	A2	20001114	<--	
	US 2000-712543	A1	20001114	<--	
	US 2001-261352P	P	20010112	<--	
	US 2001-261497P	P	20010112	<--	
	US 2001-17288	B1	20011213	<--	
	WO 2001-US48419	W	20011213	<--	

## CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 2003096798	ICM	A61K031-58
	NCL	514172000
US 2004067916	ECLA	A61K031/00 <--
US 2004102424	ECLA	A61K031/00; A61K031/00+A; A61K031/415+M; A61K031/4152; A61K031/4152+M; A61K031/437; A61K031/437+M; A61K031/5513+M; A61K031/56+M; A61K031/57; A61K031/57+M; A61K031/58; A61K031/58+M; A61K001/585; A61K031/585+M; A61K045/06; A61K045/06+M <--
AB		The present invention provides methods for the treatment or prophylaxis of

one or more aldosterone-mediated pathogenic effects in a subject suffering from or susceptible to the pathogenic effect or effects wherein the subject has one or more conditions selected from the group consisting of a sub-normal endogenous aldosterone level, salt sensitivity and an elevated dietary sodium intake. The methods comprise administering to the subject a therapeutically-effective amount of one or more epoxy-steroidal compds. that are aldosterone antagonists.

- ST **eplerenone** epoxy steroid treatment aldosterone mediated disease hypertension
- IT Human groups
  - (Japanese, American Indian, and Black ethnic groups; use of epoxy-steroidal aldosterone antagonist for treatment or prophylaxis of aldosterone-mediated pathogenic effects in various ethnic groups)
- IT Albumins, biological studies
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (albuminuria; antihypertensive, renal, and metabolic effects of **eplerenone** and enalapril in patients with type 2 diabetes, albuminuria, and hypertension)
- IT Mineralocorticoid receptors
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (antagonists; use of epoxy-steroidal aldosterone antagonist for treatment or prophylaxis of aldosterone-mediated pathogenic effects)
- IT Ion channel blockers
  - (calcium; **eplerenone** co-administration with a calcium channel blocker or a  $\beta$ -adrenoceptor blocker)
- IT Drug delivery systems
  - (capsules; antihypertensive, renal, and metabolic effects of **eplerenone** and enalapril in patients with type 2 diabetes, albuminuria, and hypertension)
- IT Cytoprotective agents
  - (cardioprotective; use of epoxy-steroidal aldosterone antagonist for treatment or prophylaxis of aldosterone-mediated pathogenic effects)
- IT Brain, disease
  - (cerebrovascular; use of epoxy-steroidal aldosterone antagonist for treatment or prophylaxis of aldosterone-mediated pathogenic effects)
- IT Menopause
  - (disorder, hot flash; use of epoxy-steroidal aldosterone antagonist for treatment or prophylaxis of aldosterone-mediated pathogenic effects)
- IT Baroreceptors
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (dysfunction; use of epoxy-steroidal aldosterone antagonist for treatment or prophylaxis of aldosterone-mediated pathogenic effects)
- IT Aging, animal
  - (elderly; use of epoxy-steroidal aldosterone antagonist for treatment or prophylaxis of aldosterone-mediated pathogenic effects)
- IT Blood vessel, disease
  - (endothelium, dysfunction; use of epoxy-steroidal aldosterone antagonist for treatment or prophylaxis of aldosterone-mediated pathogenic effects)
- IT Steroids, biological studies
  - RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); PKT (Pharmacokinetics); PRP (Properties); PUR (Purification or recovery); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (epoxy-; use of epoxy-steroidal aldosterone antagonist for treatment or prophylaxis of aldosterone-mediated pathogenic effects)
- IT Heart, disease
  - (failure; use of epoxy-steroidal aldosterone antagonist for treatment or prophylaxis of aldosterone-mediated pathogenic effects)
- IT Heart, disease
  - (infarction; use of epoxy-steroidal aldosterone antagonist for treatment or prophylaxis of aldosterone-mediated pathogenic effects)
- IT Heart, disease

(left ventricle, hypertrophy; use of epoxy-steroidal aldosterone antagonist for treatment or prophylaxis of aldosterone-mediated pathogenic effects)

- IT Diuretics
  - (loop; treatment or prophylaxis of heart failure by administering an ACE inhibitor, a loop diuretic, and one or more epoxysteroidal compds.)
- IT Kidney, disease
  - (nephrosclerosis; use of epoxy-steroidal aldosterone antagonist for treatment or prophylaxis of aldosterone-mediated pathogenic effects)
- IT Nerve, disease
  - (neuropathy; use of epoxy-steroidal aldosterone antagonist for treatment or prophylaxis of aldosterone-mediated pathogenic effects)
- IT Diabetes mellitus
  - (non-insulin-dependent; antihypertensive, renal, and metabolic effects of **eplerenone** and enalapril in patients with type 2 diabetes, albuminuria, and hypertension)
- IT Crystal structure
  - Crystallization
    - (of epoxysteroidal compds.; use of epoxy-steroidal aldosterone antagonist for treatment or prophylaxis of aldosterone-mediated pathogenic effects)
- IT Ovarian cycle
  - (premenstrual syndrome; use of epoxy-steroidal aldosterone antagonist for treatment or prophylaxis of aldosterone-mediated pathogenic effects)
- IT Size reduction
  - (preparation of amorphous **eplerenone** by comminution)
- IT Freeze drying
  - (preparation of amorphous **eplerenone** by lyophilization)
- IT Artery
  - (renal, renal arteriopathy; use of epoxy-steroidal aldosterone antagonist for treatment or prophylaxis of aldosterone-mediated pathogenic effects)
- IT Hypertension
  - (renal; use of epoxy-steroidal aldosterone antagonist for treatment or prophylaxis of aldosterone-mediated pathogenic effects)
- IT Cytoprotective agents
  - (renoprotective; use of epoxy-steroidal aldosterone antagonist for treatment or prophylaxis of aldosterone-mediated pathogenic effects)
- IT Eye, disease
  - (retinopathy; use of epoxy-steroidal aldosterone antagonist for treatment or prophylaxis of aldosterone-mediated pathogenic effects)
- IT Brain, disease
  - (stroke; use of epoxy-steroidal aldosterone antagonist for treatment or prophylaxis of aldosterone-mediated pathogenic effects)
- IT Drug delivery systems
  - (tablets; use of epoxy-steroidal aldosterone antagonist for treatment or prophylaxis of aldosterone-mediated pathogenic effects)
- IT Antihypertensives
- Antimigraine agents
- Blood vessel, disease
- Cardiovascular agents
- Edema
- Human
- Kidney, disease
- Liver, disease
- Structure-activity relationship
  - (use of epoxy-steroidal aldosterone antagonist for treatment or prophylaxis of aldosterone-mediated pathogenic effects)
- IT Atherosclerosis
  - (use of epoxy-steroidal aldosterone antagonist to improve endothelial function in diet induced atherosclerosis)
- IT **Adrenoceptor antagonists**

- ( $\beta$  -; **eplerenone** co-administration with a calcium channel blocker or a  $\beta$  -adrenoceptor blocker)
- IT 11128-99-7, Angiotensin II  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (antagonist; co-administration of **eplerenone** with an ACE inhibitor or angiotensin II antagonist in patients with mild-moderate hypertension)
- IT 107724-20-9DP, **Eplerenone**, derivs.  
 RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); PYP (Physical process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)  
 (antihypertensive, renal, and metabolic effects of **eplerenone** and enalapril in patients with type 2 diabetes, albuminuria, and hypertension)
- IT 88150-42-9, Amlodipine  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (comparison of **eplerenone** and amlodipine in ambulatory blood pressure monitoring)
- IT 114798-26-4, Losartan  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (comparison of **eplerenone** and losartan in patients with low-renin hypertension)
- IT 75847-73-3, Enalapril  
 RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (**eplerenone** and enalapril efficacy and safety in treating left ventricular hypertrophy and essential hypertension)
- IT 192704-82-8 209253-73-6  
 RL: MSC (Miscellaneous)  
 (impurity mols.; crystallization of epoxysteroidal compds.)
- IT 9015-82-1, Angiotensin-converting enzyme  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (inhibitors; treatment or prophylaxis of heart failure by administering an ACE inhibitor, a loop diuretic, and one or more epoxysteroidal compds.)
- IT 9004-10-8, Insulin, biological studies  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (resistance; use of epoxy-steroidal aldosterone antagonist for treatment or prophylaxis of aldosterone-mediated pathogenic effects)
- IT 7440-23-5, Sodium, biological studies 7647-14-5, Sodium chloride, biological studies  
 RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)  
 (salt sensitivity; use of epoxy-steroidal aldosterone antagonist for treatment or prophylaxis of aldosterone-mediated pathogenic effects)
- IT 64-17-5, Ethanol, biological studies 67-56-1, Methanol, biological studies 75-05-8, Acetonitrile, biological studies 78-93-3, Methyl ethyl ketone, biological studies 98-95-3, Nitrobenzene, biological studies 100-41-4, Ethyl benzene, biological studies 141-78-6, Ethyl acetate, biological studies  
 RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)  
 (solvent; crystallization of epoxysteroidal compds.)
- IT 52-39-1, Aldosterone  
 RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)  
 (use of epoxy-steroidal aldosterone antagonist for treatment or prophylaxis of aldosterone-mediated pathogenic effects)
- IT 107724-20-9P, **Eplerenone**  
 RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); PKT (Pharmacokinetics); PRP (Properties); PUR (Purification or



recovery); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(use of epoxy-steroidal aldosterone antagonist for treatment or prophylaxis of aldosterone-mediated pathogenic effects)

IT 95716-76-0P 95716-78-2P 95716-94-2P 95716-95-3P 95716-96-4P  
95716-97-5P 95716-98-6P 95716-99-7P 95717-02-5P 380606-04-2P  
RL: PAC (Pharmacological activity); PRP (Properties); PUR (Purification or recovery); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(use of epoxy-steroidal aldosterone antagonist for treatment or prophylaxis of aldosterone-mediated pathogenic effects)

IT 107724-20-9DP, **Eplerenone**, derivs.


RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); PYP (Physical process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)

(antihypertensive, renal, and metabolic effects of **eplerenone** and enalapril in patients with type 2 diabetes, albuminuria, and hypertension)

RN 107724-20-9 HCAPLUS

CN Pregn-4-ene-7,21-dicarboxylic acid, 9,11-epoxy-17-hydroxy-3-oxo-,  $\gamma$ -lactone, methyl ester, (7 $\alpha$ ,11 $\alpha$ ,17 $\alpha$ )- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 107724-20-9P, **Eplerenone**


RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); PKT (Pharmacokinetics); PRP (Properties); PUR (Purification or recovery); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(use of epoxy-steroidal aldosterone antagonist for treatment or prophylaxis of aldosterone-mediated pathogenic effects)

RN 107724-20-9 HCAPLUS

CN Pregn-4-ene-7,21-dicarboxylic acid, 9,11-epoxy-17-hydroxy-3-oxo-,  $\gamma$ -lactone, methyl ester, (7 $\alpha$ ,11 $\alpha$ ,17 $\alpha$ )- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L77 ANSWER 4 OF 7 HCAPLUS COPYRIGHT 2005 ACS on STN  
 AN 2003:319257 HCAPLUS  
 DN 138:343856  
 ED Entered STN: 25 Apr 2003  
 TI Buccal sprays or capsules containing cardiovascular or renal drugs  
 IN Dugger, Harry A.  
 PA USA  
 SO U.S. Pat. Appl. Publ., 15 pp., Cont.-in-part of U.S. Ser. No. 537,118.  
 CODEN: USXXCO  
 DT Patent  
 LA English  
 IC ICM A61K009-00  
 ICS A61L009-04  
 NCL 424043000  
 CC 63-6 (Pharmaceuticals)  
 FAN.CNT 16

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003077229	A1	20030424	US 2002-230075	20020829 <--
	WO 9916417	A1	19990408	WO 1997-US17899	19971001 <--
	W:			AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM	
	RW:			GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG	
EP	1029536	A1	20000823	EP 2000-109347	19971001 <--
	R:			AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO	
EP	1036561	A1	20000920	EP 2000-109357	19971001 <--
	R:			AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO	
WO	2004019909	A2	20040311	WO 2003-US26853	20030827
WO	2004019909	A3	20040708		
	W:			AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW	
	RW:			GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,	

FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,  
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI	WO 1997-US17899	A2	19971001	<--
	US 2000-537118	A2	20000329	<--
	EP 1997-911621	A3	19971001	<--
	US 2002-230075	A	20020829	

## CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
------------	-------	------------------------------------

---

US 2003077229	ICM	A61K009-00
	ICS	A61L009-04
	NCL	424043000
US 2003077229	ECLA	A61K009/00M18D; A61K009/00M20B; A61K031/085; A61K031/137; A61K031/138; A61K031/197; A61K031/27; A61K003/4178; A61K031/421; A61K031/433; A61K031/7076<--
WO 9916417	ECLA	A61K009/00M18D; A61K009/00M20B <--
EP 1029536	ECLA	A61K009/00M20B <--
EP 1036561	ECLA	A61K009/00M20B <--

AB Buccal aerosol sprays or capsules using polar and non-polar solvent have now been developed which provide biol. active compds. for rapid absorption through the oral mucosa, resulting in fast onset of effect. The buccal polar compns. of the invention comprise formulation A: aqueous polar solvent, active compound, and optional flavoring agent; formulation B: aqueous polar solvent, active compound, optionally flavoring agent, and propellant; formulation C: non-polar solvent, active compound, and optional flavoring agent; and formulation D: non-polar solvent, active compound, optional flavoring agent, and propellant. Thus, a polar lingual spray contained isoproterenol-HCl 0.5-6, water 50-75, EtOH 5-10, PEG 5-15, sorbitol 0.4-1.0, aspartame 0.04-0.1, and flavors 2-3%.

ST cardiovascular drug buccal spray; renal drug capsule

IT Fatty acids, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (C2-24; buccal sprays or capsules containing cardiovascular or renal drugs)

IT Alcohols, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (C2-8; buccal sprays or capsules containing cardiovascular or renal drugs)

IT Alcohols, biological studies  
 Hydrocarbons, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (C7-18; buccal sprays or capsules containing cardiovascular or renal drugs)

IT Drug delivery systems  
 (aerosols, sprays; buccal sprays or capsules containing cardiovascular or renal drugs)

IT Antianginal agents  
 Antiarrhythmics  
 Anticoagulants  
 Antihypertensives  
 Antihypotensives  
 Cardiovascular agents  
 Flavor  
 Polar solvents  
 Propellants (sprays and foams)  
 Sweetening agents  
 Vasodilators  
 (buccal sprays or capsules containing cardiovascular or renal drugs)

IT Esters, biological studies  
 Glycerides, biological studies  
 Pentosans  
 Polyoxyalkylenes, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (buccal sprays or capsules containing cardiovascular or renal drugs)

IT Drug delivery systems  
 (buccal; buccal sprays or capsules containing cardiovascular or renal

- drugs)
- IT Drug delivery systems  
(capsules; buccal sprays or capsules containing cardiovascular or renal drugs)
- IT Essential oils  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(citrus; buccal sprays or capsules containing cardiovascular or renal drugs)
- IT Heart, disease  
(failure; buccal sprays or capsules containing cardiovascular or renal drugs)
- IT Flavoring materials  
(fruit flavors; buccal sprays or capsules containing cardiovascular or renal drugs)
- IT Mucopolysaccharides, biological studies  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(heparinoids; buccal sprays or capsules containing cardiovascular or renal drugs)
- IT Peptides, biological studies  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(hormones; buccal sprays or capsules containing cardiovascular or renal drugs)
- IT Mouth  
(mucosa; buccal sprays or capsules containing cardiovascular or renal drugs)
- IT Drug delivery systems  
(mucosal; buccal sprays or capsules containing cardiovascular or renal drugs)
- IT Essential oils  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(peppermint; buccal sprays or capsules containing cardiovascular or renal drugs)
- IT Hormones, animal, biological studies  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(peptide; buccal sprays or capsules containing cardiovascular or renal drugs)
- IT Alcohols, biological studies  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(polyhydric, C2-8; buccal sprays or capsules containing cardiovascular or renal drugs)
- IT Heart  
(regulators for; buccal sprays or capsules containing cardiovascular or renal drugs)
- IT Essential oils  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(spearmint; buccal sprays or capsules containing cardiovascular or renal drugs)
- IT Drug delivery systems  
(sprays; buccal sprays or capsules containing cardiovascular or renal drugs)
- IT 9005-49-6, Heparin, biological studies  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(SNAC/SNAD; buccal sprays or capsules containing cardiovascular or renal drugs)
- IT 50-78-2, Aspirin 51-06-9, Procainamide 51-30-9, Isoproterenol hydrochloride 54-31-9, Furosemide 56-54-2, Quinidine 57-41-0, Phenytoin 58-00-4, Apomorphine 58-32-2, Dipyrindamole 58-54-8, Ethacrynic acid 58-55-9, Theophylline, biological studies 58-61-7, Adenosine, biological studies 59-41-6, Bretylium 60-87-7, Promethazine 64-17-5, Ethanol, biological studies 65-28-1, Phentolamine mesylate 71-63-6, Digitoxin 74-98-6, Propane, biological studies 75-28-5, Iso-butane 78-11-5, Pentaerythritol tetranitrate 78-78-4, Iso-pentane 81-81-2, Warfarin 86-54-4, Hydralazine 87-33-2, Isosorbide dinitrate

89-25-8, Edaravone 106-97-8, N-Butane, biological studies 109-66-0, N-Pentane, biological studies 114-07-8, Erythromycin 127-31-1, Fludrocortisone 137-58-6, Lidocaine 147-24-0, DiPhenhydramine hydrochloride 303-53-7, Cyclobenzaprine 364-98-7, Diazoxide 463-04-7, Amyl nitrite 463-82-1, Neo-pentane 523-87-5, Dimenhydrinate **525-66-6, Propranolol** 541-15-1, Carnitine 555-30-6, Methyldopa 569-65-3, Meclizine 630-93-3, Phenytoin sodium 745-65-3, Alprostadil 1951-25-3, Amiodarone 3239-44-9, Dexfenfluramine 3737-09-5, Disopyramide **3930-20-9, Sotalol** 4205-90-7, Clonidine 5786-21-0, Clozapine 6493-05-6, Pentoxifylline 7297-25-8, Erythrityl tetranitrate 9041-08-1 10238-21-8, Glyburide **13523-86-9, Pindolol** 15078-28-1, Nitroprusside 19216-56-9, Prazosin 20830-75-5, Digoxin 21829-25-4, Nifedipine 23031-25-6, Terbutaline 23031-32-5, Terbutaline sulfate 25322-68-3, Polyethylene glycol 25717-80-0, Molsidomine 28395-03-1, Bumetanide 29110-47-2, Guanfacine **29122-68-7, Atenolol** **30236-31-8, D-Sotalol** 30516-87-1, Zidovudine 31329-57-4, Naftidrofuryl 31828-71-4, Mexiletine 34368-04-2, Dobutamine 35700-23-3, Carboprost **36894-69-6, Labetalol** 37270-89-6, Nadroparin calcium **37517-30-9, Acebutolol** 38304-91-5, Minoxidil 39562-70-4, Nitrendipine 41708-72-9, Tocainide **42200-33-9, Nadolol** 42399-41-7, Diltiazem 42794-76-3, Midodrine 47931-85-1, Salmon calcitonin 49562-28-9, Fenofibrate **51384-51-1, Metoprolol** 54063-53-5, Propafenone 54143-55-4, Flecainide 55142-85-3, Ticlopidine 55837-25-7, Buflomedil 55985-32-5, Nicardipine 56211-40-6, Torsemide **56980-93-9, Celiprolol** 62571-86-2, Captopril 63590-64-7, Terazosin **63659-18-7, Betaxolol** 63675-72-9, Nisoldipine 64706-54-3, Bepridil 65141-46-0, Nicorandil 66085-59-4, Nimodipine **66722-44-9, Bisoprolol** 67227-56-9, Fenoldopam 70059-30-2, Cimetidine hydrochloride 72509-76-3, Felodipine **72956-09-3, Carvedilol** 73963-72-1, Cilostazol 74191-85-8, Doxazosin 74863-84-6, Argatroban 75438-57-2, Moxonidine 75695-93-1, Isradipine 75847-73-3, Enalapril 76547-98-3, Lisinopril 76824-35-6, Famotidine 78415-72-2, Milrinone 78919-13-8, Iloprost 79517-01-4, Octreotide acetate **81147-92-4, Esmolol** 81403-80-7, Alfuzosin 82956-11-4, Nafamostat mesilate 83647-97-6, Spirapril 85441-61-8, Quinapril 86541-75-5, Benazepril 87333-19-5, Ramipril 87679-37-6, Trandolapril 88069-67-4, Pilsicainide 88150-42-9, Amlodipine 88768-40-5, Cilazapril 89226-50-6, Manidipine 89371-37-9, Imidapril 93107-08-5, Ciprofloxacin hydrochloride 95635-55-5, Ranolazine 98048-97-6, Fosinopril 99614-01-4, Ondansetron hydrochloride 100427-26-7, Lercanidipine 103628-48-4, Sumatriptan succinate 103775-10-6, Moexipril 104713-75-9, Barnidipine 104993-28-4, Fondaparinux 106133-20-4, Tamsulosin 107133-36-8, Perindopril erbumine **107724-20-9, Eplerenone** 110101-66-1, Tirilazad 113665-84-2, Clopidogrel 114798-26-4, Losartan 115256-11-6, Dofetilide 116308-55-5, Vatanidipine 120993-53-5, Desirudin 125926-17-2, Sarpogrelate 128270-60-0, Bivalirudin 133040-01-4, Eprosartan 133107-64-9, Insulin lispro 137862-53-4, Valsartan 138068-37-8, Lepirudin 138402-11-6, Irbesartan 139481-59-7, Candesartan 139755-83-2, Sildenafil 141505-33-1, Levosimendan 143653-53-6, Abciximab 144494-65-5, Tirofiban 144701-48-4, Telmisartan 147536-97-8, Bosentan 159138-80-4, Cariporide 159776-70-2, Melagatran 166518-60-1, Avasimibe 167305-00-2, Omapatrilat 168626-94-6, YM087 171596-29-5, Tadalafil 180384-57-0, Tezosentan 188627-80-7, Eptifibatide 192939-46-1, H376/95 224785-90-4, Vardenafil 516482-86-3, Sermorelin acetate

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(buccal sprays or capsules containing cardiovascular or renal drugs)


IT **525-66-6, Propranolol 3930-20-9, Sotalol 13523-86-9, Pindolol**

29122-68-7, Atenolol 30236-31-8, D-  
Sotalol 36894-69-6, Labetalol  
37517-30-9, Acebutolol 42200-33-9,  
Nadolol 51384-51-1, Metoprolol  
56980-93-9, Celiprolol 63659-18-7,  
Betaxolol 66722-44-9, Bisoprolol  
72956-09-3, Carvedilol 81147-92-4,  
Esmolol 107724-20-9, Eplerenone

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(buccal sprays or capsules containing cardiovascular or renal drugs)


RN 525-66-6 HCAPLUS

CN 2-Propanol, 1-[(1-methylethyl)amino]-3-(1-naphthalenyloxy) - (9CI) (CA  
INDEX NAME)




RN 3930-20-9 HCAPLUS

CN Methanesulfonamide, N-[4-[1-hydroxy-2-[(1-methylethyl)amino]ethyl]phenyl] -  
(9CI) (CA INDEX NAME)




RN 13523-86-9 HCAPLUS

CN 2-Propanol, 1-(1H-indol-4-yloxy)-3-[(1-methylethyl)amino] - (9CI) (CA  
INDEX NAME)



RN 29122-68-7 HCAPLUS


CN Benzeneacetamide, 4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy] - (9CI)  
(CA INDEX NAME)



RN 30236-31-8 HCAPLUS


CN Methanesulfonamide, N-[4-[(1R)-1-hydroxy-2-[(1-methylethyl)amino]ethyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 36894-69-6 HCAPLUS

CN Benzamide, 2-hydroxy-5-[1-hydroxy-2-[(1-methyl-3-phenylpropyl)amino]ethyl]- (9CI) (CA INDEX NAME)




RN 37517-30-9 HCAPLUS

CN Butanamide, N-[3-acetyl-4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 42200-33-9 HCAPLUS

CN 2,3-Naphthalenediol, 5-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)




RN 51384-51-1 HCAPLUS

CN 2-Propanol, 1-[4-(2-methoxyethyl)phenoxy]-3-[(1-methylethyl)amino]- (9CI) (CA INDEX NAME)




RN 56980-93-9 HCAPLUS

CN Urea, N'-[3-acetyl-4-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]phenyl]-N,N-diethyl- (9CI) (CA INDEX NAME)



RN 63659-18-7 HCAPLUS


CN 2-Propanol, 1-[4-[2-(cyclopropylmethoxy)ethyl]phenoxy]-3-[(1-methylethyl)amino]- (9CI) (CA INDEX NAME)



RN 66722-44-9 HCAPLUS

CN 2-Propanol, 1-[4-[[2-(1-methylethoxy)ethoxy]methyl]phenoxy]-3-[(1-methylethyl)amino]- (9CI) (CA INDEX NAME)







RN 72956-09-3 HCAPLUS

CN 2-Propanol, 1-(9H-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]-(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 81147-92-4 HCAPLUS


CN Benzenepropanoic acid, 4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 107724-20-9 HCAPLUS

CN Pregn-4-ene-7,21-dicarboxylic acid, 9,11-epoxy-17-hydroxy-3-oxo-,  
 γ-lactone, methyl ester, (7α,11α,17α)- (9CI) (CA  
 INDEX NAME)

Absolute stereochemistry.



L77 ANSWER 5 OF 7 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 2002:755214 HCAPLUS

DN 137:263024

ED Entered STN: 04 Oct 2002

TI Preparation of N-isoxazolyl biphenylsulfonamides and related compounds as  
 dual angiotensin II and endothelin receptor antagonists.

IN Murugesan, Natesan; Tellew, John E.; Macor, Jhon E.; Gu, Zhengxiang

PA Bristol-Myers Squibb Co., USA

SO U.S. Pat. Appl. Publ., 206 pp., Cont.-in-part of U.S. Ser. No. 643,640,  
 abandoned.

CODEN: USXXCO

DT Patent

LA English

IC ICM A61K031-4166

ICS A61K031-4184; A61K031-4196; C07D233-32; C07D213-68; C07D215-233;  
 C07D249-08

NCL 514258000

CC 28-6 (Heterocyclic Compounds (More Than One Hetero Atom))

Section cross-reference(s): 1


FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002143024	A1	20021003	US 2000-737201	20001214 <--
	US 6638937	B2	20031028		
	US 2004106833	A1	20040603	US 2003-673100	20030926 <--
	US 6835741	B2	20041228		
	US 2004127515	A1	20040701	US 2003-672572	20030926 <--
PRAI	US 1998-91847P	P	19980706	<--	

US 1999-345392	B2	19990701	<--
US 1999-464037	B2	19991215	<--
US 2000-481197	B2	20000111	<--
US 2000-513779	A2	20000225	<--
US 2000-604322	A2	20000626	<--
US 2000-643640	B2	20000822	<--
US 2000-737201	A3	20001214	<--

## CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 2002143024	ICM	A61K031-4166
	ICS	A61K031-4184; A61K031-4196; C07D233-32; C07D213-68; C07D215-233; C07D249-08
	NCL	514258000
US 2002143024	ECLA	C07D261/16; C07D413/14+261+249B+207; C07D413/14+261+213+207; C07D413/14+261+261+235; C07D413/14261+241B+235; C07D413/14+261+235+233; C07D413/14+261+235+213; C07D413/14+261+235+207; C07D413/1+333B+261+235; C07D417/14+285B+261+235; C07D471/04+239B+221B; C07D471/04+235B+221B; C07D487/04+49C+231C; C07D401/12+231+215; C07D403/14+241B+235+207; C07D413/12+261+249B; C07D413/12+261+239; C07D413/12+261+231; C07D413/12+261+213; C07D413/12+261+235C; C07D413/12+261+233; C07D413/12+26+215; C07D413/12+261+235; C07D413/12+271+261; C07D413/12+307B+261
US 2004106833	ECLA	C07D261/16; C07D401/12+231+215; C07D403/14+241B+235+207; C07D413/12+261+213; C07D413/12+261+215; C07D413/12+261+231; C07D413/12+261+233; C07D413/12+261+235; C07D413/12+261+235C; C07D413/12+21+239; C07D413/12+261+249B; C07D413/12+271+261; C07D413/12+307B+261; C07D413/14+261+213+207; C07D413/14+261+235+213; C07D413/14+261+235+233; C07D413/14+261+241B+235; C07D413/14+261+261+235; C07D413/14+333B+261+235; C07D417/14+285B+261+235; C07D471/04+235B+221B; C07D471/04+239B+221B; C07D487/04+249C+231C
US 2004127515	ECLA	C07D261/16; C07D413/14+261+235+207; C07D413/14+333B+261+235; C07D417/14+285B+261+235; C07D471/0+239B+221B; C07D471/04+235B+221B; C07D487/04+249C+231C; C07D401/12+231+215; C07D403/14+241B+235207; C07D413/12+261+249B; C07D413/12+261+239; C07D413/12+261+231; C07D413/12+261+213; C07D413/2+261+235C; C07D413/12+261+233; C07D413/12+261+215; C07D413/12+261+235; C07D413/12+271+261; C07D413/14+261+249B+207; C07D413/14+261+213+207; C07D413/14+261+261+235; C07D013/14+261+241B+235; C07D413/14+261+235+233; C07D413/14+261+235+213
OS	MARPAT 137:263024	
GI		



- AB Title compds. (I; R1 = specified oxoimidazolyl, pyridoimidazolyl, pyridylamino, pyridyloxy, triazolyl, quinolinyl, etc.; R2 = H, halo, CHO, (halo)alkyl, cycloalkylalkyl, alkenyl, alkynyl, alkoxyalkyl, alkoxy, cyano, OH, NO<sub>2</sub>, etc.; R3 = heteroaryl; R101-R104 = H, halo, CHO, alkyl, haloalkyl, cycloalkylalkyl, alkenyl, alkynyl, alkoxyalkyl, haloalkoxyalkyl, alkoxy, alkoxyalkoxy, cyano, OH, hydroxyalkyl, NO<sub>2</sub>, etc; with provisos) were prepared as dual angiotensin II and endothelin receptor antagonists for treatment of hypertension and other diseases (no data). Thus, 4-BrC<sub>6</sub>H<sub>4</sub>CH<sub>2</sub>OH was coupled with [2-[(4,5-dimethyl-3-isoxazolyl)](2-methoxyethoxy)methyl]amino)sulfonyl]phenyl]boronic acid to give N-(4,5-dimethyl-3-isoxazolyl)-4'-(hydroxymethyl)-N-[(2-methoxyethoxy)methyl][1,1'-biphenyl]-2-sulfonamide (66%). This was brominated to give the 4'-bromomethyl derivative (90%), reacted with 2-butyl-1,3-diazaspiro[4.4]non-1-en-4-one hydrochloride, and deprotected (49% for two steps) to give 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-[1,1'-biphenyl]-2-sulfonamide.
- ST isoxazolyl biphenylsulfonamide prepn angiotensin endothelin receptor antagonist; diazaspirononemethylmethylisoxazolylbiphenylsulfonamide prepn angiotensin endothelin receptor antagonist; antihypertensive biphenylsulfonamide prepn
- IT Angiotensin receptors  
RL: BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study)  
(angiotensin II, antagonists; preparation of N-isoxazolyl biphenylsulfonamides and related compds. as dual angiotensin II and endothelin receptor antagonists)
- IT Endothelin receptors  
RL: BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study)  
(antagonists; preparation of N-isoxazolyl biphenylsulfonamides and related compds. as dual angiotensin II and endothelin receptor antagonists)
- IT Antiarteriosclerotics  
(antiatherosclerotics; preparation of N-isoxazolyl biphenylsulfonamides and related compds. as dual angiotensin II and endothelin receptor antagonists)
- IT Prostate gland, disease  
(benign hyperplasia, treatment; preparation of N-isoxazolyl biphenylsulfonamides and related compds. as dual angiotensin II and endothelin receptor antagonists)
- IT Meninges  
(disease, subarachnoid hemorrhage, treatment; preparation of N-isoxazolyl biphenylsulfonamides and related compds. as dual angiotensin II and endothelin receptor antagonists)
- IT Sexual behavior  
(disorder, treatment of female; preparation of N-isoxazolyl biphenylsulfonamides and related compds. as dual angiotensin II and

- endothelin receptor antagonists)
- IT Heart, disease  
Kidney, disease  
(failure, treatment; preparation of N-isoxazolyl biphenylsulfonamides and related compds. as dual angiotensin II and endothelin receptor antagonists)
- IT Sexual behavior  
(impotence, treatment; preparation of N-isoxazolyl biphenylsulfonamides and related compds. as dual angiotensin II and endothelin receptor antagonists)
- IT Antiasthmatics  
Antihypertensives  
Antimigraine agents  
Antitumor agents  
Human  
(preparation of N-isoxazolyl biphenylsulfonamides and related compds. as dual angiotensin II and endothelin receptor antagonists)
- IT Growth inhibitors, animal  
RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of N-isoxazolyl biphenylsulfonamides and related compds. as dual angiotensin II and endothelin receptor antagonists)
- IT Artery, disease  
(restenosis, treatment; preparation of N-isoxazolyl biphenylsulfonamides and related compds. as dual angiotensin II and endothelin receptor antagonists)
- IT Atherosclerosis  
Endotoxemia  
Hypertension  
Ischemia  
(treatment; preparation of N-isoxazolyl biphenylsulfonamides and related compds. as dual angiotensin II and endothelin receptor antagonists)
- IT 62571-86-2, Captopril 74258-86-9, Alacepril 75847-73-3, Enalapril 76547-98-3, Lisinopril 81872-10-8, Zofenopril 82924-03-6, Pentopril 83435-66-9, Delapril 85441-61-8, Quinapril 87333-19-5, Ramipril 98048-97-6, Fosinopril 111223-26-8, Ceranapril 160135-92-2, Gemopatrilat 167305-00-2, Omapatrilat  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(coadministration; preparation of N-isoxazolyl biphenylsulfonamides and related compds. as dual angiotensin II and endothelin receptor antagonists)
- IT 254737-84-3P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-  
254737-85-4P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-2'-[(methylamino)methyl]-  
254737-86-5P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-2'-formyl-  
254737-87-6P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-  
254737-88-7P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-2'-[(3-methyl-2-oxo-1-imidazolidinyl)methyl]-  
254737-89-8P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-N-pyrazinyl-  
254737-90-1P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3-chloropyrazinyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-  
254737-91-2P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-2'-[(2-oxo-1-pyrrolidinyl)methyl]-  
254737-92-3P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[(3,3-

dimethyl-2-oxo-1-pyrrolidinyl)methyl]-N-(3,6-dimethylpyrazinyl)-  
 254737-94-5P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-N-(3-methoxypyrazinyl)- 254737-96-7P,  
 [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-formyl- 254737-98-9P,  
 [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-[(2-oxo-1-pyrrolidinyl)methyl]- 254738-00-6P, Pentanamide, N-[[2'-[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl)methyl]-N-[(1S)-2-methyl-1-(3-methyl-1,2,4-oxadiazol-5-yl)propyl]- 254738-03-9P,  
 [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]- 254738-05-1P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[[2-(2-methoxyethyl)-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)- 254738-06-2P,  
 [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-[[2-(ethoxymethyl)-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]- 254738-07-3P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-2'-[(2-oxo-1-pyrrolidinyl)methyl]- 254738-09-5P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-2'-[(3-methyl-2-oxo-1-imidazolidinyl)methyl]- 254738-10-8P, Pentanamide, N-[[2'-[(3-methyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl)methyl]-N-[(1S)-2-methyl-1-[(methylamino)carbonyl]propyl]- 254738-11-9P, Pentanamide, N-[[2'-[(4-bromo-3-methyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl)methyl]-N-[(1S)-2-methyl-1-[(methylamino)carbonyl]propyl]- 254738-12-0P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-2'-propyl- 254738-13-1P, 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl)methyl]-2-ethoxy-, methyl ester 254738-14-2P, 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl)methyl]-2-ethoxy- 254738-15-3P, 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl)methyl]-2-ethyl-, methyl ester 254738-16-4P, 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl)methyl]-2-ethyl- 254738-17-5P, 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]-2-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl][1,1'-biphenyl]-4-yl)methyl]-2-ethoxy-, methylester 254738-18-6P, 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]-2-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl][1,1'-biphenyl]-4-yl)methyl]-2-ethoxy- 254738-19-7P, 1H-Benzimidazole-7-carboxamide, 1-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]-2-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl][1,1'-biphenyl]-4-yl)methyl]-2-ethoxy-N-methyl- 254738-20-0P, 1H-Benzimidazole-7-carboxamide, 1-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]-2-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl][1,1'-biphenyl]-4-yl)methyl]-2-ethoxy-N,N-dimethyl- 254738-21-1P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[[2-ethyl-4-quinolinyl)oxy]methyl]-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)- 254738-22-2P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(5-acetyl-4-chloro-2-propyl-1H-imidazol-1-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)- 254738-23-3P, 1H-Imidazole-5-carboxylic acid, 4-chloro-1-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl)methyl]-2-propyl-, methyl ester 254738-24-4P, 1H-Imidazole-5-carboxamide, 1-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl)methyl]-4-ethyl-N-dimethyl-2-propyl- 254738-25-5P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-2'-(hydroxymethyl)- 254738-26-6P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-

en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-2'-(ethoxymethyl)-  
254738-27-7P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-  
diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-2'-(2-  
methoxyethyl)- 254738-28-8P, [1,1'-Biphenyl]-2-sulfonamide,  
4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[(3,3-  
dimethyl-2-oxo-1-pyrrolidinyl)methyl]-N-(3-methoxy-5-methylpyrazinyl)-  
254738-29-9P, [1,1'-Biphenyl]-2-sulfonamide, N-(4-bromo-3-methyl-5-  
isoxazolyl)-4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-  
[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]- 254738-30-2P,  
[1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-  
en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-2'-  
[(formylmethylamino)methyl]- 254738-31-3P, Propanamide,  
N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[(3,4-  
dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl)methyl]-N-methyl-  
254738-32-4P, Cyclopropanecarboxamide, N-[[4-[(2-butyl-4-oxo-1,3-  
diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[(3,4-dimethyl-5-  
isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl)methyl]-N-methyl-  
254738-33-5P, Propanamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-  
en-3-yl)methyl]-2'-[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-  
biphenyl]-2-yl)methyl]-N,2-dimethyl- 254738-34-6P, Butanamide,  
N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[(3,4-  
dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl)methyl]-N-methyl-  
254738-35-7P, Acetamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-  
en-3-yl)methyl]-2'-[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-  
biphenyl]-2-yl)methyl]-2-methoxy-N-methyl- 254738-36-8P, 4-Pentynamide,  
N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[(3,4-  
dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl)methyl]-N-methyl-  
254738-37-9P, Cyclobutanecarboxamide, N-[[4-[(2-butyl-4-oxo-1,3-  
diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[(3,4-dimethyl-5-  
isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl)methyl]-N-methyl-  
254738-38-0P, Butanamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-  
en-3-yl)methyl]-2'-[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-  
biphenyl]-2-yl)methyl]-N,3-dimethyl- 254738-39-1P, Propanamide,  
N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[(3,4-  
dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl)methyl]-N,2,2-  
trimethyl- 254738-40-4P, Propanamide, N-[[4-[(2-butyl-4-oxo-1,3-  
diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[(3,4-dimethyl-5-  
isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl)methyl]-3-methoxy-N-methyl-  
254738-41-5P, Acetamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-  
3-yl)methyl]-2'-[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-  
biphenyl]-2-yl)methyl]-2-ethoxy-N-methyl- 254738-42-6P,  
2-Furancarboxamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-  
yl)methyl]-2'-[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-  
2-yl)methyl]-N-methyl- 254738-43-7P, Pentanamide, N-[[4-[(2-butyl-4-oxo-  
1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[(3,4-dimethyl-5-  
isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl)methyl]-N,4-dimethyl-  
254738-44-8P, Benzamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-  
3-yl)methyl]-2'-[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-  
biphenyl]-2-yl)methyl]-N-methyl- 254738-45-9P, 3-Thiophenecarboxamide,  
N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[(3,4-  
dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl)methyl]-N-methyl-  
254738-46-0P, Cyclopentaneacetamide, N-[[4-[(2-butyl-4-oxo-1,3-  
diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[(3,4-dimethyl-5-  
isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl)methyl]-N-methyl-  
254738-47-1P, Cyclohexanecarboxamide, N-[[4-[(2-butyl-4-oxo-1,3-  
diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[(3,4-dimethyl-5-  
isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl)methyl]-N-methyl-  
254738-48-2P, Benzamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-  
3-yl)methyl]-2'-[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-  
biphenyl]-2-yl)methyl]-N,3-dimethyl- 254738-49-3P, Benzeneacetamide,  
N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[(3,4-  
dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl)methyl]-N-methyl-  
254738-50-6P, Benzamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-

en-3-yl)methyl]-2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl)methyl]-2-fluoro-N-methyl- 254738-51-7P, Benzamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl)methyl]-3-fluoro-N-methyl- 254738-52-8P, Benzamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl)methyl]-4-fluoro-N-methyl-254738-53-9P, Cyclohexaneacetamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl)methyl]-N-methyl-254738-54-0P, Benzeneacetamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl)methyl]-2-fluoro-N-methyl-254738-55-1P, Benzeneacetamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl)methyl]-3-fluoro-N-methyl-254738-56-2P, Benzeneacetamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl)methyl]-4-fluoro-N-methyl-254738-57-3P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[[(dimethylamino)carbonyl]methylamino]methyl]-N-(3,4-dimethyl-5-isoxazolyl)- 254738-58-4P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[[(1,1-dimethylethyl)amino]carbonyl]methylamino]methyl]-N-(3,4-dimethyl-5-isoxazolyl)- 254738-59-5P, Carbamic acid, [[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl)methyl]methyl-, ethyl ester 254738-60-8P, Carbamic acid, [[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl)methyl]methyl-, 2-methylpropyl ester 254738-61-9P, Butanamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl)methyl]-N,3,3-trimethyl-254738-62-0P, 2-Pyridinecarboxamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl)methyl]-N-methyl-254738-63-1P, 3-Pyridinecarboxamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl)methyl]-N-methyl-254738-64-2P, Pyrazinecarboxamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl)methyl]-N-methyl-254738-65-3P, 1H-Pyrrole-2-carboxamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl)methyl]-N,1-dimethyl-254738-66-4P, 1,2,3-Thiadiazole-4-carboxamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl)methyl]-N-methyl-254738-67-5P, Pyrazinecarboxamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl)methyl]-N,5-dimethyl-254738-68-6P, 4-Isoxazolecarboxamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl)methyl]-N,3,5-trimethyl-254738-69-7P, 2-Thiophenecarboxamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl)methyl]-N,3-dimethyl-254738-70-0P, 2-Thiophenecarboxamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl)methyl]-N,5-dimethyl-254738-71-1P, Benzamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl)methyl]-3-cyano-N-methyl- 254738-72-2P, Benzamide,



N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl)methyl]-4-cyano-N-methyl- 254738-73-3P, Benzamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl)methyl]-2-methoxy-N-methyl- 254738-74-4P, Benzamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl)methyl]-2-chloro-N-methyl- 254738-75-5P, Benzamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl)methyl]-3-chloro-N-methyl- 254738-76-6P, Benzamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl)methyl]-4-chloro-N-methyl- 254738-78-8P, Benzamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl)methyl]-2,3-difluoro-N-methyl- 254738-79-9P, Benzamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl)methyl]-3,4-difluoro-N-methyl- 254738-80-2P, Benzamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl)methyl]-3,5-difluoro-N-methyl- 254738-81-3P, Benzamide, 4-acetyl-N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl)methyl]-N-methyl- 254738-82-4P, 2-Thiophenecarboxamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl)methyl]-3-ethoxy-N-methyl- 254738-83-5P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)- 254738-84-6P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-2'-[(propylsulfonyl)amino]- 254738-85-7P, L-Valine, N-[[2'-[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl)methyl]-N-(1-oxopentyl)-, methyl ester 254738-86-8P, L-Valine, N-[[2'-[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl)methyl]-N-(1-oxopentyl)- 254738-87-9P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-[(4-oxo-2-propyl-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]- 254738-88-0P, Butanamide, N-[[2'-[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]-4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl][1,1'-biphenyl]-2-yl)methyl]-N,3,3-trimethyl- 254738-89-1P, Pentanamide, N-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-N-[[2'-[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl)methyl]- 254738-90-4P, Pentanamide, N-[[2'-[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl)methyl]-N-[(1S)-2-methyl-1-[(methylamino)carbonyl]propyl]- 254738-91-5P, Pentanamide, N-[(1S)-1-[(dimethylamino)carbonyl]-2-methylpropyl]-N-[[2'-[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl)methyl]- 254738-92-6P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-2'-[(2,2,2-trifluoroethyl)amino]methyl]- 254738-93-7P, [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]- 254738-94-8P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-2'-(trifluoromethyl)- 254738-95-9P, [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]-, methyl ester 254738-96-0P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-2'-(methoxymethyl)- 254738-97-1P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-2'-fluoro- 254738-98-2P, [1,1'-Biphenyl]-2-sulfonamide, 2'-(cyanomethyl)-N-(3,4-dimethyl-5-isoxazolyl)-4'-[(2-ethyl-5,7-dimethyl-

3H-imidazo[4,5-b]pyridin-3-yl)methyl]- 254738-99-3P,  
[1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-(cyanomethyl)-N-(3,4-dimethyl-5-isoxazolyl)-  
254739-00-9P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-cyano-N-(3,4-dimethyl-5-isoxazolyl)- 254739-01-0P, [1,1'-Biphenyl]-2-sulfonamide,  
4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-2'-methyl- 254739-02-1P, [1,1'-Biphenyl]-2-sulfonamide, 2'-cyano-N-(3,4-dimethyl-5-isoxazolyl)-4'-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]- 254739-03-2P,  
Pentanamide, N-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]-2-methyl[1,1'-biphenyl]-4-yl)methyl]-N-[(1S)-2-methyl-1-[(methylamino)carbonyl]propyl]- 254739-04-3P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-2'-[[2,2,2-trifluoroethyl)amino]methyl]- 254739-05-4P, Benzeneacetamide,  
N-[4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]- 254739-06-5P, Butanamide, N-[4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]-3,3-dimethyl-  
254739-07-6P, [1,1'-Biphenyl]-2-sulfonamide, 2'-amino-4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)- 254739-08-7P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-2'-nitro- 254739-09-8P, Pentanamide, 2-[[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl)methyl](1-oxopropyl)amino]-N,3-dimethyl-, (2S,3S)- 254739-10-1P, Cyclopropanecarboxamide,  
N-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl)methyl]-N-[(1S,2S)-2-methyl-1-[(methylamino)carbonyl]butyl]- 254739-11-2P, Benzenepropanamide, N-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl)methyl]-N-[(1S,2S)-2-methyl-1-[(methylamino)carbonyl]butyl]- 254739-12-3P, Pentanamide,  
2-[[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl)methyl](3-methyl-1-oxobutyl)amino]-N,3-dimethyl-, (2S,3S)- 254739-13-4P, Hexanamide, N-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl)methyl]-N-[(1S,2S)-2-methyl-1-[(methylamino)carbonyl]butyl]- 254739-14-5P, Pentanamide,  
2-[[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl)methyl](1-oxobutyl)amino]-N,3-dimethyl-, (2S,3S)- 254739-15-6P, Pentanamide, 2-[[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl)methyl](1-oxopropyl)amino]-N,4-dimethyl-, (2S)- 254739-16-7P, Cyclopropanecarboxamide, N-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl)methyl]-N-[(1S)-3-methyl-1-[(methylamino)carbonyl]butyl]- 254739-17-8P, Benzenepropanamide,  
N-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl)methyl]-N-[(1S)-3-methyl-1-[(methylamino)carbonyl]butyl]- 254739-18-9P, Benzeneacetamide, N-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl)methyl]-N-[(1S)-3-methyl-1-[(methylamino)carbonyl]butyl]- 254739-19-0P, Pentanamide,  
2-[[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl)methyl](3-methyl-1-oxobutyl)amino]-N,4-dimethyl-, (2S)- 254739-20-3P, Hexanamide, N-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl)methyl]-N-[(1S)-3-methyl-1-[(methylamino)carbonyl]butyl]- 254739-21-4P, Pentanamide, 2-[[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl)methyl](1-oxobutyl)amino]-N,4-dimethyl-, (2S)- 254739-22-5P, Butanamide, 2-[[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl)methyl](1-oxopropyl)amino]-N,3-dimethyl-, (2S)- 254739-23-6P, Cyclopropanecarboxamide,  
N-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl)methyl]-N-[(1S)-2-methyl-1-[(methylamino)carbonyl]propyl]- 254739-24-7P, Benzenepropanamide, N-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl)methyl]-N-[(1S)-2-methyl-1-

[(methylamino)carbonyl]propyl]- 254739-25-8P, Benzeneacetamide, N-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-N-[(1S)-2-methyl-1-[(methylamino)carbonyl]propyl]- 254739-26-9P, Butanamide, 2-[[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl](3-methyl-1-oxobutyl)amino]-N,3-dimethyl-, (2S)- 254739-27-0P, Hexanamide, N-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-N-[(1S)-2-methyl-1-[(methylamino)carbonyl]propyl]- 254739-28-1P, Butanamide, 2-[[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl](1-oxobutyl)amino]-N,3-dimethyl-, (2S)- 254739-29-2P, Pentanamide, N-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-N-[(1S)-1-[(ethylamino)carbonyl]-2-methylpropyl]- 254739-30-5P, Pentanamide, N-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-N-[(1S)-1-[(hexylamino)carbonyl]-2-methylpropyl]- 254739-31-6P, Pentanamide, N-[[2'-cyano-2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-N-[(1S)-2-methyl-1-[(methylamino)carbonyl]propyl]- 254739-32-7P, Pentanamide, N-[[2-(cyanomethyl)-2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-N-[(1S)-2-methyl-1-[(methylamino)carbonyl]propyl]- 254739-33-8P, [1,1'-Biphenyl]-2-carboxamide, 4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]- 254739-34-9P, [1,1'-Biphenyl]-2-carboxamide, 4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]-N,N-dimethyl- 254739-35-0P, [1,1'-Biphenyl]-2-carboxamide, 4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]-N-methyl- 254739-36-1P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-(methoxymethyl)-4'-[(5,6,7,8-tetrahydro-8-oxo-2-propyl-1(4H)-cycloheptimidazolyl)methyl]- 254739-37-2P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-[[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]-2'-methyl- 254739-38-3P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-methyl-4'-[(5,6,7,8-tetrahydro-8-oxo-2-propyl-1(4H)-cycloheptimidazolyl)methyl]- 254739-39-4P, Butanamide, 2-[[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]-2-(methoxymethyl)[1,1'-biphenyl]-4-yl]methyl](1-oxobutyl)amino]-N,3-dimethyl-, (2S)- 254739-40-7P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-(hydroxymethyl)-4'-[(5,6,7,8-tetrahydro-8-oxo-2-propyl-1(4H)-cycloheptimidazolyl)methyl]- 254739-41-8P, [1,1'-Biphenyl]-2-sulfonamide, 2'-chloro-N-(3,4-dimethyl-5-isoxazolyl)-4'-[[[(2-ethyl-5,6,7,8-tetrahydro-4-quinolinyl)oxy]methyl]- 254739-42-9P, Butanamide, 2-[[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]-2-fluoro[1,1'-biphenyl]-4-yl]methyl](1-oxobutyl)amino]-N,3-dimethyl-, (2S)- 254739-43-0P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-2'-(phenoxymethyl)- 254739-44-1P, Butanamide, 2-[[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]-2-(1H-pyrazol-1-yl)methyl][1,1'-biphenyl]-4-yl]methyl](1-oxobutyl)amino]-N,3-dimethyl-, (2S)- 254739-45-2P, Cyclopropanecarboxamide, N-[(1S)-1-[(dimethylamino)carbonyl]-2-methylpropyl]-N-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]- 254739-46-3P, Butanamide, 2-[[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl](1-oxobutyl)amino]-N,N,3-trimethyl-, (2S)- 254739-47-4P, Cyclopropanecarboxamide, N-[(1S)-1-[(dimethylamino)carbonyl]-2-methylpropyl]-N-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]-2-(methoxymethyl)[1,1'-biphenyl]-4-yl]methyl]- 254739-48-5P, Butanamide, 2-[[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]-2-(methoxymethyl)[1,1'-biphenyl]-4-yl]methyl](1-oxobutyl)amino]-N,N,3-trimethyl-, (2S)- 254739-49-6P, Pentanamide, N-[[2-chloro-2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-N-[(1S)-2-methyl-1-[(methylamino)carbonyl]propyl]- 254739-50-9P, Pentanamide, N-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]-2-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]-N-[(1S)-2-methyl-1-

[(methylamino)carbonyl]propyl]- 254739-51-0P, Cyclobutanecarboxamide, N-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-N-[(1S)-2-methyl-1-[(methylamino)carbonyl]propyl]- 254739-52-1P, 1H-Imidazole-5-carboxylic acid, 1-[[2-chloro-2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-4-ethyl-2-propyl]- 254739-53-2P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-2'-[(methylsulfonyl)amino]- 254739-54-3P, Pentanamide, N-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-N-[(1S)-2-methyl-1-[(4-methyl-1-piperazinyl)carbonyl]propyl]- 254739-55-4P, Pentanamide, N-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-N-[(1S)-2-methyl-1-(1-piperidinylcarbonyl)propyl]- 254739-56-5P, Pentanamide, N-[(1S)-1-[[[(3,3-dimethylbutyl)amino]carbonyl]-2-methylpropyl]-N-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]- 254739-57-6P, Pentanamide, N-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-N-[(1S)-1-[[[(4-fluorophenyl)methyl]amino]carbonyl]-2-methylpropyl]- 254739-58-7P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-2'-[(1-methylethoxy)methyl]-  
 RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of N-isoxazolyl biphenylsulfonamides and related compds. as dual angiotensin II and endothelin receptor antagonists)

IT 254739-59-8P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-2'-(propoxymethyl)- 254739-60-1P, 1H-Imidazole-5-carboxamide, 4-chloro-1-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-propyl]- 254739-61-2P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-fluoro-4'-[(5,6,7,8-tetrahydro-8-oxo-2-propyl-1(4H)-cycloheptimidazolyl)methyl]- 254739-62-3P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-2'-[(2-oxo-1(2H)-pyridinyl)methyl]- 254739-63-4P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-2'-(1H-pyrazol-1-yl)methyl)- 254739-64-5P, 1H-Imidazole-5-carboxamide, 2-butyl-4-chloro-1-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]- 254739-65-6P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-[[[(2-methyl-4-quinolinyl)oxy]methyl]- 254739-66-7P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-[[[(2-ethyl-4-quinolinyl)oxy]methyl]- 254739-67-8P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-[[[(2-ethyl-5,6,7,8-tetrahydro-4-quinolinyl)oxy]methyl]- 254739-68-9P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-[[[(2-propyl-4-quinolinyl)oxy]methyl]- 254739-69-0P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(6,7-dihydro-2,4-dimethyl-7-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)- 254739-70-3P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-[[[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-[[[(2-ethyl-4-quinolinyl)oxy]methyl]- 254739-71-4P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-[[[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-[[[(2-ethyl-5,6,7,8-tetrahydro-4-quinolinyl)oxy]methyl]- 254739-72-5P, 1H-Benzimidazole-7-carboxamide, 1-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethyl-N-methyl- 254739-73-6P, 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethyl-, phenylmethyl ester 254739-74-7P, 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethyl-, 2-phenylethyl ester 254739-75-8P, 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-

yl)methyl]-2-ethyl-, 2-(2-oxo-1-pyrrolidinyl)ethyl ester 254739-76-9P,  
1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl)methyl]-2-ethyl-,  
3-(2-oxo-1-pyrrolidinyl)propyl ester 254739-77-0P, [1,1'-Biphenyl]-2-sulfonamide, 2'-cyano-N-(3,4-dimethyl-5-isoxazolyl)-4'-[[2-ethyl-4-quinolinyl]oxy)methyl]- 254739-79-2P, [1,1'-Biphenyl]-2-sulfonamide, 2'-(cyanomethyl)-N-(3,4-dimethyl-5-isoxazolyl)-4'-[(5,6,7,8-tetrahydro-8-oxo-2-propyl-1(4H)-cycloheptimidazolyl)methyl]- 254739-80-5P,  
1H-Imidazole-5-carboxamide, 1-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl)methyl]-4-ethyl-N-methyl-2-propyl- 254739-81-6P, 1H-Imidazole-5-carboxamide, 1-[[2-chloro-2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl)methyl]-4-ethyl-2-propyl- 254739-82-7P, 1H-Imidazole-5-carboxamide, 1-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl)methyl]-4-ethyl-2-propyl- 254739-83-8P, 1H-Benzimidazole-7-carboxamide, 1-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl)methyl]-2-ethoxy-N-methyl- 254739-84-9P, 1H-Benzimidazole-7-carboxamide, 1-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl)methyl]-2-ethoxy-N,N-dimethyl- 254739-85-0P,  
3-Pyridinecarboxylic acid, 2-[[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl)methyl]propylamino]- 254739-86-1P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(3,5-dibutyl-1H-1,2,4-triazol-1-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)- 254739-87-2P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-[(5,6,7,8-tetrahydro-8-oxo-2-propyl-1(4H)-cycloheptimidazolyl)methyl]- 254739-88-3P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2,7-diethyl-5H-pyrazolo[1,5-b][1,2,4]triazol-5-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)- 254739-89-4P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[[2-butyl-6-[[[methyl(1-methylethyl)amino]carbonyl]amino]-4-oxo-3(4H)-quinazolinyl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)- 254739-90-7P, 3-Pyridinecarboxamide, 2-[[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl)methyl]propylamino]-N-methyl- 254739-91-8P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-[[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy)methyl]- 254739-92-9P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-[[[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-[[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy)methyl]-2'-[(methoxymethyl)- 254739-93-0P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-[[[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-[[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy)methyl]-2'-[(methoxymethyl)- 254739-95-2P, 1H-Imidazole-5-carboxamide, 1-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl)methyl]-2-ethyl-4-methyl- 254739-96-3P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-3(4H)-quinazolinyl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)- 254739-97-4P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]- 254739-98-5P, Pentanamide, N-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]-2-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl][1,1'-biphenyl]-4-yl)methyl]-N-[(1S)-2-methyl-1-[(methylamino)carbonyl]propyl]- 254739-99-6P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-2'-[[4,4-dimethyl-2-oxo-1-pyrrolidinyl)methyl]- 254740-00-6P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(3,5-dibutyl-1H-1,2,4-triazol-1-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-2'-[[[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]- 254740-01-7P, Acetamide, N-[2-[[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]-4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl][1,1'-biphenyl]-2-yl)methyl]methylamino]ethyl]- 254740-02-8P, [1,1'-Biphenyl]-2-acetic acid, 2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]-4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-, ethyl ester 254740-03-9P, Pentanamide, N-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-

yl)methyl]-N-[(1S)-2-methyl-1-[(propylamino)carbonyl]propyl]-  
254740-04-0P, Pentanamide, N-[[2'-[(3,4-dimethyl-5-  
isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl)methyl]-N-[(1S)-2-methyl-1-  
[[[(tetrahydro-2-furanyl)methyl]amino]carbonyl]propyl]- 254740-05-1P,  
[1,1'-Biphenyl]-2-sulfonamide, 2'-chloro-N-(3,4-dimethyl-5-isoxazolyl)-4'-  
[[2-ethyl-4-quinolinyl]oxy]methyl]- 254740-06-2P, [1,1'-Biphenyl]-2-  
sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-[[2-ethyl-4-  
quinolinyl]oxy]methyl]-2'-(trifluoromethyl)- 254740-07-3P,  
[1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-  
en-3-yl)methyl]-2'-chloro-N-(3,4-dimethyl-5-isoxazolyl)- 254740-08-4P,  
[1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-  
en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-2'-[(2-methylpropoxy)methyl]-  
254740-09-5P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-  
diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-2'-  
[(ethylsulfonyl)amino]- 254740-10-8P, [1,1'-Biphenyl]-2-sulfonamide,  
4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3,4-  
dimethyl-5-isoxazolyl)-2'-[(2,2,2-trifluoroethoxy)methyl]- 254740-11-9P,  
[1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-  
en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-2'-[(2-fluoroethoxy)methyl]-  
254740-12-0P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-  
2'-(ethoxymethyl)-4'-[[3-methoxy-2,6-dimethyl-4-pyridinyl]oxy]methyl]-  
254740-15-3P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-  
2'-(ethoxymethyl)-4'-[(5,6,7,8-tetrahydro-8-oxo-2-propyl-1(4H)-  
cycloheptimidazolyl)methyl]- 254740-18-6P, [1,1'-Biphenyl]-2-  
sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-  
(3,4-dimethyl-5-isoxazolyl)-2'-(3,3,3-trifluoropropyl)- 254740-20-0P,  
[1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-  
en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-2'-(3-fluoropropyl)-  
254740-21-1P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-  
diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-(1,1-difluoroethyl)-N-(3,4-  
dimethyl-5-isoxazolyl)- 254740-22-2P, [1,1'-Biphenyl]-2-sulfonamide,  
4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3,4-  
dimethyl-5-isoxazolyl)-2'-(2,2,2-trifluoroethyl)- 254740-23-3P,  
[1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-  
en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-2'-(2-methylpropoxy)-  
254740-24-4P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-  
diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-2'-(2-  
methoxyethoxy)- 254740-25-5P, [1,1'-Biphenyl]-2-sulfonamide,  
2'-butyl-4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-  
(3,4-dimethyl-5-isoxazolyl)- 254740-26-6P, [1,1'-Biphenyl]-2-  
sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-  
(3-methyl-5-isoxazolyl)-2'-(trifluoromethyl)- 254740-27-7P,  
[1,1'-Biphenyl]-2-sulfonamide, N-(4-bromo-3-methyl-5-isoxazolyl)-4'-[(2-  
butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-(trifluoromethyl)-  
254740-28-8P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-  
diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4-chloro-3-methyl-5-isoxazolyl)-2'-  
(trifluoromethyl)- 254740-29-9P, [1,1'-Biphenyl]-2-sulfonamide,  
4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3,4-  
dimethyl-5-isoxazolyl)-2'-[(methoxymethylamino)methyl]- 254740-30-2P,  
[1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-  
en-3-yl)methyl]-2'-[(2,2-difluoroethoxy)methyl]-N-(3,4-dimethyl-5-  
isoxazolyl)- 254740-31-3P, [1,1'-Biphenyl]-2-sulfonamide,  
4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3,4-  
dimethyl-5-isoxazolyl)-2'-(2-fluoroethyl)- 254740-32-4P,  
[1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-  
en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-2'-(2-hydroxyethyl)-  
254740-33-5P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-  
diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-2'-(3-  
methylbutyl)- 254740-34-6P, [1,1'-Biphenyl]-2-sulfonamide,  
4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3,4-  
dimethyl-5-isoxazolyl)-2'-(2-methylpropyl)- 254740-35-7P,  
[1,1'-Biphenyl]-2-sulfonamide, 4'-[[2-(3,3-difluorobutyl)-4-oxo-1,3-  
diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-2'-

(ethoxymethyl)- 254740-36-8P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-[[[3-methoxy-2,6-dimethyl-4-pyridinyl]oxy]methyl]-2'-(3,3,3-trifluoropropyl)- 254740-37-9P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[(1,1-dimethylethoxy)methyl]-N-(3,4-dimethyl-5-isoxazolyl)- 254740-38-0P, 1H-Imidazole-5-carboxamide, 1-[[2'-[[[3,4-dimethyl-5-isoxazolyl]amino]sulfonyl]-2-(methoxymethyl)[1,1'-biphenyl]-4-yl]methyl]-4-ethyl-2-propyl- 254740-39-1P, 1H-Imidazole-5-carboxamide, 1-[[2'-[[[3,4-dimethyl-5-isoxazolyl]amino]sulfonyl]-2-(methoxymethyl)[1,1'-biphenyl]-4-yl]methyl]-4-ethyl-N-methyl-2-propyl- 254740-40-4P, 1H-Imidazole-5-carboxamide, 1-[[2'-[[[3,4-dimethyl-5-isoxazolyl]amino]sulfonyl]-2-methyl[1,1'-biphenyl]-4-yl]methyl]-4-ethyl-2-propyl- 254740-41-5P, 1H-Imidazole-5-carboxamide, 1-[[2'-[[[3,4-dimethyl-5-isoxazolyl]amino]sulfonyl]-2-methyl[1,1'-biphenyl]-4-yl]methyl]-4-ethyl-N-methyl-2-propyl- 254740-42-6P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-[(methyldiamino)methyl]- 254740-43-7P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3-methyl-2-oxo-1-imidazolidinyl)methyl]- 254740-44-8P, Pentanamide, N-[[2'-[[[4,5-dimethyl-3-isoxazolyl]amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-N-[(1S)-2-methyl-1-(3-methyl-1,2,4-oxadiazol-5-yl)propyl]- 254740-45-9P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]- 254740-46-0P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-4'-[[2-(2-methoxyethyl)-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl]methyl]- 254740-47-1P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-4'-[[2-(ethoxymethyl)-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl]methyl]- 254740-48-2P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-4'-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-2'-[(2-oxo-1-pyrrolidinyl)methyl]- 254740-49-3P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-4'-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-2'-[(3-methyl-2-oxo-1-imidazolidinyl)methyl]- 254740-50-6P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-propyl- 254740-51-7P, 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[4,5-dimethyl-3-isoxazolyl]amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-, methyl ester 254740-52-8P, 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[4,5-dimethyl-3-isoxazolyl]amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy- 254740-53-9P, 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[4,5-dimethyl-3-isoxazolyl]amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethyl-, methyl ester 254740-54-0P, 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[4,5-dimethyl-3-isoxazolyl]amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethyl- 254740-55-1P, 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[4,5-dimethyl-3-isoxazolyl]amino]sulfonyl]-2-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-, methylester 254740-56-2P, 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[4,5-dimethyl-3-isoxazolyl]amino]sulfonyl]-2-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy- 254740-57-3P, 1H-Benzimidazole-7-carboxamide, 1-[[2'-[[[4,5-dimethyl-3-isoxazolyl]amino]sulfonyl]-2-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-N-methyl- 254740-58-4P, 1H-Benzimidazole-7-carboxamide, 1-[[2'-[[[4,5-dimethyl-3-isoxazolyl]amino]sulfonyl]-2-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-N,N-dimethyl- 254740-59-5P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[[2-ethyl-4-quinolinyl]oxy]methyl]-N-(3-methyl-5-isoxazolyl)- 254740-60-8P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(5-acetyl-4-chloro-2-propyl-1H-imidazol-1-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)- 254740-61-9P, 1H-Imidazole-5-carboxylic acid, 4-chloro-1-[[2'-[[[4,5-dimethyl-3-



isoxazolyl)amino]sulfonyl [1,1'-biphenyl]-4-yl)methyl]-2-propyl-, methyl ester 254740-62-0P, 1H-Imidazole-5-carboxamide, 1-[[2'-[[4,5-dimethyl-3-isoxazolyl)amino]sulfonyl [1,1'-biphenyl]-4-yl)methyl]-4-ethyl-N,N-dimethyl-2-propyl- 254740-63-1P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-(hydroxymethyl)- 254740-64-2P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-(ethoxymethyl)- 254740-65-3P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-(2-methoxyethyl)- 254740-66-4P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-[(formylmethylamino)methyl]- 254740-67-5P, Propanamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[4,5-dimethyl-3-isoxazolyl)amino]sulfonyl [1,1'-biphenyl]-2-yl)methyl]-N-methyl- 254740-68-6P, Cyclopropanecarboxamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[4,5-dimethyl-3-isoxazolyl)amino]sulfonyl [1,1'-biphenyl]-2-yl)methyl]-N-methyl- 254740-69-7P, Propanamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[4,5-dimethyl-3-isoxazolyl)amino]sulfonyl [1,1'-biphenyl]-2-yl)methyl]-N,2-dimethyl- 254740-70-0P, Butanamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[4,5-dimethyl-3-isoxazolyl)amino]sulfonyl [1,1'-biphenyl]-2-yl)methyl]-N-methyl- 254740-71-1P, Acetamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[4,5-dimethyl-3-isoxazolyl)amino]sulfonyl [1,1'-biphenyl]-2-yl)methyl]-2-methoxy-N-methyl- 254740-72-2P, 4-Pentynamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[4,5-dimethyl-3-isoxazolyl)amino]sulfonyl [1,1'-biphenyl]-2-yl)methyl]-N-methyl- 254740-73-3P, Cyclobutanecarboxamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[4,5-dimethyl-3-isoxazolyl)amino]sulfonyl [1,1'-biphenyl]-2-yl)methyl]-N-methyl- 254740-74-4P, Butanamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[4,5-dimethyl-3-isoxazolyl)amino]sulfonyl [1,1'-biphenyl]-2-yl)methyl]-N,3-dimethyl- 254740-75-5P, Propanamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[4,5-dimethyl-3-isoxazolyl)amino]sulfonyl [1,1'-biphenyl]-2-yl)methyl]-N,2,2-trimethyl- 254740-76-6P, Propanamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[4,5-dimethyl-3-isoxazolyl)amino]sulfonyl [1,1'-biphenyl]-2-yl)methyl]-3-methoxy-N-methyl- 254740-77-7P, Acetamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[4,5-dimethyl-3-isoxazolyl)amino]sulfonyl [1,1'-biphenyl]-2-yl)methyl]-2-ethoxy-N-methyl- 254740-78-8P, 2-Furancarboxamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[4,5-dimethyl-3-isoxazolyl)amino]sulfonyl [1,1'-biphenyl]-2-yl)methyl]-N-methyl- 254740-79-9P, Pentanamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[4,5-dimethyl-3-isoxazolyl)amino]sulfonyl [1,1'-biphenyl]-2-yl)methyl]-N,4-dimethyl- 254740-80-2P, Benzamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[4,5-dimethyl-3-isoxazolyl)amino]sulfonyl [1,1'-biphenyl]-2-yl)methyl]-N-methyl- 254740-81-3P, 3-Thiophenecarboxamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[4,5-dimethyl-3-isoxazolyl)amino]sulfonyl [1,1'-biphenyl]-2-yl)methyl]-N-methyl- 254740-82-4P, Cyclopentaneacetamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[4,5-dimethyl-3-isoxazolyl)amino]sulfonyl [1,1'-biphenyl]-2-yl)methyl]-N-methyl- 254740-83-5P, Cyclohexanecarboxamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[4,5-dimethyl-3-isoxazolyl)amino]sulfonyl [1,1'-biphenyl]-2-yl)methyl]-N-methyl- 254740-84-6P, Benzamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[4,5-dimethyl-3-isoxazolyl)amino]sulfonyl [1,1'-biphenyl]-2-yl)methyl]-N,3-dimethyl- 254740-85-7P, Benzeneacetamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[4,5-dimethyl-3-isoxazolyl)amino]sulfonyl [1,1'-biphenyl]-2-yl)methyl]-N-methyl-



254740-86-8P, Benzamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[4,5-dimethyl-3-isoxazolyl)amino)sulfonyl][1,1'-biphenyl]-2-yl)methyl]-2-fluoro-N-methyl- 254740-87-9P, Benzamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[4,5-dimethyl-3-isoxazolyl)amino)sulfonyl][1,1'-biphenyl]-2-yl)methyl]-3-fluoro-N-methyl- 254740-88-0P, Benzamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[4,5-dimethyl-3-isoxazolyl)amino)sulfonyl][1,1'-biphenyl]-2-yl)methyl]-4-fluoro-N-methyl- 254740-89-1P, Cyclohexaneacetamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[4,5-dimethyl-3-isoxazolyl)amino)sulfonyl][1,1'-biphenyl]-2-yl)methyl]-N-methyl- 254740-90-4P, Benzeneacetamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[4,5-dimethyl-3-isoxazolyl)amino)sulfonyl][1,1'-biphenyl]-2-yl)methyl]-2-fluoro-N-methyl- 254740-91-5P

, Benzeneacetamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[4,5-dimethyl-3-isoxazolyl)amino)sulfonyl][1,1'-biphenyl]-2-yl)methyl]-3-fluoro-N-methyl- 254740-92-6P, Benzeneacetamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[4,5-dimethyl-3-isoxazolyl)amino)sulfonyl][1,1'-biphenyl]-2-yl)methyl]-4-fluoro-N-methyl- 254740-93-7P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[[(dimethylamino)carbonyl)methylamino)methyl]-N-(4,5-dimethyl-3-isoxazolyl)- 254740-94-8P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[[(1,1-dimethylethyl)amino)carbonyl)methylamino)methyl]-N-(4,5-dimethyl-3-isoxazolyl)- 254740-95-9P, Carbamic acid, [[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[4,5-dimethyl-3-isoxazolyl)amino)sulfonyl][1,1'-biphenyl]-2-yl)methyl]methyl-, ethyl ester 254740-96-0P, Carbamic acid, [[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[4,5-dimethyl-3-isoxazolyl)amino)sulfonyl][1,1'-biphenyl]-2-yl)methyl]methyl-, 2-methylpropyl ester 254740-97-1P, Butanamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[4,5-dimethyl-3-isoxazolyl)amino)sulfonyl][1,1'-biphenyl]-2-yl)methyl]-N,3,3-trimethyl- 254740-98-2P, 2-Pyridinecarboxamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[4,5-dimethyl-3-isoxazolyl)amino)sulfonyl][1,1'-biphenyl]-2-yl)methyl]-N-methyl- 254740-99-3P, 3-Pyridinecarboxamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[4,5-dimethyl-3-isoxazolyl)amino)sulfonyl][1,1'-biphenyl]-2-yl)methyl]-N-methyl- 254741-00-9P, Pyrazinecarboxamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[4,5-dimethyl-3-isoxazolyl)amino)sulfonyl][1,1'-biphenyl]-2-yl)methyl]-N-methyl- 254741-01-0P, 1H-Pyrrole-2-carboxamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[4,5-dimethyl-3-isoxazolyl)amino)sulfonyl][1,1'-biphenyl]-2-yl)methyl]-N,1-dimethyl- 254741-02-1P, 1,2,3-Thiadiazole-4-carboxamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[4,5-dimethyl-3-isoxazolyl)amino)sulfonyl][1,1'-biphenyl]-2-yl)methyl]-N-methyl- 254741-03-2P, Pyrazinecarboxamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[4,5-dimethyl-3-isoxazolyl)amino)sulfonyl][1,1'-biphenyl]-2-yl)methyl]-N,5-dimethyl- 254741-04-3P, 4-Isioxazolecarboxamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[4,5-dimethyl-3-isoxazolyl)amino)sulfonyl][1,1'-biphenyl]-2-yl)methyl]-N,3,5-trimethyl- 254741-05-4P, 2-Thiophenecarboxamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[4,5-dimethyl-3-isoxazolyl)amino)sulfonyl][1,1'-biphenyl]-2-yl)methyl]-N,3-dimethyl- 254741-06-5P, 2-Thiophenecarboxamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[4,5-dimethyl-3-isoxazolyl)amino)sulfonyl][1,1'-biphenyl]-2-yl)methyl]-N,5-dimethyl- 254741-07-6P, Benzamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[4,5-dimethyl-3-isoxazolyl)amino)sulfonyl][1,1'-

biphenyl]-2-yl)methyl]-3-cyano-N-methyl- 254741-08-7P, Benzamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[4,5-dimethyl-3-isoxazolyl)amino)sulfonyl][1,1'-biphenyl]-2-yl)methyl]-4-cyano-N-methyl- 254741-09-8P, Benzamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[4,5-dimethyl-3-isoxazolyl)amino)sulfonyl][1,1'-biphenyl]-2-yl)methyl]-2-methoxy-N-methyl- 254741-10-1P, Benzamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[4,5-dimethyl-3-isoxazolyl)amino)sulfonyl][1,1'-biphenyl]-2-yl)methyl]-2-chloro-N-methyl- 254741-11-2P, Benzamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[4,5-dimethyl-3-isoxazolyl)amino)sulfonyl][1,1'-biphenyl]-2-yl)methyl]-3-chloro-N-methyl- 254741-12-3P, Benzamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[4,5-dimethyl-3-isoxazolyl)amino)sulfonyl][1,1'-biphenyl]-2-yl)methyl]-4-chloro-N-methyl- 254741-13-4P, Benzamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[4,5-dimethyl-3-isoxazolyl)amino)sulfonyl][1,1'-biphenyl]-2-yl)methyl]-2,3-difluoro-N-methyl- 254741-14-5P, Benzamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[4,5-dimethyl-3-isoxazolyl)amino)sulfonyl][1,1'-biphenyl]-2-yl)methyl]-3,4-difluoro-N-methyl- 254741-15-6P, Benzamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[4,5-dimethyl-3-isoxazolyl)amino)sulfonyl][1,1'-biphenyl]-2-yl)methyl]-3,5-difluoro-N-methyl- 254741-16-7P, Benzamide, 4-acetyl-N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[4,5-dimethyl-3-isoxazolyl)amino)sulfonyl][1,1'-biphenyl]-2-yl)methyl]-N-methyl- 254741-17-8P, 2-Thiophenecarboxamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[4,5-dimethyl-3-isoxazolyl)amino)sulfonyl][1,1'-biphenyl]-2-yl)methyl]-3-ethoxy-N-methyl- 254741-19-0P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-[(propylsulfonyl)amino]- 254741-20-3P, L-Valine, N-[[2'-[[4,5-dimethyl-3-isoxazolyl)amino)sulfonyl][1,1'-biphenyl]-4-yl)methyl]-N-(1-oxopentyl)-, methyl ester 254741-22-5P, L-Valine, N-[[2'-[[4,5-dimethyl-3-isoxazolyl)amino)sulfonyl][1,1'-biphenyl]-4-yl)methyl]-N-(1-oxopentyl)- 254741-24-7P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-[(4-oxo-2-propyl-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]- 254741-26-9P, Butanamide, N-[[2'-[[4,5-dimethyl-3-isoxazolyl)amino)sulfonyl]-4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl][1,1'-biphenyl]-2-yl)methyl]-N,3,3-trimethyl- 254741-27-0P, Pentanamide, N-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-N-[[2'-[[4,5-dimethyl-3-isoxazolyl)amino)sulfonyl][1,1'-biphenyl]-4-yl)methyl]- 254741-28-1P, Pentanamide, N-[[2'-[[4,5-dimethyl-3-isoxazolyl)amino)sulfonyl][1,1'-biphenyl]-4-yl)methyl]-N-[(1S)-2-methyl-1-[(methylamino)carbonyl]propyl]- 254741-30-5P, Pentanamide, N-[(1S)-1-[(dimethylamino)carbonyl]-2-methylpropyl]-N-[[2'-[[4,5-dimethyl-3-isoxazolyl)amino)sulfonyl][1,1'-biphenyl]-4-yl)methyl]- 254741-31-6P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-[(2,2,2-trifluoroethyl)amino)methyl]- 254741-32-7P, [1,1'-Biphenyl]-2-carboxylic acid, 4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[4,5-dimethyl-3-isoxazolyl)amino)sulfonyl]- 254741-33-8P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-[(trifluoromethyl)- 254741-34-9P, [1,1'-Biphenyl]-2-carboxylic acid, 4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[4,5-dimethyl-3-isoxazolyl)amino)sulfonyl]-, methyl ester 254741-35-0P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-[(methoxymethyl)- 254741-36-1P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-fluoro- 254741-37-2P, [1,1'-Biphenyl]-2-sulfonamide, 2'-(cyanomethyl)-N-(4,5-dimethyl-3-isoxazolyl)-4'-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-

RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of N-isoxazolyl biphenylsulfonamides and related compds. as dual angiotensin II and endothelin receptor antagonists)

IT 254741-38-3P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-(cyanomethyl)-N-(4,5-dimethyl-3-isoxazolyl)- 254741-39-4P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-cyano-N-(4,5-dimethyl-3-isoxazolyl)- 254741-40-7P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-methyl- 254741-41-8P, [1,1'-Biphenyl]-2-sulfonamide, 2'-cyano-N-(4,5-dimethyl-3-isoxazolyl)-4'-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]- 254741-42-9P, Pentanamide, N-[[2'-[[[4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-2-methyl[1,1'-biphenyl]-4-yl)methyl]-N-[(1S)-2-methyl-1-[(methylamino)carbonyl]propyl]- 254741-43-0P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-4'-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-2'-[[[2,2,2-trifluoroethyl)amino]methyl]- 254741-44-1P, Benzeneacetamide, N-[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[[4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]- 254741-45-2P, Butanamide, N-[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[[4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]-3,3-dimethyl- 254741-46-3P, [1,1'-Biphenyl]-2-sulfonamide, 2'-amino-4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)- 254741-48-5P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-nitro- 254741-50-9P, Pentanamide, 2-[[[2'-[[[4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl)methyl](1-oxopropyl)amino]-N,3-dimethyl-, (2S,3S)- 254741-52-1P, Cyclopropanecarboxamide, N-[[2'-[[[4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl)methyl]-N-[(1S,2S)-2-methyl-1-[(methylamino)carbonyl]butyl]- 254741-54-3P, Benzenepropanamide, N-[[2'-[[[4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl)methyl]-N-[(1S,2S)-2-methyl-1-[(methylamino)carbonyl]butyl]- 254741-56-5P, Pentanamide, 2-[[[2'-[[[4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl)methyl](3-methyl-1-oxobutyl)amino]-N,3-dimethyl-, (2S,3S)- 254741-58-7P, Hexanamide, N-[[2'-[[[4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl)methyl]-N-[(1S,2S)-2-methyl-1-[(methylamino)carbonyl]butyl]- 254741-60-1P, Pentanamide, 2-[[[2'-[[[4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl)methyl](1-oxobutyl)amino]-N,3-dimethyl-, (2S,3S)- 254741-62-3P, Pentanamide, 2-[[[2'-[[[4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl)methyl](1-oxopropyl)amino]-N,4-dimethyl-, (2S)- 254741-64-5P, Cyclopropanecarboxamide, N-[[2'-[[[4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl)methyl]-N-[(1S)-3-methyl-1-[(methylamino)carbonyl]butyl]- 254741-66-7P, Benzenepropanamide, N-[[2'-[[[4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl)methyl]-N-[(1S)-3-methyl-1-[(methylamino)carbonyl]butyl]- 254741-68-9P, Benzeneacetamide, N-[[2'-[[[4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl)methyl]-N-[(1S)-3-methyl-1-[(methylamino)carbonyl]butyl]- 254741-70-3P, Pentanamide, 2-[[[2'-[[[4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl)methyl](3-methyl-1-oxobutyl)amino]-N,4-dimethyl-, (2S)- 254741-72-5P, Hexanamide, N-[[2'-[[[4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl)methyl]-N-[(1S)-3-methyl-1-[(methylamino)carbonyl]butyl]- 254741-74-7P, Pentanamide, 2-[[[2'-[[[4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl)methyl](1-oxobutyl)amino]-N,4-dimethyl-, (2S)- 254741-76-9P, Butanamide, 2-[[[2'-[[[4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl)methyl](1-oxopropyl)amino]-N,3-dimethyl-, (2S)- 254741-78-1P, Cyclopropanecarboxamide,

N-[[2'-[[[4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl)methyl]-N-[(1S)-2-methyl-1-[(methylamino)carbonyl]propyl]-254741-80-5P, Benzenepropanamide, N-[[2'-[[[4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl)methyl]-N-[(1S)-2-methyl-1-[(methylamino)carbonyl]propyl]-254741-82-7P, Benzeneacetamide, N-[[2'-[[[4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl)methyl]-N-[(1S)-2-methyl-1-[(methylamino)carbonyl]propyl]-254741-85-0P, Butanamide, N-[[2'-[[[4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl)methyl]-3-methyl-N-[(1S)-2-methyl-1-[(methylamino)carbonyl]propyl]-254741-87-2P, Hexanamide, N-[[2'-[[[4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl)methyl]-N-[(1S)-2-methyl-1-[(methylamino)carbonyl]propyl]-254741-89-4P, Butanamide, 2-[[[2'-[[[4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl)methyl](1-oxobutyl)amino]-N,3-dimethyl-, (2S)-254741-91-8P, Pentanamide, N-[[2'-[[[4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl)methyl]-N-[(1S)-1-(ethylamino)carbonyl]-2-methylpropyl]-254741-93-0P, Pentanamide, N-[[2'-[[[4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl)methyl]-N-[(1S)-1-(hexylamino)carbonyl]-2-methylpropyl]-254741-95-2P, Pentanamide, N-[[2-cyano-2'-[[[4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl)methyl]-N-[(1S)-2-methyl-1-[(methylamino)carbonyl]propyl]-254741-97-4P, Pentanamide, N-[[2-(cyanomethyl)-2'-[[[4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl)methyl]-N-[(1S)-2-methyl-1-[(methylamino)carbonyl]propyl]-254741-99-6P, [1,1'-Biphenyl]-2-carboxamide, 4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[[4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-254742-01-3P, [1,1'-Biphenyl]-2-carboxamide, 4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[[4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-N,N-dimethyl-254742-03-5P, [1,1'-Biphenyl]-2-carboxamide, 4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[[4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-N-methyl-254742-05-7P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-2'-(methoxymethyl)-4'-[(5,6,7,8-tetrahydro-8-oxo-2-propyl-1(4H)-cycloheptimidazolyl)methyl]-254742-06-8P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-4'-[[[3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]-2'-methyl-254742-07-9P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-2'-methyl-4'-[(5,6,7,8-tetrahydro-8-oxo-2-propyl-1(4H)-cycloheptimidazolyl)methyl]-254742-08-0P, Butanamide, 2-[[[2'-[[[4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-2-(methoxymethyl)[1,1'-biphenyl]-4-yl)methyl](1-oxobutyl)amino]-N,3-dimethyl-, (2S)-254742-09-1P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-2'-(hydroxymethyl)-4'-[(5,6,7,8-tetrahydro-8-oxo-2-propyl-1(4H)-cycloheptimidazolyl)methyl]-254742-10-4P, [1,1'-Biphenyl]-2-sulfonamide, 2'-chloro-N-(4,5-dimethyl-3-isoxazolyl)-4'-[[[2-ethyl-5,6,7,8-tetrahydro-4-quinolinyl)oxy]methyl]-254742-11-5P, Butanamide, 2-[[[2'-[[[4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-2-fluoro[1,1'-biphenyl]-4-yl)methyl](1-oxobutyl)amino]-N,3-dimethyl-, (2S)-254742-12-6P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-(phenoxymethyl)-254742-13-7P, Butanamide, 2-[[[2'-[[[4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-2-(1H-pyrazol-1-yl)methyl][1,1'-biphenyl]-4-yl)methyl](1-oxobutyl)amino]-N,3-dimethyl-, (2S)-254742-14-8P, Cyclopropanecarboxamide, N-[(1S)-1-[(dimethylamino)carbonyl]-2-methylpropyl]-N-[[2'-[[[4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl)methyl]-254742-15-9P, Butanamide, 2-[[[2'-[[[4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl)methyl](1-oxobutyl)amino]-N,N,3-trimethyl-, (2S)-254742-16-0P, Cyclopropanecarboxamide, N-[(1S)-1-[(dimethylamino)carbonyl]-2-methylpropyl]-N-[[2'-[[[4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-2-(methoxymethyl)[1,1'-biphenyl]-4-yl)methyl]-254742-17-1P, Butanamide, 2-[[[2'-[[[4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-2-(methoxymethyl)[1,1'-biphenyl]-4-yl)methyl](1-oxobutyl)amino]-N,N,3-trimethyl-, (2S)-254742-18-2P, Pentanamide, N-[[2-chloro-2'-[[[4,5-

dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl)methyl]-N-[(1S)-2-methyl-1-[(methylamino)carbonyl]propyl]- 254742-19-3P, Pentanamide, N-[[2'-[[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-2-(trifluoromethyl)][1,1'-biphenyl]-4-yl)methyl]-N-[(1S)-2-methyl-1-[(methylamino)carbonyl]propyl]- 254742-20-6P, Cyclobutanecarboxamide, N-[[2'-[[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl)methyl]-N-[(1S)-2-methyl-1-[(methylamino)carbonyl]propyl]- 254742-21-7P, 1H-Imidazole-5-carboxylic acid, 1-[[2-chloro-2'-[[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl)methyl]-4-ethyl-2-propyl]- 254742-22-8P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-[(methylsulfonyl)amino]- 254742-23-9P, Pentanamide, N-[[2'-[[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl)methyl]-N-[(1S)-2-methyl-1-[(4-methyl-1-piperazinyl)carbonyl]propyl]- 254742-24-0P, Pentanamide, N-[[2'-[[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl)methyl]-N-[(1S)-2-methyl-1-(1-piperidinylcarbonyl)propyl]- 254742-25-1P, Pentanamide, N-[(1S)-1-[[[(3,3-dimethylbutyl)amino]carbonyl]-2-methylpropyl]-N-[[2'-[[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl)methyl]- 254742-28-4P, Pentanamide, N-[[2'-[[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl)methyl]-N-[(1S)-1-[[[(4-fluorophenyl)methyl]amino]carbonyl]-2-methylpropyl]- 254742-29-5P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-[(1-methylethoxy)methyl]- 254742-31-9P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-[(propoxymethyl)- 254742-33-1P, 1H-Imidazole-5-carboxamide, 4-chloro-1-[[2'-[[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl)methyl]-2-propyl]- 254742-35-3P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-2'-fluoro-4'-[(5,6,7,8-tetrahydro-8-oxo-2-propyl-1(4H)-cycloheptimidazolyl)methyl]- 254742-36-4P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-[(2-oxo-1(2H)-pyridinyl)methyl]- 254742-37-5P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-[(1H-pyrazol-1-yl)methyl]- 254742-38-6P, 1H-Imidazole-5-carboxamide, 2-butyl-4-chloro-1-[[2'-[[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl)methyl]- 254742-39-7P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-4'-[[[(2-methyl-4-quinolinyl)oxy]methyl]- 254742-41-1P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-4'-[[[(2-ethyl-4-quinolinyl)oxy]methyl]- 254742-43-3P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-4'-[[[(2-ethyl-5,6,7,8-tetrahydro-4-quinolinyl)oxy]methyl]- 254742-45-5P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-4'-[[[(2-propyl-4-quinolinyl)oxy]methyl]- 254742-46-6P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(6,7-dihydro-2,4-dimethyl-7-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)- 254742-47-7P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-[[[(2-ethyl-4-quinolinyl)oxy]methyl]- 254742-49-9P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-2'-[[[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-[[[(2-ethyl-5,6,7,8-tetrahydro-4-quinolinyl)oxy]methyl]- 254742-51-3P, 1H-Benzimidazole-7-carboxamide, 1-[[2'-[[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl)methyl]-2-ethyl-N-methyl- 254742-53-5P, 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl)methyl]-2-ethyl-, phenylmethyl ester 254742-54-6P, 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl)methyl]-2-ethyl-, 2-phenylethyl ester 254742-56-8P, 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl)methyl]-2-ethyl-, 2-(2-oxo-1-pyrrolidinyl)ethyl ester 254742-58-0P,

1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl)methyl]-2-ethyl-, 3-(2-oxo-1-pyrrolidinyl)propyl ester 254742-60-4P, [1,1'-Biphenyl]-2-sulfonamide, 2'-cyano-N-(4,5-dimethyl-3-isoxazolyl)-4'-[[[2-ethyl-4-quinolinyl)oxy]methyl]- 254742-62-6P, [1,1'-Biphenyl]-2-sulfonamide, 2'-(cyanomethyl)-N-(4,5-dimethyl-3-isoxazolyl)-4'-[(5,6,7,8-tetrahydro-8-oxo-2-propyl-1(4H)-cycloheptimidazolyl)methyl]- 254742-64-8P, 1H-Imidazole-5-carboxamide, 1-[[2'-[[[4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl)methyl]-4-ethyl-N-methyl-2-propyl- 254742-65-9P, 1H-Imidazole-5-carboxamide, 1-[[2-chloro-2'-[[[4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl)methyl]-4-ethyl-2-propyl- 254742-66-0P, 1H-Imidazole-5-carboxamide, 1-[[2'-[[[4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl)methyl]-4-ethyl-2-propyl- 254742-67-1P, 1H-Benzimidazole-7-carboxamide, 1-[[2'-[[[4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl)methyl]-2-ethoxy-N-methyl- 254742-68-2P, 1H-Benzimidazole-7-carboxamide, 1-[[2'-[[[4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl)methyl]-2-ethoxy-N,N-dimethyl- 254742-69-3P, 3-Pyridinecarboxylic acid, 2-[[[2'-[[[4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl)methyl]propylamino]- 254742-70-6P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(3,5-dibutyl-1H-1,2,4-triazol-1-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)- 254742-71-7P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-4'-[(5,6,7,8-tetrahydro-8-oxo-2-propyl-1(4H)-cycloheptimidazolyl)methyl]- 254742-72-8P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2,7-diethyl-5H-pyrazolo[1,5-b][1,2,4]triazol-5-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)- 254742-73-9P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[[2-butyl-6-[[[methyl(1-methylethyl)amino]carbonyl]amino]-4-oxo-3(4H)-quinazolinyl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)- 254742-75-1P, 3-Pyridinecarboxamide, 2-[[[2'-[[[4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl)methyl]propylamino]-N-methyl- 254742-76-2P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-4'-[[[3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]- 254742-77-3P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-[[[3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]- 254742-78-4P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-[(5,6,7,8-tetrahydro-8-oxo-2-propyl-1(4H)-cycloheptimidazolyl)methyl]- 254742-79-5P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-4'-[[[3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]-2'-(methoxymethyl)- 254742-80-8P, 1H-Imidazole-5-carboxamide, 1-[[2'-[[[4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl)methyl]-2-ethyl-4-methyl-254742-81-9P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-3(4H)-quinazolinyl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)- 254742-82-0P, Pentanamide, N-[[2'-[[[4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-2-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl][1,1'-biphenyl]-4-yl)methyl]-N-[(1S)-2-methyl-1-[(methylamino)carbonyl]propyl]- 254742-83-1P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-[(4,4-dimethyl-2-oxo-1-pyrrolidinyl)methyl]- 254742-84-2P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(3,5-dibutyl-1H-1,2,4-triazol-1-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]- 254742-85-3P, Acetamide, N-[2-[[[2'-[[[4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl][1,1'-biphenyl]-2-yl)methyl]methylamino]ethyl]- 254742-86-4P, [1,1'-Biphenyl]-2-acetic acid, 2'-[[[4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-, ethyl ester 254742-87-5P, Pentanamide, N-[[2'-[[[4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl)methyl]-N-[(1S)-2-methyl-1-[(propylamino)carbonyl]propyl]- 254742-88-6P, Pentanamide, N-[[2'-[[[4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl)methyl]-N-[(1S)-2-methyl-1-[[[(tetrahydro-2-furanyl)methyl]amino]carbonyl]propyl]- 254742-89-7P

, [1,1'-Biphenyl]-2-sulfonamide, 2'-chloro-N-(4,5-dimethyl-3-isoxazolyl)-4'-[[2-ethyl-4-quinolinyl]oxy]methyl]- 254742-91-1P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-4'-[[2-ethyl-4-quinolinyl]oxy]methyl]-2'-(trifluoromethyl)- 254742-92-2P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-chloro-N-(4,5-dimethyl-3-isoxazolyl)- 254742-93-3P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-[(2-methylpropoxy)methyl]- 254742-94-4P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-[(ethylsulfonyl)amino]- 254742-95-5P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-[(2,2,2-trifluoroethoxy)methyl]- 254742-96-6P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-[(2-fluoroethoxy)methyl]- 254742-97-7P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-2'-[(ethoxymethyl)-4'-[[3-methoxy-2,6-dimethyl-4-pyridinyl]oxy]methyl]- 254742-98-8P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-2'-[(ethoxymethyl)-4'-[(5,6,7,8-tetrahydro-8-oxo-2-propyl-1(4H)-cycloheptimidazolyl)methyl]- 254742-99-9P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-(3,3,3-trifluoropropyl)- 254743-00-5P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-(3-fluoropropyl)- 254743-01-6P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-(1,1-difluoroethyl)-N-(4,5-dimethyl-3-isoxazolyl)- 254743-03-8P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-(2,2,2-trifluoroethyl)- 254743-05-0P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-(2-methylpropoxy)- 254743-06-1P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-(2-methoxyethoxy)- 254743-08-3P, [1,1'-Biphenyl]-2-sulfonamide, 2'-butyl-4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)- 254743-10-7P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-(methoxymethylamino)methyl]- 254743-12-9P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[(2,2-difluoroethoxy)methyl]-N-(4,5-dimethyl-3-isoxazolyl)- 254743-15-2P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-(2-fluoroethyl)- 254743-16-3P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-(2-hydroxyethyl)- 254743-17-4P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-(3-methylbutyl)- 254743-18-5P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-(2-methylpropyl)- 254743-19-6P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[[2-(3,3-difluorobutyl)-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-(ethoxymethyl)- 254743-20-9P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-4'-[[3-methoxy-2,6-dimethyl-4-pyridinyl]oxy]methyl]-2'-(3,3,3-trifluoropropyl)- 254743-22-1P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[(1,1-dimethylethoxy)methyl]-N-(4,5-dimethyl-3-isoxazolyl)- 254743-24-3P, 1H-Imidazole-5-carboxamide, 1-[[2'-[[4,5-dimethyl-3-isoxazolyl]amino]sulfonyl]-2-(methoxymethyl)[1,1'-biphenyl]-4-yl)methyl]-4-ethyl-2-propyl- 254743-25-4P, 1H-Imidazole-5-carboxamide, 1-[[2'-[[4,5-dimethyl-3-isoxazolyl]amino]sulfonyl]-2-(methoxymethyl)[1,1'-biphenyl]-4-yl)methyl]-4-ethyl-N-methyl-2-propyl- 254743-26-5P, 1H-Imidazole-5-carboxamide,



1-[[2'-[[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-2-methyl[1,1'-biphenyl]-4-yl)methyl]-4-ethyl-2-propyl]-254743-27-6P,  
1H-Imidazole-5-carboxamide, 1-[[2'-[[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-2-methyl[1,1'-biphenyl]-4-yl)methyl]-4-ethyl-N-methyl-2-propyl]-254743-28-7P 254743-29-8P 254743-30-1P  
254743-31-2P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-ethyl-254743-32-3P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-(2,2-dimethylpropyl)-254743-33-4P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-(2-ethoxyethyl)-254743-34-5P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-ethyl-4'-[[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]-254743-35-6P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-(2,2-dimethylpropyl)-4'-[[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]-254743-36-7P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-(2-ethoxyethyl)-4'-[[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]-254743-37-8P, [1,1'-Biphenyl]-2-sulfonamide, 2'-[(1,1-dimethylethoxy)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-4'-[[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]-254743-38-9P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-2'-ethyl-4'-[[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]-254743-39-0P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-2'-(2,2-dimethylpropyl)-4'-[[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]-254743-40-3P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-2'-(2-ethoxyethyl)-4'-[[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]-254743-41-4P, [1,1'-Biphenyl]-2-sulfonamide, 2'-[(1,1-dimethylethoxy)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-4'-[[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]-254743-42-5P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-2'-ethyl-4'-[(5,6,7,8-tetrahydro-8-oxo-2-propyl-1(4H)-cycloheptimidazolyl)methyl]-254743-43-6P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-(2,2-dimethylpropyl)-4'-[(5,6,7,8-tetrahydro-8-oxo-2-propyl-1(4H)-cycloheptimidazolyl)methyl]-254743-44-7P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-(2-ethoxyethyl)-4'-[(5,6,7,8-tetrahydro-8-oxo-2-propyl-1(4H)-cycloheptimidazolyl)methyl]-254743-45-8P, [1,1'-Biphenyl]-2-sulfonamide, 2'-[(1,1-dimethylethoxy)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-4'-[(5,6,7,8-tetrahydro-8-oxo-2-propyl-1(4H)-cycloheptimidazolyl)methyl]-254743-46-9P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-ethyl-4'-[(5,6,7,8-tetrahydro-8-oxo-2-propyl-1(4H)-cycloheptimidazolyl)methyl]-254743-47-0P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-2'-(2,2-dimethylpropyl)-4'-[(5,6,7,8-tetrahydro-8-oxo-2-propyl-1(4H)-cycloheptimidazolyl)methyl]-254743-48-1P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-2'-(2-ethoxyethyl)-4'-[(5,6,7,8-tetrahydro-8-oxo-2-propyl-1(4H)-cycloheptimidazolyl)methyl]-254743-49-2P, [1,1'-Biphenyl]-2-sulfonamide, 2'-[(1,1-dimethylethoxy)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-4'-[(5,6,7,8-tetrahydro-8-oxo-2-propyl-1(4H)-cycloheptimidazolyl)methyl]-254743-50-5P 254743-51-6P 254743-53-8P 254743-56-1P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-2'-(1-hydroxyethyl)-4'-[[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]-254743-57-2P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-2'-(1-hydroxy-1-methylethyl)-4'-[[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]-254743-58-3P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-4'-[[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]-2'-(tetrahydro-2-furanyl)-254743-59-4P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-(1-hydroxyethyl)-4'-[(5,6,7,8-tetrahydro-8-oxo-2-propyl-1(4H)-cycloheptimidazolyl)methyl]-254743-61-8P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-(1-hydroxy-1-methylethyl)-4'-[(5,6,7,8-tetrahydro-8-oxo-2-propyl-1(4H)-cycloheptimidazolyl)methyl]-



254743-62-9P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'--(tetrahydro-2-furanyl)-4'-[(5,6,7,8-tetrahydro-8-oxo-2-propyl-1(4H)-cycloheptimidazolyl)methyl]- 254743-63-0P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'--(1-hydroxyethyl)- 254743-64-1P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'--(1-hydroxy-1-methylethyl)- 254743-65-2P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'--(tetrahydro-2-furanyl)- 254743-66-3P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'--(1-hydroxyethyl)-4'-[[3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]- 254743-67-4P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'--(1-hydroxy-1-methylethyl)-4'-[[3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]- 254743-68-5P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-[[3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]-2'--(tetrahydro-2-furanyl)- 254743-69-6P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-2'--(1-hydroxyethyl)-4'-[(5,6,7,8-tetrahydro-8-oxo-2-propyl-1(4H)-cycloheptimidazolyl)methyl]- 254743-70-9P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-2'--(1-hydroxy-1-methylethyl)-4'-[(5,6,7,8-tetrahydro-8-oxo-2-propyl-1(4H)-cycloheptimidazolyl)methyl]- 254743-71-0P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-2'--(tetrahydro-2-furanyl)-4'-[(5,6,7,8-tetrahydro-8-oxo-2-propyl-1(4H)-cycloheptimidazolyl)methyl]- 254743-72-1P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-4'-[(5,6,7,8-tetrahydro-8-oxo-2-propyl-1(4H)-cycloheptimidazolyl)methyl]-2'--(3,3,3-trifluoropropyl)- 254743-73-2P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-[(5,6,7,8-tetrahydro-8-oxo-2-propyl-1(4H)-cycloheptimidazolyl)methyl]-2'--(3,3,3-trifluoropropyl)- 254743-74-3P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-[[3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]-2'-propyl- 254743-75-4P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-4'-[[3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]-2'-propyl- 254743-76-5P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-2'-propyl-4'-[(5,6,7,8-tetrahydro-8-oxo-2-propyl-1(4H)-cycloheptimidazolyl)methyl]- 254743-77-6P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-propyl-4'-[(5,6,7,8-tetrahydro-8-oxo-2-propyl-1(4H)-cycloheptimidazolyl)methyl]- 254743-78-7P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-[(2-fluoroethoxy)methyl]-4'-[[3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]-

RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of N-isoxazolyl biphenylsulfonamides and related compds. as dual angiotensin II and endothelin receptor antagonists)

IT 254743-79-8P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-2'-[(2-fluoroethoxy)methyl]-4'-[[3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]- 254743-80-1P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-2'-[(2-fluoroethoxy)methyl]-4'-[(5,6,7,8-tetrahydro-8-oxo-2-propyl-1(4H)-cycloheptimidazolyl)methyl]- 254743-81-2P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-[(2-fluoroethoxy)methyl]-4'-[(5,6,7,8-tetrahydro-8-oxo-2-propyl-1(4H)-cycloheptimidazolyl)methyl]- 254743-82-3P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[[2-(2,2-difluorobutyl)-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-propyl- 254743-83-4P 254743-84-5P 254743-85-6P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-2'--(ethoxymethyl)-4'-[[4-oxo-2-(4,4,4-trifluorobutyl)-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]- 254743-86-7P 254743-87-8P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-4'-[[4-oxo-2-(4,4,4-trifluorobutyl)-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-propyl- 254743-88-9P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-2'--(ethoxymethyl)-4'-[[4-oxo-2-(3,3,3-trifluoropropyl)-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]- 254743-89-0P

254743-90-3P 254743-91-4P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-4'-[[4-oxo-2-(3,3,3-trifluoropropyl)-1,3-diazaspiro[4.4]non-1-en-3-yl]methyl]-2'-propyl- 254743-92-5P, [1,1'-Biphenyl]-2-sulfonamide, 2'-(1,1-difluoropropyl)-N-(3,4-dimethyl-5-isoxazolyl)-4'-[[3-methoxy-2,6-dimethyl-4-pyridinyl]oxy]methyl]- 254743-93-6P, [1,1'-Biphenyl]-2-sulfonamide, 2'-(1,1-difluoropropyl)-N-(4,5-dimethyl-3-isoxazolyl)-4'-[[3-methoxy-2,6-dimethyl-4-pyridinyl]oxy]methyl]- 254743-94-7P, [1,1'-Biphenyl]-2-sulfonamide, 2'-(1,1-difluoropropyl)-N-(4,5-dimethyl-3-isoxazolyl)-4'-[(5,6,7,8-tetrahydro-8-oxo-2-propyl-1(4H)-cycloheptimidazolyl)methyl]- 254743-95-8P, [1,1'-Biphenyl]-2-sulfonamide, 2'-(1,1-difluoropropyl)-N-(3,4-dimethyl-5-isoxazolyl)-4'-[(5,6,7,8-tetrahydro-8-oxo-2-propyl-1(4H)-cycloheptimidazolyl)methyl]- 254743-96-9P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-(1,1,3,3,3-pentafluoropropyl)- 254743-97-0P 254743-98-1P, 1H-Imidazole-5-carboxamide, 1-[[2'-[[3,4-dimethyl-5-isoxazolyl]amino]sulfonyl]-2-ethyl[1,1'-biphenyl]-4-yl]methyl]-4-ethyl-N-methyl-2-propyl- 254743-99-2P, 1H-Imidazole-5-carboxamide, 1-[[2'-[[3,4-dimethyl-5-isoxazolyl]amino]sulfonyl]-2-propyl[1,1'-biphenyl]-4-yl]methyl]-4-ethyl-N-methyl-2-propyl- 254744-00-8P, 1H-Imidazole-5-carboxamide, 1-[[2'-[[3,4-dimethyl-5-isoxazolyl]amino]sulfonyl]-2-[(2-fluoroethoxy)methyl][1,1'-biphenyl]-4-yl]methyl]-4-ethyl-N-methyl-2-propyl- 254744-01-9P, 1H-Imidazole-5-carboxamide, 1-[[2'-[[3,4-dimethyl-5-isoxazolyl]amino]sulfonyl]-2-(ethoxymethyl)[1,1'-biphenyl]-4-yl]methyl]-4-ethyl-N-methyl-2-propyl- 254744-02-0P, 1H-Imidazole-5-carboxamide, 1-[[2'-[[3,4-dimethyl-5-isoxazolyl]amino]sulfonyl]-2-ethyl[1,1'-biphenyl]-4-yl]methyl]-4-ethyl-2-propyl- 254744-03-1P, 1H-Imidazole-5-carboxamide, 1-[[2'-[[3,4-dimethyl-5-isoxazolyl]amino]sulfonyl]-2-propyl[1,1'-biphenyl]-4-yl]methyl]-4-ethyl-2-propyl- 254744-04-2P, 1H-Imidazole-5-carboxamide, 1-[[2'-[[3,4-dimethyl-5-isoxazolyl]amino]sulfonyl]-2-[(2-fluoroethoxy)methyl][1,1'-biphenyl]-4-yl]methyl]-4-ethyl-2-propyl- 254744-05-3P, 1H-Imidazole-5-carboxamide, 1-[[2'-[[3,4-dimethyl-5-isoxazolyl]amino]sulfonyl]-2-(ethoxymethyl)[1,1'-biphenyl]-4-yl]methyl]-4-ethyl-2-propyl- 254744-06-4P, 1H-Imidazole-5-carboxamide, 1-[[2'-[[4,5-dimethyl-3-isoxazolyl]amino]sulfonyl]-2-ethyl[1,1'-biphenyl]-4-yl]methyl]-4-ethyl-N-methyl-2-propyl- 254744-07-5P, 1H-Imidazole-5-carboxamide, 1-[[2'-[[4,5-dimethyl-3-isoxazolyl]amino]sulfonyl]-2-propyl[1,1'-biphenyl]-4-yl]methyl]-4-ethyl-N-methyl-2-propyl- 254744-08-6P, 1H-Imidazole-5-carboxamide, 1-[[2'-[[4,5-dimethyl-3-isoxazolyl]amino]sulfonyl]-2-[(2-fluoroethoxy)methyl][1,1'-biphenyl]-4-yl]methyl]-4-ethyl-N-methyl-2-propyl- 254744-09-7P, 1H-Imidazole-5-carboxamide, 1-[[2'-[[4,5-dimethyl-3-isoxazolyl]amino]sulfonyl]-2-(ethoxymethyl)[1,1'-biphenyl]-4-yl]methyl]-4-ethyl-N-methyl-2-propyl- 254744-10-0P, 1H-Imidazole-5-carboxamide, 1-[[2'-[[4,5-dimethyl-3-isoxazolyl]amino]sulfonyl]-2-ethyl[1,1'-biphenyl]-4-yl]methyl]-4-ethyl-2-propyl- 254744-11-1P, 1H-Imidazole-5-carboxamide, 1-[[2'-[[4,5-dimethyl-3-isoxazolyl]amino]sulfonyl]-2-propyl[1,1'-biphenyl]-4-yl]methyl]-4-ethyl-2-propyl- 254744-12-2P, 1H-Imidazole-5-carboxamide, 1-[[2'-[[4,5-dimethyl-3-isoxazolyl]amino]sulfonyl]-2-[(2-fluoroethoxy)methyl][1,1'-biphenyl]-4-yl]methyl]-4-ethyl-2-propyl- 254744-13-3P, 1H-Imidazole-5-carboxamide, 1-[[2'-[[4,5-dimethyl-3-isoxazolyl]amino]sulfonyl]-2-(ethoxymethyl)[1,1'-biphenyl]-4-yl]methyl]-4-ethyl-2-propyl-

RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of N-isoxazolyl biphenylsulfonamides and related compds. as dual angiotensin II and endothelin receptor antagonists)

IT 56-12-2, 4-Aminobutyric acid, reactions 75-03-6, Iodoethane 78-09-1, Tetraethyl orthocarbonate 79-03-8, Propionyl chloride 79-44-7, Dimethylcarbamy chloride 95-89-6, 2-Chloro-3,6-dimethylpyrazine

109-81-9, N-Methylethylenediamine 124-40-3, Dimethylamine, reactions  
 127-08-2, Potassium acetate 541-41-3, Ethyl chloroformate 543-27-1,  
 Isobutyl chloroformate 589-15-1, 4-Bromobenzyl bromide 627-03-2,  
 Ethoxyacetic acid 638-29-9, Valeryl chloride 676-58-4, Methylmagnesium  
 chloride 680-15-9, Acetic acid, difluoro(fluorosulfonyl)-, methyl ester  
 767-00-0, 4-Cyanophenol 865-33-8, Potassium methoxide 873-75-6,  
 4-Bromobenzyl alcohol 1117-97-1, N-Methoxy-N-methylamine 1122-91-4,  
 4-Bromobenzaldehyde 1450-75-5, Ethanone, 1-(5-bromo-2-hydroxyphenyl)-  
 1530-32-1, Ethyltriphenylphosphonium bromide 1609-86-5, tert-Butyl  
 isocyanate 2835-98-5, Phenol, 2-amino-5-methyl- 2905-25-1,  
 2-Bromobenzenesulfonyl chloride 3959-07-7, 4-Bromobenzylamine  
 4858-85-9, 2,3-Dichloropyrazine 5326-34-1, 4-Bromo-3-nitrotoluene  
 6228-47-3, Propyltriphenylphosphonium bromide 6482-24-2,  
 1-Bromo-2-methoxyethane 13734-41-3, L-Valine, N-[(1,1-  
 dimethylethoxy)carbonyl]- 14508-49-7, 2-Chloropyrazine 14678-02-5,  
 5-Amino-3-methylisoxazole 22059-22-9, Acetamide oxime 22884-29-3,  
 Isobutyltriphenylphosphonium bromide 28466-21-9, 4-Amino-1,3,5-  
 trimethylpyrazole 29006-02-8, Butanoic acid, 4-methoxy- 33670-32-5,  
 Methoxymethyltriphenylphosphonium bromide 34328-47-7, Benzaldehyde,  
 4-bromo-3-(trifluoromethyl)- 34841-06-0, 3-Bromo-4-methoxybenzaldehyde  
 40155-28-0, 2-Chloro-3-methoxypyrazine 41963-20-6, 4-Bromo-3-  
 methylbenzonitrile 53553-14-3, Methyl 2-chloro-3-nitrobenzoate  
 53596-60-4, Benzoic acid, 4-hydroxy-3-(2-propenyl)-, methyl ester  
 60421-23-0, Cyclopentanecarboxylic acid, 1-amino-, methyl ester,  
 hydrochloride 74410-26-7, Butanamide, 2-amino-N,3-dimethyl-,  
 monohydrochloride, (2S)- 76513-69-4, 2-(Trimethylsilyl)ethoxymethyl  
 chloride 78775-11-8, Benzaldehyde, 4-bromo-3-methyl- 87199-17-5,  
 4-Formylphenylboronic acid 89464-87-9, 2-Amino-3-methoxy-5-  
 methylpyrazine 98946-18-0, tert-Butyl 2,2,2-trichloroacetimidate  
 109072-25-5, 4(1H)-Quinolinone, 2-ethyl- 120077-69-2, Benzaldehyde,  
 4-bromo-3-chloro- 124750-49-8, 1H-Imidazole-4-carboxaldehyde,  
 5-chloro-2-propyl- 125110-82-9, 4,4-Difluoropentanoic acid  
 133059-43-5, Benzaldehyde, 4-bromo-3-fluoro- 133240-06-9,  
 1H-Imidazo[4,5-b]pyridine, 2-ethyl-5,7-dimethyl- 138402-05-8,  
 1,3-Diazaspiro[4.4]non-1-en-4-one, 2-butyl- 148547-19-7, Methyl  
 4-bromo-3-methylbenzoate 150691-04-6, Boronic acid, [2-[(1,1-  
 dimethylethyl)amino]sulfonyl]phenyl]- 151257-01-1, 1,3-  
 Diazaspiro[4.4]non-1-en-4-one, 2-butyl-, monohydrochloride 153039-15-7,  
 Butanoic acid, 4-amino-2,2-dimethyl-, hydrochloride 160313-50-8,  
 Benzonitrile, 4-bromo-3-(1,3-dioxolan-2-yl)- 162647-41-8, 4-Pyridinol,  
 3-methoxy-2,6-dimethyl- 167985-34-4, 1H-Imidazole-4-carboxylic acid,  
 5-ethyl-2-propyl-, ethyl ester 176961-13-0, Boronic acid,  
 [2-[(3,4-dimethyl-5-isoxazolyl)[(2-methoxyethoxy)methyl]amino]sulfonyl]ph  
 enyl]- 195436-86-3, Benzenesulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-N-  
 [(2-methoxyethoxy)methyl]-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-  
 254746-77-5, Boronic acid, [2-[(4,5-dimethyl-3-isoxazolyl)[(2-  
 methoxyethoxy)methyl]amino]sulfonyl]phenyl]- 254746-78-6, Butanoic acid,  
 4-amino-2,2-dimethyl-, ethyl ester, hydrochloride 254746-79-7, Boronic  
 acid, [2-[(3,4-dimethyl-5-isoxazolyl)[2-[(trimethylsilyl)oxy]ethoxy]meth  
 yl]amino]sulfonyl]phenyl]- 254746-80-0, [1,1'-Biphenyl]-2-sulfonamide,  
 4'-(bromomethyl)-N-(3,4-dimethyl-5-isoxazolyl)-2'-(ethoxymethyl)-N-[(2-  
 methoxyethoxy)methyl]- 254746-81-1

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of N-isoxazolyl biphenylsulfonamides and related compds. as  
 dual angiotensin II and endothelin receptor antagonists)

IT 14847-51-9P, Phenol, 2-bromo-5-methyl- 79047-47-5P, 1H-Imidazole-4-  
 methanol, 5-chloro-2-propyl- 89003-95-2P, Benzonitrile,  
 4-bromo-3-formyl- 123652-98-2P, Benzene, 2-bromo-4-(dimethoxymethyl)-1-  
 methoxy- 142031-67-2P, Benzoic acid, 4-bromo-3-(bromomethyl)-, methyl  
 ester 160313-48-4P, Benzenemethanol, 4-bromo-3-(1,3-dioxolan-2-yl)-  
 176961-30-1P, [1,1'-Biphenyl]-2-sulfonamide, 4'-(bromomethyl)-N-(3,4-  
 dimethyl-5-isoxazolyl)-N-[(2-methoxyethoxy)methyl]- 189762-06-9P,  
 [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-formyl-N-

[(2-methoxyethoxy)methyl]- 189762-08-1P, [1,1'-Biphenyl]-2-sulfonamide,  
 N-(3,4-dimethyl-5-isoxazolyl)-4'-formyl- 190197-86-5P, Benzonitrile,  
 4-bromo-3-(bromomethyl)- 254744-14-4P, Benzonitrile,  
 3-[(acetyloxy)methyl]-4-bromo- 254744-15-5P, Benzaldehyde,  
 4-bromo-3-(hydroxymethyl)- 254744-16-6P, [1,1'-Biphenyl]-2-sulfonamide,  
 N-(3,4-dimethyl-5-isoxazolyl)-4'-formyl-2'-(hydroxymethyl)-N-[[2-  
 [(trimethylsilyl)oxy]ethoxy]methyl]- 254744-17-7P, Benzonitrile,  
 4-bromo-3-(methoxymethyl)- 254744-18-8P, Benzaldehyde,  
 4-bromo-3-(methoxymethyl)- 254744-19-9P, [1,1'-Biphenyl]-2-sulfonamide,  
 N-(3,4-dimethyl-5-isoxazolyl)-4'-formyl-N-[(2-methoxyethoxy)methyl]-2'-  
 (methoxymethyl)- 254744-20-2P, [1,1'-Biphenyl]-2-sulfonamide,  
 N-(3,4-dimethyl-5-isoxazolyl)-4'-(hydroxymethyl)-N-[(2-  
 methoxyethoxy)methyl]-2'-(methoxymethyl)- 254744-21-3P,  
 [1,1'-Biphenyl]-2-sulfonamide, 4'-(bromomethyl)-N-(3,4-dimethyl-5-  
 isoxazolyl)-N-[(2-methoxyethoxy)methyl]-2'-(methoxymethyl)-  
 254744-22-4P, [1,1'-Biphenyl]-2-sulfonamide, 2'-cyano-N-(3,4-dimethyl-5-  
 isoxazolyl)-4'-(hydroxymethyl)-N-[[2-[(trimethylsilyl)oxy]ethoxy]methyl]-  
 254744-23-5P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-  
 2'-formyl-4'-(hydroxymethyl)-N-[[2-[(trimethylsilyl)oxy]ethoxy]methyl]-  
 254744-24-6P, [1,1'-Biphenyl]-2-sulfonamide, 2'-chloro-N-(3,4-dimethyl-5-  
 isoxazolyl)-4'-formyl-N-[[2-[(trimethylsilyl)oxy]ethoxy]methyl]-  
 254744-25-7P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-  
 4'-formyl-2'-(trifluoromethyl)-N-[[2-[(trimethylsilyl)oxy]ethoxy]methyl]-  
 254744-26-8P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-  
 4'-formyl-N-[(2-methoxyethoxy)methyl]-2'-methyl- 254744-27-9P,  
 [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-fluoro-4'-  
 formyl-N-[(2-methoxyethoxy)methyl]- 254744-28-0P, [1,1'-Biphenyl]-2-  
 sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-  
 [[(methylsulfonyl)oxy]methyl]-2'-(trifluoromethyl)-N-[[2-  
 [(trimethylsilyl)oxy]ethoxy]methyl]- 254744-29-1P, [1,1'-Biphenyl]-2-  
 sulfonamide, 2'-chloro-N-(3,4-dimethyl-5-isoxazolyl)-4'-  
 [[(methylsulfonyl)oxy]methyl]-N-[[2-[(trimethylsilyl)oxy]ethoxy]methyl]-  
 254744-30-4P, [1,1'-Biphenyl]-2-sulfonamide, 4'-(bromomethyl)-N-(3,4-  
 dimethyl-5-isoxazolyl)-2'-fluoro-N-[(2-methoxyethoxy)methyl]-  
 254744-31-5P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-  
 4'-(hydroxymethyl)-2'-[[[(methylsulfonyl)oxy]methyl]-N-[[2-  
 [(trimethylsilyl)oxy]ethoxy]methyl]- 254744-32-6P, [1,1'-Biphenyl]-2-  
 sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-N-[(2-methoxyethoxy)methyl]-2'-  
 methyl-4'-[[[(methylsulfonyl)oxy]methyl]- 254744-33-7P,  
 [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-  
 (hydroxymethyl)-4'-[[[(methylsulfonyl)oxy]methyl]-N-[[2-  
 [(trimethylsilyl)oxy]ethoxy]methyl]- 254744-34-8P, [1,1'-Biphenyl]-2-  
 sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-formyl-2'-methyl-N-[[2-  
 [(trimethylsilyl)oxy]ethoxy]methyl]- 254744-35-9P, [1,1'-Biphenyl]-2-  
 sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-formyl-N-[[2-  
 [(trimethylsilyl)oxy]ethoxy]methyl]- 254744-36-0P, [1,1'-Biphenyl]-2-  
 sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-  
 [[(methylsulfonyl)oxy]methyl]-N-[[2-[(trimethylsilyl)oxy]ethoxy]methyl]-  
 254744-37-1P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-  
 4'-formyl-2'-(methoxymethyl)-N-[[2-[(trimethylsilyl)oxy]ethoxy]methyl]-  
 254744-38-2P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-  
 2'-formyl-4'-(hydroxymethyl)-N-[(2-methoxyethoxy)methyl]- 254744-39-3P  
 254744-40-6P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-  
 4'-(hydroxymethyl)-N-[(2-methoxyethoxy)methyl]- 254744-41-7P,  
 [1,1'-Biphenyl]-2-sulfonamide, 4'-(bromomethyl)-N-(4,5-dimethyl-3-  
 isoxazolyl)-N-[(2-methoxyethoxy)methyl]- 254744-42-8P 254744-43-9P,  
 [1,1'-Biphenyl]-2-sulfonamide, 4'-cyano-N-(3,4-dimethyl-5-isoxazolyl)-2'-  
 formyl-N-[(2-methoxyethoxy)methyl]- 254744-44-0P, [1,1'-Biphenyl]-2-  
 sulfonamide, 4'-cyano-N-(3,4-dimethyl-5-isoxazolyl)-N-[(2-  
 methoxyethoxy)methyl]-2'-[(methylamino)methyl]- 254744-45-1P, Carbamic  
 acid, [[4-cyano-2'-[[[(3,4-dimethyl-5-isoxazolyl) [(2-  
 methoxyethoxy)methyl]amino]sulfonyl] [1,1'-biphenyl]-2-yl]methyl]methyl-,  
 1,1-dimethylethyl ester 254744-46-2P, Carbamic acid,

[[2'-[[[(3,4-dimethyl-5-isoxazolyl)[(2-methoxyethoxy)methyl]amino]sulfonyl]-4-formyl[1,1'-biphenyl]-2-yl]methyl]methyl-, 1,1-dimethylethyl ester 254744-47-3P, Carbamic acid, [[4-(bromomethyl)-2'-[[[(3,4-dimethyl-5-isoxazolyl)[(2-methoxyethoxy)methyl]amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]methyl-, 1,1-dimethylethyl ester 254744-48-4P 254744-49-5P, [1,1'-Biphenyl]-2-sulfonamide, 4'-cyano-N-(3,4-dimethyl-5-isoxazolyl)-2'-(1,3-dioxolan-2-yl)-N-[(2-methoxyethoxy)methyl]- 254744-50-8P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-(1,3-dioxolan-2-yl)-4'-formyl-N-[(2-methoxyethoxy)methyl]- 254744-51-9P, [1,1'-Biphenyl]-2-sulfonamide, 4'-(bromomethyl)-N-(3,4-dimethyl-5-isoxazolyl)-2'-(1,3-dioxolan-2-yl)-N-[(2-methoxyethoxy)methyl]- 254744-52-0P 254744-53-1P, Benzaldehyde, 4-bromo-3-(1,3-dioxolan-2-yl)- 254744-54-2P, 1,3-Dioxolane, 2-[2-bromo-5-(bromomethyl)phenyl]- 254744-55-3P, 1,3-Diazaspiro[4.4]non-1-en-4-one, 3-[[4-bromo-3-(1,3-dioxolan-2-yl)phenyl]methyl]-2-butyl- 254744-56-4P 254744-58-6P 254744-60-0P 254744-63-3P 254744-65-5P 254744-68-8P 254744-70-2P 254744-73-5P, 1,2,4-Oxadiazole-5-methanamine, 3-methyl- $\alpha$ -(1-methylethyl)-, ( $\alpha$ S)- 254744-78-0P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-[[[(1S)-2-methyl-1-(3-methyl-1,2,4-oxadiazol-5-yl)propyl]amino]methyl]- 254744-81-5P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(hydroxymethyl)-N-[(2-methoxyethoxy)methyl]- 254744-84-8P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-N-[(2-methoxyethoxy)methyl]- 254744-86-0P, Cyclopentanecarboxylic acid, 1-[(3-methoxy-1-oxopropyl)amino]-, methyl ester 254744-87-1P, Cyclopentanecarboxylic acid, 1-[(3-methoxy-1-oxopropyl)amino]- 254744-90-6P, Cyclopentanecarboxamide, 1-[(3-methoxy-1-oxopropyl)amino]- 254744-91-7P, 1,3-Diazaspiro[4.4]non-1-en-4-one, 2-(2-methoxyethyl)- 254744-95-1P, Cyclopentanecarboxylic acid, 1-[(ethoxyacetyl)amino]-, methyl ester 254744-98-4P, 1,3-Diazaspiro[4.4]non-1-en-4-one, 2-(ethoxymethyl)- 254745-00-1P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-formyl-N-[(2-methoxyethoxy)methyl]-4'-[(methylsulfonyl)oxy]- 254745-03-4P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-2'-formyl-N-[(2-methoxyethoxy)methyl]- 254745-06-7P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-N-[(2-methoxyethoxy)methyl]-2'-[(2-oxo-1-pyrrolidinyl)methyl]- 254745-08-9P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-N-[(2-methoxyethoxy)methyl]-2'-[(3-methyl-2-oxo-1-imidazolidinyl)methyl]- 254745-12-5P, Benzenesulfonamide, 2-bromo-N-(3-methyl-5-isoxazolyl)- 254745-14-7P, Benzenesulfonamide, 2-bromo-N-(3-methyl-5-isoxazolyl)-N-[[2-[(trimethylsilyl)oxy]ethoxy]methyl]- 254745-19-2P, [1,1'-Biphenyl]-2-sulfonamide, 4'-formyl-N-(3-methyl-5-isoxazolyl)-N-[[2-[(trimethylsilyl)oxy]ethoxy]methyl]- 254745-23-8P, Butanamide, N,3-dimethyl-2-[[[2'-[[[(3-methyl-5-isoxazolyl)[(2-[(trimethylsilyl)oxy]ethoxy]methyl]amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]amino]-, (2S)- 254745-28-3P, Pentanamide, N-[[2'-[[[(3-methyl-5-isoxazolyl)[(2-[(trimethylsilyl)oxy]ethoxy]methyl]amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-N-[(1S)-2-methyl-1-[(methylamino)carbonyl]propyl]- 254745-31-8P, Benzonitrile, 4-bromo-3-(1-propenyl)- 254745-36-3P, Benzonitrile, 4-bromo-3-propyl- 254745-39-6P, Benzaldehyde, 4-bromo-3-propyl- 254745-42-1P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-formyl-N-[(2-methoxyethoxy)methyl]-2'-propyl- 254745-43-2P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-(hydroxymethyl)-N-[(2-methoxyethoxy)methyl]-2'-propyl- 254745-45-4P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-N-[(2-methoxyethoxy)methyl]-4'-[[[(methylsulfonyl)oxy]methyl]-2'-propyl- 254745-46-5P 254745-48-7P, Benzoic acid, 2-[[[(4-bromophenyl)methyl]amino]-3-nitro-, methyl ester 254745-49-8P, Benzoic acid, 2-[[[2'-[[[(3,4-dimethyl-5-isoxazolyl)[(2-

[(trimethylsilyl)oxy]ethoxy)methyl]amino)sulfonyl][1,1'-biphenyl]-4-yl)methyl]amino]-3-nitro-, methyl ester 254745-50-1P, Benzoic acid, 3-amino-2-[[[2'-[[[(3,4-dimethyl-5-isoxazolyl)][2-[(trimethylsilyl)oxy]ethoxy)methyl]amino)sulfonyl][1,1'-biphenyl]-4-yl)methyl]amino]-, methyl ester 254745-51-2P, 1H-Benzimidazole-7-carboxylic acid, 1-[[[2'-[[[(3,4-dimethyl-5-isoxazolyl)][2-[(trimethylsilyl)oxy]ethoxy)methyl]amino)sulfonyl][1,1'-biphenyl]-4-yl)methyl]-2-ethoxy-, methyl ester 254745-52-3P, Benzenemethanamine, 4-bromo-3-(1,3-dioxolan-2-yl)- 254745-53-4P, Benzoic acid, 2-[[[4-bromo-3-(1,3-dioxolan-2-yl)phenyl)methyl]amino]-3-nitro-, methyl ester 254745-54-5P, Benzoic acid, 2-[[[2'-[[[(3,4-dimethyl-5-isoxazolyl)][2-[(trimethylsilyl)oxy]ethoxy)methyl]amino)sulfonyl]-2-formyl][1,1'-biphenyl]-4-yl)methyl]amino]-3-nitro-, methyl ester 254745-55-6P, Benzoic acid, 2-[[[2'-[[[(3,4-dimethyl-5-isoxazolyl)][2-[(trimethylsilyl)oxy]ethoxy)methyl]amino)sulfonyl]-2-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl][1,1'-biphenyl]-4-yl)methyl]amino]-3-nitro-, methyl ester 254745-57-8P, Benzoic acid, 3-amino-2-[[[2'-[[[(3,4-dimethyl-5-isoxazolyl)][2-[(trimethylsilyl)oxy]ethoxy)methyl]amino)sulfonyl]-2-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl][1,1'-biphenyl]-4-yl)methyl]amino]-, methyl ester 254745-58-9P, 1H-Benzimidazole-7-carboxylic acid, 1-[[[2'-[[[(3,4-dimethyl-5-isoxazolyl)][2-[(trimethylsilyl)oxy]ethoxy)methyl]amino)sulfonyl]-2-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl][1,1'-biphenyl]-4-yl)methyl]-2-ethoxy-, methyl ester 254745-60-3P, Quinoline, 4-[(4-bromophenyl)methoxy]-2-ethyl- 254745-61-4P, [1,1'-Biphenyl]-2-sulfonamide, N-(1,1-dimethylethyl)-4'-[[[2-ethyl-4-quinolinyl)oxy)methyl]-254745-62-5P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[[[2-ethyl-4-quinolinyl)oxy)methyl]- 254745-64-7P, [1,1'-Biphenyl]-2-sulfonic acid, 4'-[[[2-ethyl-4-quinolinyl)oxy)methyl]- 254745-66-9P, Ethanone, 1-(5-chloro-2-propyl-1H-imidazol-4-yl)- 254745-68-1P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(5-acetyl-4-chloro-2-propyl-1H-imidazol-1-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-N-[[2-[(trimethylsilyl)oxy]ethoxy)methyl]- 254745-70-5P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(4-chloro-5-formyl-2-propyl-1H-imidazol-1-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-N-[[2-[(trimethylsilyl)oxy]ethoxy)methyl]- 254745-72-7P, 1H-Imidazole-5-carboxylic acid, 4-chloro-1-[[[2'-[[[(3,4-dimethyl-5-isoxazolyl)][2-[(trimethylsilyl)oxy]ethoxy)methyl]amino)sulfonyl][1,1'-biphenyl]-4-yl)methyl]-2-propyl- 254745-73-8P, 1H-Imidazole-5-carboxylic acid, 4-chloro-1-[[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino)sulfonyl][1,1'-biphenyl]-4-yl)methyl]-2-propyl- 254745-76-1P, 1H-Imidazole-5-carboxylic acid, 1-[[[2'-[[[(3,4-dimethyl-5-isoxazolyl)][2-methoxyethoxy)methyl]amino)sulfonyl][1,1'-biphenyl]-4-yl)methyl]-4-ethyl-2-propyl-, ethyl ester 254745-77-2P, 1H-Imidazole-5-carboxylic acid, 1-[[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino)sulfonyl][1,1'-biphenyl]-4-yl)methyl]-4-ethyl-2-propyl- 254745-78-3P 254745-79-4P 254745-80-7P 254745-81-8P 254745-82-9P, Benzenesulfonamide, 2-bromo-N-(3-methoxy-5-methylpyrazinyl)- 254745-83-0P, Benzenesulfonamide, 2-bromo-N-(3-methoxy-5-methylpyrazinyl)-N-[[2-[(trimethylsilyl)oxy]ethoxy)methyl]- 254745-84-1P 254745-85-2P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-formyl-N-(3-methoxy-5-methylpyrazinyl)- 254745-86-3P, Benzenesulfonamide, 2-bromo-N-[[2-methoxyethoxy)methyl]-N-(3-methyl-5-isoxazolyl)- 254745-87-4P, Boronic acid, [2-[[[(2-methoxyethoxy)methyl](3-methyl-5-isoxazolyl)amino)sulfonyl]phenyl]- 254745-88-5P 254745-89-6P 254745-90-9P 254745-91-0P, Benzene, 4-(dimethoxymethyl)-1-methoxy-2-(3,3,3-trifluoropropyl)- 254745-92-1P, Benzaldehyde, 4-methoxy-3-(3,3,3-trifluoropropyl)- 254745-93-2P, Benzaldehyde, 4-hydroxy-3-(3,3,3-trifluoropropyl)- 254745-94-3P, Methanesulfonic acid, trifluoro-, 4-formyl-2-(3,3,3-trifluoropropyl)phenyl ester 254745-95-4P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-formyl-2'-(3,3,3-trifluoropropyl)-N-[[2-[(trimethylsilyl)oxy]ethoxy)methyl]- 254745-96-5P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-(hydroxymethyl)-2'-(3,3,3-trifluoropropyl)-N-[[2-[(trimethylsilyl)oxy]ethoxy)methyl]- 254745-97-6P

254745-98-7P, Benzoic acid, 3-(2-propenyl)-4-[[[(trifluoromethyl)sulfonyl]oxy]-, methyl ester 254745-99-8P, Benzoic acid, 3-(3-hydroxypropyl)-4-[[[(trifluoromethyl)sulfonyl]oxy]-, methyl ester 254746-00-4P, [1,1'-Biphenyl]-4-carboxylic acid, 2'-[[[(3,4-dimethyl-5-isoxazolyl)[2-[(trimethylsilyl)oxy]ethoxy)methyl]amino]sulfonyl]-2-(3-hydroxypropyl)-, methyl ester 254746-01-5P, [1,1'-Biphenyl]-4-carboxylic acid, 2'-[[[(3,4-dimethyl-5-isoxazolyl)[2-[(trimethylsilyl)oxy]ethoxy)methyl]amino]sulfonyl]-2-(3-fluoropropyl)-, methyl ester 254746-03-7P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-(3-fluoropropyl)-4'-(hydroxymethyl)-N-[[2-[(trimethylsilyl)oxy]ethoxy)methyl]-254746-04-8P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-(3-fluoropropyl)-4'-[[[(methylsulfonyl)oxy)methyl]-N-[[2-[(trimethylsilyl)oxy]ethoxy)methyl]-254746-06-0P 254746-07-1P, Methanesulfonic acid, trifluoro-, 2-acetyl-4-bromophenyl ester 254746-08-2P, Methanesulfonic acid, trifluoro-, 4-bromo-2-(1,1-difluoroethyl)phenyl ester 254746-09-3P, Methanesulfonic acid, trifluoro-, 2-(1,1-difluoroethyl)-4-formylphenyl ester 254746-10-6P, [1,1'-Biphenyl]-2-sulfonamide, 2'-(1,1-difluoroethyl)-N-(3,4-dimethyl-5-isoxazolyl)-4'-formyl-N-[[2-[(trimethylsilyl)oxy]ethoxy)methyl]-254746-11-7P, [1,1'-Biphenyl]-2-sulfonamide, 2'-(1,1-difluoroethyl)-N-(3,4-dimethyl-5-isoxazolyl)-4'-(hydroxymethyl)-N-[[2-[(trimethylsilyl)oxy]ethoxy)methyl]-254746-12-8P, [1,1'-Biphenyl]-2-sulfonamide, 2'-(1,1-difluoroethyl)-N-(3,4-dimethyl-5-isoxazolyl)-4'-[[[(methylsulfonyl)oxy)methyl]-N-[[2-[(trimethylsilyl)oxy]ethoxy)methyl]-254746-13-9P 254746-14-0P, Benzoic acid, 4-bromo-3-(2,2,2-trifluoroethyl)-, methyl ester 254746-15-1P, [1,1'-Biphenyl]-4-carboxylic acid, 2'-[[[(3,4-dimethyl-5-isoxazolyl)[2-[(trimethylsilyl)oxy]ethoxy)methyl]amino]sulfonyl]-2-(2,2,2-trifluoroethyl)-, methyl ester 254746-16-2P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-(hydroxymethyl)-2'-(2,2,2-trifluoroethyl)-N-[[2-[(trimethylsilyl)oxy]ethoxy)methyl]-254746-18-4P 254746-19-5P, Benzene, 1-bromo-4-methyl-2-(2-methylpropoxy)-254746-20-8P, Benzene, 1-bromo-4-(bromomethyl)-2-(2-methylpropoxy)-254746-21-9P, 1,3-Diazaspiro[4.4]non-1-en-4-one, 3-[[4-bromo-3-(2-methylpropoxy)phenyl]methyl]-2-butyl-254746-22-0P 254746-23-1P, Benzene, 1-bromo-2-(2-methoxyethoxy)-4-methyl-254746-24-2P, Benzene, 1-bromo-4-(bromomethyl)-2-(2-methoxyethoxy)-254746-25-3P, 1,3-Diazaspiro[4.4]non-1-en-4-one, 3-[[4-bromo-3-(2-methoxyethoxy)phenyl]methyl]-2-butyl-254746-26-4P 254746-27-5P, Benzonitrile, 4-bromo-3-(1-butenyl)-254746-28-6P, Benzonitrile, 4-bromo-3-butyl-254746-29-7P, Benzaldehyde, 4-bromo-3-butyl-254746-30-0P, [1,1'-Biphenyl]-2-sulfonamide, 2'-butyl-N-(3,4-dimethyl-5-isoxazolyl)-4'-(hydroxymethyl)-N-[[2-[(trimethylsilyl)oxy]ethoxy)methyl]-254746-31-1P, [1,1'-Biphenyl]-2-sulfonamide, 2'-butyl-N-(3,4-dimethyl-5-isoxazolyl)-4'-[[[(methylsulfonyl)oxy)methyl]-N-[[2-[(trimethylsilyl)oxy]ethoxy)methyl]-254746-32-2P 254746-33-3P, Boronic acid, [2-[[[(3-methyl-5-isoxazolyl)[2-[(trimethylsilyl)oxy]ethoxy)methyl]amino]sulfonyl]phenyl]-254746-34-4P, [1,1'-Biphenyl]-2-sulfonamide, 4'-formyl-N-(3-methyl-5-isoxazolyl)-2'-(trifluoromethyl)-N-[[2-[(trimethylsilyl)oxy]ethoxy)methyl]-254746-35-5P, [1,1'-Biphenyl]-2-sulfonamide, 4'-(hydroxymethyl)-N-(3-methyl-5-isoxazolyl)-2'-(trifluoromethyl)-N-[[2-[(trimethylsilyl)oxy]ethoxy)methyl]-254746-36-6P 254746-37-7P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-(hydroxymethyl)-N-[[2-methoxyethoxy)methyl]-2'-[(methoxymethylamino)methyl]-254746-38-8P, [1,1'-Biphenyl]-2-sulfonamide, 4'-(bromomethyl)-N-(3,4-dimethyl-5-isoxazolyl)-N-[[2-methoxyethoxy)methyl]-2'-[(methoxymethylamino)methyl]-254746-39-9P 254746-40-2P, Benzoic acid, 4-bromo-3-(hydroxymethyl)-, methyl ester 254746-41-3P, Benzoic acid, 3-[[acetyloxy)methyl]-4-bromo-, methyl ester 254746-42-4P, Benzoic acid, 4-bromo-3-[[[(tetrahydro-2H-pyran-2-yl)oxy)methyl]-, methyl ester 254746-43-5P, [1,1'-Biphenyl]-4-carboxylic acid, 2'-[[[(3,4-dimethyl-5-isoxazolyl)[2-[(trimethylsilyl)oxy]ethoxy)meth



yl]amino]sulfonyl]-2-[[[(tetrahydro-2H-pyran-2-yl)oxy]methyl]-, methyl ester 254746-44-6P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-(hydroxymethyl)-2'-[[[(tetrahydro-2H-pyran-2-yl)oxy]methyl]-N-[[2-[(trimethylsilyl)oxy]ethoxy]methyl]- 254746-45-7P 254746-46-8P 254746-47-9P 254746-48-0P, Benzoic acid, 3-(2-hydroxyethyl)-4-[[[(trifluoromethyl)sulfonyl]oxy]-, methyl ester 254746-49-1P, [1,1'-Biphenyl]-4-carboxylic acid, 2'-[[[(3,4-dimethyl-5-isoxazolyl)[2-[(trimethylsilyl)oxy]ethoxy]methyl]amino]sulfonyl]-2-(2-hydroxyethyl)-, methyl ester 254746-50-4P, [1,1'-Biphenyl]-4-carboxylic acid, 2'-[[[(3,4-dimethyl-5-isoxazolyl)[2-[(trimethylsilyl)oxy]ethoxy]methyl]amino]sulfonyl]-2-(2-fluoroethyl)-, methyl ester 254746-51-5P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-(2-fluoroethyl)-4'-(hydroxymethyl)-N-[[2-[(trimethylsilyl)oxy]ethoxy]methyl]- 254746-52-6P 254746-53-7P

[1,1'-Biphenyl]-4-carboxylic acid, 2'-[[[(3,4-dimethyl-5-isoxazolyl)[2-[(trimethylsilyl)oxy]ethoxy]methyl]amino]sulfonyl]-2-[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethyl]-, methyl ester 254746-54-8P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-(hydroxymethyl)-2'-[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethyl]-N-[[2-[(trimethylsilyl)oxy]ethoxy]methyl]- 254746-55-9P, Benzonitrile, 4-bromo-3-(3-methyl-1-butenyl)- 254746-56-0P, Benzonitrile, 4-bromo-3-(3-methylbutyl)- 254746-57-1P, Benzaldehyde, 4-bromo-3-(3-methylbutyl)- 254746-58-2P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-(hydroxymethyl)-N-[(2-methoxyethoxy)methyl]-2'-(3-methylbutyl)- 254746-59-3P, [1,1'-Biphenyl]-2-sulfonamide, 4'-(bromomethyl)-N-(3,4-dimethyl-5-isoxazolyl)-N-[(2-methoxyethoxy)methyl]-2'-(3-methylbutyl)- 254746-60-6P, Benzonitrile, 4-[(2-methyl-2-propenyl)oxy]- 254746-61-7P, Benzonitrile, 4-hydroxy-3-(2-methyl-2-propenyl)- 254746-62-8P, Benzonitrile, 4-hydroxy-3-(2-methylpropyl)- 254746-63-9P, Benzaldehyde, 4-hydroxy-3-(2-methylpropyl)- 254746-64-0P, Methanesulfonic acid, trifluoro-, 4-formyl-2-(2-methylpropyl)phenyl ester 254746-65-1P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-formyl-N-[(2-methoxyethoxy)methyl]-2'-(2-methylpropyl)- 254746-66-2P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-(hydroxymethyl)-N-[(2-methoxyethoxy)methyl]-2'-(2-methylpropyl)- 254746-67-3P, [1,1'-Biphenyl]-2-sulfonamide, 4'-(bromomethyl)-N-(3,4-dimethyl-5-isoxazolyl)-N-[(2-methoxyethoxy)methyl]-2'-(2-methylpropyl)- 254746-68-4P 254746-69-5P, Cyclopentanecarboxylic acid, 1-[(3,3-difluoro-1-oxobutyl)amino]-, methyl ester 254746-70-8P, 1,3-Diazaspiro[4.4]non-1-en-4-one, 2-(3,3-difluorobutyl)- 254746-71-9P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-[[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]-2'-(3,3,3-trifluoropropyl)-N-[[2-[(trimethylsilyl)oxy]ethoxy]methyl]- 254746-72-0P, Benzoic acid, 4-bromo-3-[(1,1-dimethylethoxy)methyl]-, methyl ester 254746-73-1P, [1,1'-Biphenyl]-4-carboxylic acid, 2-[(1,1-dimethylethoxy)methyl]-2'-[[[(3,4-dimethyl-5-isoxazolyl)[2-[(trimethylsilyl)oxy]ethoxy]methyl]amino]sulfonyl]-, methyl ester 254746-74-2P, [1,1'-Biphenyl]-2-sulfonamide, 2'-[(1,1-dimethylethoxy)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-4'-(hydroxymethyl)-N-[[2-[(trimethylsilyl)oxy]ethoxy]methyl]- 254746-75-3P, [1,1'-Biphenyl]-2-sulfonamide, 4'-(bromomethyl)-2'-[(1,1-dimethylethoxy)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-N-[[2-[(trimethylsilyl)oxy]ethoxy]methyl]- 254746-76-4P 254746-82-2P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of N-isoxazolyl biphenylsulfonamides and related compds. as dual angiotensin II and endothelin receptor antagonists)

IT 50-78-2, Aspirin 52-01-7, Spironolactone 10238-21-8, Glyburide 51384-51-1, Metoprolol 55142-85-3, Ticlopidine 72956-09-3, Carvedilol 75330-75-5, Lovastatin 79902-63-9, Simvastatin 81093-37-0, Pravastatin 107724-20-9, Eplerenone 113665-84-2, Clopidogrel 134523-00-5, Atorvastatin 147098-20-2, Zd-4522 147526-32-7, NK 104 150322-43-3, Cs-747  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)



(preparation of N-isoxazolyl biphenylsulfonamides and related compds. as dual angiotensin II and endothelin receptor antagonists)


IT 51384-51-1, Metoprolol 72956-09-3,  
Carvedilol 107724-20-9, Eplerenone

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(preparation of N-isoxazolyl biphenylsulfonamides and related compds. as dual angiotensin II and endothelin receptor antagonists)


RN 51384-51-1 HCAPLUS

CN 2-Propanol, 1-[4-(2-methoxyethyl)phenoxy]-3-[(1-methylethyl)amino]- (9CI)  
(CA INDEX NAME)




RN 72956-09-3 HCAPLUS

CN 2-Propanol, 1-(9H-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]- (9CI) (CA INDEX NAME)



PAGE 1-A




PAGE 2-A

RN 107724-20-9 HCAPLUS

CN Pregn-4-ene-7,21-dicarboxylic acid, 9,11-epoxy-17-hydroxy-3-oxo-,  
 $\gamma$ -lactone, methyl ester, (7 $\alpha$ ,11 $\alpha$ ,17 $\alpha$ )- (9CI) (CA  
 INDEX NAME)

Absolute stereochemistry.



L77 ANSWER 6 OF 7 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 2002:107159 HCAPLUS

DN 136:172753

ED Entered STN: 10 Feb 2002

TI Epoxy-steroidal aldosterone antagonist and **beta-adrenergic antagonist** combination therapy for treatment of congestive heart failure

IN Alexander, John C.; Schuh, Joseph R.

PA Pharmacia Corporation, USA

SO PCT Int. Appl., 190 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM A61K045-06

ICS A61K031-58; A61P009-00; A61K031-58; A61K031-135; A61K045-06;  
 A61K031-58

CC 63-6 (Pharmaceuticals)

Section cross-reference(s): 1, 2

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002009760	A2	20020207	WO 2001-US23670	20010727 <--
	WO 2002009760	A3	20030123		
	WO 2002009760	C2	20030904		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	CA 2415789	AA	20020207	CA 2001-2415789	20010727 <--
	US 2002123485	A1	20020905	US 2001-917403	20010727 <--
	EP 1303306	A2	20030423	EP 2001-957290	20010727 <--
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			

JP 2004511435	T2	20040415	JP 2002-515312	20010727 <--
US 2004235809	A1	20041125	US 2004-343166	20040607 <--
PRAI US 2000-221365P	P	20000727	<--	
WO 2001-US23670	W	20010727	<--	

## CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES	
WO 2002009760	ICM	A61K045-06	
	ICS	A61K031-58; A61P009-00; A61K031-58; A61K031-135; A61K045-06; A61K031-58	
US 2002123485	ECLA	A61K031/58; A61K045/06	<--
JP 2004511435	FTERM	4C084/AA02; 4C084/AA03; 4C084/AA20; 4C084/BA36; 4C084/BA44; 4C084/CA59; 4C084/MA02; 4C084/NA05; 4C084/NA14; 4C084/ZA362; 4C084/ZA422; 4C084/ZC022; 4C086/AA01; 4C086/AA02; 4C086/BC12; 4C086/DA12; 4C086/DA13; 4C086/MA02; 4C086/MA04; 4C086/NA05; 4C086/NA14; 4C086/ZA36; 4C086/ZA42; 4C086/ZC02; 4C091/AA02; 4C091/BB05; 4C091/CC01; 4C091/DD01; 4C091/EE07; 4C091/FF01; 4C091/GG01; 4C091/GG02; 4C091/GG16; 4C091/HH01; 4C091/JJ03; 4C091/KK01; 4C091/LL01; 4C091/MM03; 4C091/NN01; 4C091/PA01; 4C091/PA03; 4C091/PA09; 4C091/PB01; 4C091/PB03; 4C091/QQ07; 4C091/QQ15; 4C091/QQ18; 4C204/BB01; 4C204/CB25; 4C204/DB01; 4C204/EB01; 4C204/FB01; 4C204/GB25; 4C206/AA01; 4C206/AA02; 4C206/FA14; 4C206/FA19; 4C206/FA21; 4C206/GA01; 4C206/GA31; 4C206/JA11; 4C206/MA02; 4C206/MA04; 4C206/MA21; 4C206/NA05; 4C206/NA14; 4C206/ZA36; 4C206/ZA42; 4C206/ZC02	<--
US 2004235809	ECLA	A61K031/58+M	<--
AB		A combination therapy comprising a therapeutically-effective amount of an epoxy-steroidal aldosterone receptor antagonist and a therapeutically-effective amount of a <b>beta-adrenergic antagonist</b> is described for treatment of circulatory disorders, including cardiovascular disorders such as hypertension, congestive heart failure, cirrhosis and ascites. Preferred <b>beta-adrenergic antagonists</b> are those compds. having high potency and bioavailability. Preferred epoxy-steroidal aldosterone receptor antagonists are 20-spiroxane steroidal compds. characterized by the presence of a 9 $\alpha$ , 11 $\alpha$ -substituted epoxy moiety. A preferred combination therapy includes the <b>beta-adrenergic antagonist metoprolol succinate</b> and the aldosterone receptor antagonist <b>epoxymexrenone</b> . Crystal forms of <b>eplexrenone</b> were prepared as well as the Me Et ketone solvate.	
ST		epoxy steroid aldosterone antagonist <b>beta adrenergic antagonist</b> ; congestive heart failure treatment compn	
IT		Cardiovascular agents Crystal morphology Crystallization Human (epoxy-steroidal aldosterone antagonist and <b>beta-adrenergic antagonist</b> combination therapy for treatment of congestive heart failure)	
IT		Mineralocorticoid receptors RL: BSU (Biological study, unclassified); BIOL (Biological study) (epoxy-steroidal aldosterone antagonist and <b>beta-adrenergic antagonist</b> combination therapy for treatment of congestive heart failure)	
IT		Steroids, biological studies RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (epoxy-steroidal aldosterone antagonist and <b>beta-adrenergic antagonist</b> combination therapy for treatment of congestive heart failure)	

- IT Heart, disease  
(failure; epoxy-steroidal aldosterone antagonist and **beta-adrenergic antagonist** combination therapy for treatment of congestive heart failure)
- IT **Adrenoceptor antagonists**  
( $\beta$  -; epoxy-steroidal aldosterone antagonist and **beta-adrenergic antagonist** combination therapy for treatment of congestive heart failure)
- IT 170684-14-7, UK 1745  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(UK 1745; epoxy-steroidal aldosterone antagonist and **beta-adrenergic antagonist** combination therapy for treatment of congestive heart failure)
- IT 52-39-1, Aldosterone  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(antagonists; epoxy-steroidal aldosterone antagonist and **beta-adrenergic antagonist** combination therapy for treatment of congestive heart failure)
- IT 395665-44-8P 395665-46-0P  
RL: BYP (Byproduct); PREP (Preparation)  
(epoxy-steroidal aldosterone antagonist and **beta-adrenergic antagonist** combination therapy for treatment of congestive heart failure)
- IT **344449-96-3**  
RL: FMU (Formation, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); FORM (Formation, nonpreparative); USES (Uses)  
(epoxy-steroidal aldosterone antagonist and **beta-adrenergic antagonist** combination therapy for treatment of congestive heart failure)
- IT **107724-20-9, Eplerenone**  
RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); PRP (Properties); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)  
(epoxy-steroidal aldosterone antagonist and **beta-adrenergic antagonist** combination therapy for treatment of congestive heart failure)
- IT 52-01-7, Spironolactone 525-66-6, Propranolol 3930-20-9, Sotalol 6452-71-7, Oxprenolol 7413-36-7, Nifenalol 13523-86-9, Pindolol 13655-52-2, Alprenolol 22664-55-7, Metipranolol 23694-81-7, Mepindolol 26839-75-8, Timolol 29122-68-7, Atenolol 34915-68-9, Bunitrolol 36894-69-6, Labetalol 37517-30-9, Acebutolol 38363-40-5, Penbutolol 39552-01-7, Befunolol 39563-28-5, Cloranolol 42200-33-9, Nadolol 47141-42-4, Levobunolol 51384-51-1, Metoprolol 51781-06-7, Carteolol 56980-93-9, Celiprolol 57460-41-0, Talinolol 57775-29-8, Carazolol 58409-59-9, Bucumolol 58930-32-8, Butofilolol 59170-23-9, Bevantolol 60607-68-3, Indenolol 62658-63-3, Bopindolol 63659-18-7, Betaxolol 66722-44-9, Bisoprolol 66848-46-2, Viskenit 68377-92-4, Arotinolol 71119-11-4, Bucindolol 72956-09-3, Carvedilol 77164-20-6, Levomoprolol 81147-92-4, Esmolol 81447-80-5, Diprafenone 81486-22-8, Nipradilol 81801-12-9, Xamoterol 83688-84-0, Tertatolol 85136-71-6, Tilisolol 85320-68-9, Amosulalol 93379-54-5, S-Atenolol 98418-47-4, Toprol xl 102203-23-6, Acc 9369 114856-47-2, TZC-5665 115609-61-5, L-653328 118457-14-0, Nebivolol 125279-79-0, Ersentilide 132017-03-9, SR 58894A 133242-30-5, Landiolol 153192-22-4, YM-430 153601-03-7, Capsinolol 165337-66-6, LM-2616 174689-39-5, SR-59230A

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(epoxy-steroidal aldosterone antagonist and **beta-adrenergic antagonist** combination therapy for treatment of congestive heart failure)


RL: FMU (Formation, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); FORM (Formation, nonpreparative); USES (Uses)

(epoxy-steroidal aldosterone antagonist and **beta-adrenergic antagonist** combination therapy for treatment of congestive heart failure)


CN Pregn-4-ene-7,21-dicarboxylic acid, 9,11-epoxy-17-hydroxy-3-oxo-,  
 γ-lactone, methyl ester, (7α,11α,17α)-, compd.  
 with 2-butanone (9CI) (CA INDEX NAME)

CMF C24 H30 O6

Absolute stereochemistry.



CMF C4 H8 O




RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); PRP (Properties); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)  
(epoxy-steroidal aldosterone antagonist and **beta-adrenergic antagonist** combination therapy for

treatment of congestive heart failure)

RN 107724-20-9 HCAPLUS

CN Pregn-4-ene-7,21-dicarboxylic acid, 9,11-epoxy-17-hydroxy-3-oxo-,  
 γ-lactone, methyl ester, (7α,11α,17α)- (9CI) (CA  
 INDEX NAME)

Absolute stereochemistry.




IT 525-66-6, Propranolol 3930-20-9,  
 Sotalol 6452-71-7, Oxprenolol  
 13523-86-9, Pindolol 22664-55-7,  
 Metipranolol 26839-75-8, Timolol  
 29122-68-7, Atenolol 36894-69-6,  
 Labetalol 37517-30-9, Acebutolol  
 38363-40-5, Penbutolol 42200-33-9,  
 Nadolol 47141-42-4, Levobunolol  
 51384-51-1, Metoprolol 51781-06-7,  
 Carteolol 56980-93-9, Celiprolol  
 62658-63-3, Bopindolol 63659-18-7,  
 Betaxolol 66722-44-9, Bisoprolol  
 66848-46-2, Viskenit 71119-11-4, Bucindolol  
 72956-09-3, Carvedilol 81147-92-4,  
 Esmolol 98418-47-4, Toprol xl 118457-14-0,  
 Nebivolol 395665-48-2

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (epoxy-steroidal aldosterone antagonist and **beta-**  
**adrenergic antagonist** combination therapy for  
 treatment of congestive heart failure)


RN 525-66-6 HCAPLUS

CN 2-Propanol, 1-[(1-methylethyl)amino]-3-(1-naphthalenyloxy)- (9CI) (CA  
 INDEX NAME)




RN 3930-20-9 HCAPLUS

CN Methanesulfonamide, N-[4-[1-hydroxy-2-[(1-methylethyl)amino]ethyl]phenyl]-  
 (9CI) (CA INDEX NAME)




RN 6452-71-7 HCAPLUS

CN 2-Propanol, 1-[(1-methylethyl)amino]-3-[2-(2-propenyloxy)phenoxy]- (9CI)  
(CA INDEX NAME)




RN 13523-86-9 HCAPLUS

CN 2-Propanol, 1-(1H-indol-4-yloxy)-3-[(1-methylethyl)amino]- (9CI) (CA  
INDEX NAME)



RN 22664-55-7 HCAPLUS


CN Phenol, 4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]-2,3,6-trimethyl-,  
1-acetate (9CI) (CA INDEX NAME)



RN 26839-75-8 HCAPLUS


CN 2-Propanol, 1-[(1,1-dimethylethyl)amino]-3-[[4-(4-morpholinyl)-1,2,5-  
thiadiazol-3-yl]oxy]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 29122-68-7 HCAPLUS

CN Benzeneacetamide, 4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy] - (9CI)  
(CA INDEX NAME)




RN 36894-69-6 HCAPLUS

CN Benzamide, 2-hydroxy-5-[1-hydroxy-2-[(1-methyl-3-phenylpropyl)amino]ethyl] -  
(9CI) (CA INDEX NAME)



RN 37517-30-9 HCAPLUS

CN Butanamide, N-[3-acetyl-4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]phenyl] -  
(9CI) (CA INDEX NAME)






RN 38363-40-5 HCAPLUS


CN 2-Propanol, 1-(2-cyclopentylphenoxy)-3-[(1,1-dimethylethyl)amino]-, (2S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 42200-33-9 HCAPLUS


CN 2,3-Naphthalenediol, 5-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)



RN 47141-42-4 HCAPLUS


CN 1(2H)-Naphthalenone, 5-[(2S)-3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-3,4-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 51384-51-1 HCAPLUS

CN 2-Propanol, 1-[4-(2-methoxyethyl)phenoxy]-3-[(1-methylethyl)amino]- (9CI) (CA INDEX NAME)




RN 51781-06-7 HCAPLUS

CN 2 (1H)-Quinolinone, 5-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-3,4-dihydro- (9CI) (CA INDEX NAME)




RN 56980-93-9 HCAPLUS

CN Urea, N'-[3-acetyl-4-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]phenyl]-N,N-diethyl- (9CI) (CA INDEX NAME)




RN 62658-63-3 HCAPLUS

CN 2-Propanol, 1-[(1,1-dimethylethyl)amino]-3-[(2-methyl-1H-indol-4-yl)oxy]-, benzoate (ester) (9CI) (CA INDEX NAME)




RN 63659-18-7 HCAPLUS

CN 2-Propanol, 1-[4-[2-(cyclopropylmethoxy)ethyl]phenoxy]-3-[(1-methylethyl)amino]- (9CI) (CA INDEX NAME)



RN 66722-44-9 HCAPLUS

CN 2-Propanol, 1-[4-[[2-(1-methylethoxy)ethoxy]methyl]phenoxy]-3-[(1-methylethyl)amino]- (9CI) (CA INDEX NAME)




RN 66848-46-2 HCAPLUS

CN	D-Glucitol, 1,4:3,6-dianhydro-, dinitrate, mixt. with 1-(1H-indol-4-yloxy)-3-[(1-methylethyl)amino]-2-propanol (9CI) (CA INDEX NAME)
----	--

CM 1

CRN 13523-86-9

CMF C14 H20 N2 O2




CM 2

CRN 87-33-2


CMF C6 H8 N2 O8

Absolute stereochemistry.



RN 71119-11-4 HCAPLUS


CN Benzonitrile, 2-[2-hydroxy-3-[[2-(1H-indol-3-yl)-1,1-dimethylethyl]amino]propoxy] - (9CI) (CA INDEX NAME)




RN 72956-09-3 HCAPLUS

CN 2-Propanol, 1-(9H-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]-  
(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 81147-92-4 HCAPLUS

CN Benzenepropanoic acid, 4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 98418-47-4 HCAPLUS

CN Butanedioic acid, compd. with 1-[4-(2-methoxyethyl)phenoxy]-3-[(1-methylethyl)amino]-2-propanol (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 51384-51-1


CMF C15 H25 N O3



CM 2

CRN 110-15-6


CMF C4 H6 O4



RN 118457-14-0 HCAPLUS

CN 2H-1-Benzopyran-2-methanol,  $\alpha,\alpha'$ -[iminobis(methylene)]bis[6-fluoro-3,4-dihydro-, ( $\alpha R,\alpha'R,2R,2'S$ )-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 395665-48-2 HCAPLUS

CN Pregn-4-ene-7,21-dicarboxylic acid, 9,11-epoxy-17-hydroxy-3-oxo-,  $\gamma$ -lactone, methyl ester, ( $7\alpha,11\alpha$ )- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L77 ANSWER 7 OF 7 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 2000:259979 HCAPLUS

DN 132:288794

ED Entered STN: 21 Apr 2000

TI Sympathetic nervous system activity-reducing agents for treatment of disease- or age-related weight loss and for enhancement of exercise performance

IN Anker, Stefan Dietmar; Coats, Andrew Justin Stewart

PA Imperial College Innovations Limited, UK

SO PCT Int. Appl., 72 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM A61K031-00

CC 1-12 (Pharmacology)

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000021509	A2	20000420	WO 1999-GB3302	19991015 <--
	WO 2000021509	A3	20001109		
	W: JP, US				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	EP 1121111	A2	20010808	EP 1999-947762	19991015 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 2002527378	T2	20020827	JP 2000-575485	19991015 <--
PRAI	GB 1998-22458	A	19981015	<--	
	GB 1998-22459	A	19981015	<--	
	GB 1999-17181	A	19990723	<--	
	WO 1999-GB3302	W	19991015	<--	

#### CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
------------	-------	------------------------------------

WO 2000021509	ICM	A61K031-00
---------------	-----	------------

AB A method of treating weight loss due to underlying disease in a patient, the method comprising administering to the patient an effective amount of an agent which reduces sympathetic nervous system activity. A method of treating weight loss due to underlying disease in a patient, the method comprising administering to the patient an effective amount of any one or more of the following: a compound which inhibits the effect of aldosterone such as an aldosterone antagonist; a chymase inhibitor; a cathepsin B inhibitor; a  $\beta$  receptor blocker; an imidazoline receptor antagonist; a centrally acting  $\alpha$  receptor antagonist; a peripherally acting  $\alpha$  receptor antagonist; a ganglion blocking agent; a drug that has an effect on cardiovascular reflexes and thereby reduces SNS activity such as an opiate; scopolamine; an endothelin receptor antagonist; and a xanthine oxidase inhibitor. The methods are particularly useful in treating cardiac cachexia. The sympathetic nervous system activity-reducing agents may also be used to treat weight loss due to aging and to enhance exercise performance.

ST sympathetic agent disease related wt loss; age related wt loss sympathetic agent; exercise performance cardiac cachexia sympathetic agent

IT Anabolic agents

(anabolic growth factors; sympathetic nervous system activity-reducing agents for treatment of disease- or age-related weight loss and for enhancement of exercise performance)

IT Angiotensin receptor antagonists

(angiotensin II; sympathetic nervous system activity-reducing agents for treatment of disease- or age-related weight loss and for enhancement of exercise performance)

IT Endothelin receptors

Imidazoline receptors

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(antagonists; sympathetic nervous system activity-reducing agents for treatment of disease- or age-related weight loss and for enhancement of exercise performance)

IT Reflex  
(cardiovascular; sympathetic nervous system activity-reducing agents for treatment of disease- or age-related weight loss and for enhancement of exercise performance)

IT Lung, disease  
(chronic obstructive; sympathetic nervous system activity-reducing agents for treatment of disease- or age-related weight loss and for enhancement of exercise performance)

IT Infection  
(chronic; sympathetic nervous system activity-reducing agents for treatment of disease- or age-related weight loss and for enhancement of exercise performance)

IT Muscle  
(elec. stimulation of; sympathetic nervous system activity-reducing agents for treatment of disease- or age-related weight loss and for enhancement of exercise performance)

IT Peptides, biological studies  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(epoxysuccinyl; sympathetic nervous system activity-reducing agents for treatment of disease- or age-related weight loss and for enhancement of exercise performance)

IT Heart, disease  
Kidney, disease  
(failure, chronic; sympathetic nervous system activity-reducing agents for treatment of disease- or age-related weight loss and for enhancement of exercise performance)

IT Nervous system agents  
(ganglionic blocking agents; sympathetic nervous system activity-reducing agents for treatment of disease- or age-related weight loss and for enhancement of exercise performance)

IT Body weight  
(loss; sympathetic nervous system activity-reducing agents for treatment of disease- or age-related weight loss and for enhancement of exercise performance)

IT AIDS (disease)  
Aging, animal  
Cachexia  
Cirrhosis  
Disease, animal  
Emphysema  
Exercise  
Heart, disease  
Hypertension  
Malnutrition  
Neoplasm  
Nervous system agents  
(sympathetic nervous system activity-reducing agents for treatment of disease- or age-related weight loss and for enhancement of exercise performance)

IT Opioids  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(sympathetic nervous system activity-reducing agents for treatment of disease- or age-related weight loss and for enhancement of exercise performance)

IT Nervous system  
(sympathetic; sympathetic nervous system activity-reducing agents for treatment of disease- or age-related weight loss and for enhancement of exercise performance)

IT Tumor necrosis factors

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 ( $\alpha$ , antagonists; sympathetic nervous system activity-reducing  
 agents for treatment of disease- or age-related weight loss and for  
 enhancement of exercise performance)

IT Adrenoceptor antagonists  
 ( $\alpha$ -; sympathetic nervous system activity-reducing agents for  
 treatment of disease- or age-related weight loss and for enhancement of  
 exercise performance)

IT **Adrenoceptor antagonists**  
 ( $\beta$  -; sympathetic nervous system activity-reducing agents  
 for treatment of disease- or age-related weight loss and for enhancement  
 of exercise performance)

IT 180384-56-9, Ro 61-1790

RL: BAC (Biological activity or effector, except adverse); BSU (Biological  
 study, unclassified); BUU (Biological use, unclassified); THU (Therapeutic  
 use); BIOL (Biological study); USES (Uses)  
 (Ro 61-1790; sympathetic nervous system activity-reducing agents for  
 treatment of disease- or age-related weight loss and for enhancement of  
 exercise performance)

IT 188307-16-6, T 0201

RL: BAC (Biological activity or effector, except adverse); BSU (Biological  
 study, unclassified); BUU (Biological use, unclassified); THU (Therapeutic  
 use); BIOL (Biological study); USES (Uses)  
 (T 0201; sympathetic nervous system activity-reducing agents for  
 treatment of disease- or age-related weight loss and for enhancement of  
 exercise performance)

IT 52-39-1, Aldosterone

RL: BOC (Biological occurrence); BSU (Biological study, unclassified);  
 BIOL (Biological study); OCCU (Occurrence)  
 (and aldosterone antagonists; sympathetic nervous system  
 activity-reducing agents for treatment of disease- or age-related weight  
 loss and for enhancement of exercise performance)

IT 9002-17-9, Xanthine oxidase 9004-08-4, Cathepsin 9015-82-1,  
 Angiotensin-converting enzyme 9047-22-7, Cathepsin B 97501-92-3,  
 Chymase

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (inhibitors; sympathetic nervous system activity-reducing agents for  
 treatment of disease- or age-related weight loss and for enhancement of  
 exercise performance)

IT 9002-72-6, Growth hormone 67763-96-6, IGF-1

RL: BAC (Biological activity or effector, except adverse); BSU (Biological  
 study, unclassified); BUU (Biological use, unclassified); BIOL (Biological  
 study); USES (Uses)  
 (sympathetic nervous system activity-reducing agents for treatment of  
 disease- or age-related weight loss and for enhancement of exercise  
 performance)

IT 51-34-3, Scopolamine 52-01-7, Spironolactone 52-01-7D, Spironolactone,  
 15,16-methylene derivs. 57-27-2, Morphine, biological studies 60-26-4,  
 Hexamethonium 60-30-0, Azamethonium 60-40-2, Mecamylamine 68-91-7  
 71-91-0, Tetraethylammonium bromide 100-33-4, Pentamidine 119-44-8,  
 Xanthopterin 125-28-0, Dihydrocodeine 144-44-5, Pentolinium  
 315-30-0, Allopurinol 382-82-1 492-11-5, Leukopterin 497-23-4,  
 2(5H)-Furanone 525-66-6, Propranolol 546-48-5,  
 Synapleg 555-30-6,  $\alpha$ -Methyldopa 561-27-3, Diamorphine  
 968-93-4, Testolactone 971-60-8, Benzohexonium 1218-98-0,  
 7,8-Dihydroneopterin 2009-64-5, Neopterin 2365-25-5, Pentamethonium  
 2465-59-0, Oxypurinol 3613-69-2, Cypenam 3930-20-9,  
 Sotalol 4138-96-9 4205-90-7, Clonidine 4844-10-4,  
 Hexafluorenum 5472-41-3, 4-Amino-6-hydroxypyrazolo[3,4-d]pyrimidine  
 6452-71-7, Oxprenolol 7187-66-8, Trimetaphan  
 9087-70-1, Aprotinin 11096-26-7, Erythropoietin 13523-86-9,  
 Pindolol 13655-52-2, Alprenolol 17528-72-2 19216-56-9,  
 Prazosin 22150-76-1, Bioppterin 22664-55-7,



Metipranolol 26839-75-8, Timolol  
 29122-68-7, Atenolol 36894-69-6  
 37517-30-9, Acebutolol 38363-40-5,  
 Penbutolol 42200-33-9, Nadolol  
 47141-42-4, Levobunolol 51384-51-1,  
 Metoprolol 51781-06-7, Carteolol 52485-79-7,  
 Buprenorphine 54187-04-1, Rilmenidine 56980-93-9,  
 Celiprolol 63590-64-7, Terazosin 63659-18-7,  
 Betaxolol 66376-36-1, Alendronate 66722-44-9  
 67392-87-4, Dihydrospirorenone 71119-11-4, Bucindolol  
 72956-09-3, Carvedilol 74191-85-8, Doxazosin  
 74220-07-8, Spirorenone 75438-57-2, Moxonidine 76676-33-0, RU26752  
 76684-89-4, E 64c 81147-92-4, Esmolol 86102-31-0,  
 Tissue inhibitor of matrix metalloproteinase 87952-98-5, Mespirenone  
 91448-99-6, Cystatin C 93519-21-2 95847-70-4, Ipsapirone  
 107544-29-6, Stefin A 107724-20-9, Eplerenone  
 118457-14-0, Nebivolol 134448-10-5, CA-074  
 136553-74-7, WS 7338B 136553-81-6, BQ123 144602-02-8, IRL 1038  
 145380-08-1, RU40555 151039-33-7, PD 142893 156161-89-6, BQ-788  
 157659-79-5, SB 209670 162117-90-0, S 0139 162412-70-6, PD 156707  
 171714-84-4, LU135252 173189-01-0, IRL 3461 173937-91-2, ABT-627  
 204326-22-7, PD 164333 223756-43-2, A-216546 264276-89-3

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(sympathetic nervous system activity-reducing agents for treatment of disease- or age-related weight loss and for enhancement of exercise performance)

IT 75847-73-3, Enalapril 114798-26-4, Losartan

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(sympathetic nervous system activity-reducing agents for treatment of disease- or age-related weight loss and for enhancement of exercise performance)

IT 51-41-2, Noradrenaline 51-43-4, Epinephrine 11128-99-7, Angiotensin II 123626-67-5, Endothelin 1

RL: BOC (Biological occurrence); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence)

(sympathetic nervous system activity-reducing agents for treatment of disease- or age-related weight loss and for enhancement of exercise performance)


IT 525-66-6, Propranolol 3930-20-9,  
 Sotalol 6452-71-7, Oxprenolol  
 13523-86-9, Pindolol 22664-55-7,  
 Metipranolol 26839-75-8, Timolol  
 29122-68-7, Atenolol 36894-69-6  
 37517-30-9, Acebutolol 38363-40-5,  
 Penbutolol 42200-33-9, Nadolol  
 47141-42-4, Levobunolol 51384-51-1,  
 Metoprolol 51781-06-7, Carteolol  
 56980-93-9, Celiprolol 63659-18-7,  
 Betaxolol 66722-44-9 71119-11-4,  
 Bucindolol 72956-09-3, Carvedilol  
 81147-92-4, Esmolol 107724-20-9,  
 Eplerenone 118457-14-0, Nebivolol

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(sympathetic nervous system activity-reducing agents for treatment of disease- or age-related weight loss and for enhancement of exercise performance)


RN 525-66-6 HCAPLUS

CN 2-Propanol, 1-[(1-methylethyl)amino]-3-(1-naphthalenyloxy) - (9CI) (CA INDEX NAME)




RN 3930-20-9 HCAPLUS

CN Methanesulfonamide, N-[4-[1-hydroxy-2-[(1-methylethyl)amino]ethyl]phenyl] - (9CI) (CA INDEX NAME)




RN 6452-71-7 HCAPLUS

CN 2-Propanol, 1-[(1-methylethyl)amino]-3-[2-(2-propenyloxy)phenoxy] - (9CI) (CA INDEX NAME)




RN 13523-86-9 HCAPLUS

CN 2-Propanol, 1-(1H-indol-4-yloxy)-3-[(1-methylethyl)amino] - (9CI) (CA INDEX NAME)



RN 22664-55-7 HCAPLUS


CN Phenol, 4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]-2,3,6-trimethyl-, 1-acetate (9CI) (CA INDEX NAME)



RN 26839-75-8 HCAPLUS


CN 2-Propanol, 1-[(1,1-dimethylethyl)amino]-3-[[4-(4-morpholinyl)-1,2,5-thiadiazol-3-yl]oxy]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 29122-68-7 HCAPLUS

CN Benzeneacetamide, 4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]- (9CI) (CA INDEX NAME)




RN 36894-69-6 HCAPLUS

CN Benzamide, 2-hydroxy-5-[1-hydroxy-2-[(1-methyl-3-phenylpropyl)amino]ethyl]- (9CI) (CA INDEX NAME)



RN 37517-30-9 HCAPLUS


CN Butanamide, N-[3-acetyl-4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 38363-40-5 HCAPLUS


CN 2-Propanol, 1-(2-cyclopentylphenoxy)-3-[(1,1-dimethylethyl)amino]-, (2S)-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 42200-33-9 HCAPLUS


CN 2,3-Naphthalenediol, 5-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-  
1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)




RN 47141-42-4 HCAPLUS

CN 1(2H)-Naphthalenone, 5-[(2S)-3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-3,4-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 51384-51-1 HCAPLUS

CN 2-Propanol, 1-[4-(2-methoxyethyl)phenoxy]-3-[(1-methylethyl)amino]- (9CI)  
(CA INDEX NAME)


RN 51781-06-7 HCAPLUS

CN 2(1H)-Quinololinone, 5-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-3,4-dihydro- (9CI) (CA INDEX NAME)




RN 56980-93-9 HCAPLUS

CN Urea, N'-[3-acetyl-4-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]phenyl]-N,N-diethyl- (9CI) (CA INDEX NAME)




RN 63659-18-7 HCAPLUS

CN 2-Propanol, 1-[4-[2-(cyclopropylmethoxy)ethyl]phenoxy]-3-[(1-methylethyl)amino]- (9CI) (CA INDEX NAME)




RN 66722-44-9 HCAPLUS

CN 2-Propanol, 1-[4-[[2-(1-methylethoxy)ethoxy]methyl]phenoxy]-3-[(1-methylethyl)amino]- (9CI) (CA INDEX NAME)



RN 71119-11-4 HCAPLUS


CN Benzonitrile, 2-[2-hydroxy-3-[[2-(1H-indol-3-yl)-1,1-dimethylethyl]amino]propoxy]-(9CI) (CA INDEX NAME)




RN 72956-09-3 HCAPLUS

CN 2-Propanol, 1-(9H-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]-(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 81147-92-4 HCAPLUS


CN Benzenepropanoic acid, 4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 107724-20-9 HCAPLUS

CN Pregn-4-ene-7,21-dicarboxylic acid, 9,11-epoxy-17-hydroxy-3-oxo-,  $\gamma$ -lactone, methyl ester, (7 $\alpha$ ,11 $\alpha$ ,17 $\alpha$ )- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 118457-14-0 HCAPLUS

CN 2H-1-Benzopyran-2-methanol,  $\alpha,\alpha'$ -[iminobis(methylene)]bis[6-fluoro-3,4-dihydro-, ( $\alpha$ R, $\alpha'$ R,2R,2'S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



=&gt; =&gt; d 178 all hitstr tot

L78 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 2004:927079 HCAPLUS

DN 141:360723

ED Entered STN: 04 Nov 2004

TI Growth hormone receptor antagonist-COX-2 inhibitor combination with

antihypertension agents for use in treatment of patients with acromegaly

IN Fryklund, Linda; Harris, Philip

PA Pharmacia & Upjohn Company, USA

SO PCT Int. Appl., 54 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM A61K045-06

ICS A61K038-27; A61K031-585; A61P009-12

CC 1-12 (Pharmacology)

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004093913	A1	20041104	WO 2004-GB1771	20040426
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,				
	CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,				
	GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,				
	LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,				
	NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,				
	TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,				
	AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,				
	EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,				
	SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,				
	SN, TD, TG				
PRAI	GB 2003-9328	A	20030424		

CLASS

	PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
	WO 2004093913	ICM	A61K045-06
		ICS	A61K038-27; A61K031-585; A61P009-12
	WO 2004093913	ECLA	A61K031/585+M; A61K038/27+M; A61K045/06
AB	The invention provides a method for the treatment of hypertension in a patient characterized by using a growth hormone receptor antagonist in combination with an antihypertension agent.		
ST	hypertension treatment acromegaly growth hormone receptor antagonist; pegvisomant treatment hypertension acromegaly		
IT	Angiotensin receptors		
	RL: BSU (Biological study, unclassified); BIOL (Biological study) (angiotensin II, inhibitors, as anti-hypertensive agents; growth hormone receptor antagonist-COX-2 inhibitor combination with antihypertension agents for use in treatment of patients with acromegaly)		
IT	Mineralocorticoid receptors		
	RL: BSU (Biological study, unclassified); BIOL (Biological study) (antagonist, as anti-hypertensive agents; growth hormone receptor antagonist-COX-2 inhibitor combination with antihypertension agents for use in treatment of patients with acromegaly)		
IT	Diuretics		
	Vasodilators (as anti-hypertensive agents; growth hormone receptor antagonist-COX-2 inhibitor combination with antihypertension agents for use in treatment of patients with acromegaly)		
IT	Ion channel blockers		
	(calcium, as anti-hypertensive agents; growth hormone receptor antagonist-COX-2 inhibitor combination with antihypertension agents for use in treatment of patients with acromegaly)		
IT	Acromegaly		
	Antihypertensives		
	Drug delivery systems		
	Human		
	Hypertension		
	(growth hormone receptor antagonist-COX-2 inhibitor combination with		



- antihypertension agents for use in treatment of patients with acromegaly)
- IT Growth hormone receptors  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(growth hormone receptor antagonist-COX-2 inhibitor combination with antihypertension agents for use in treatment of patients with acromegaly)
- IT Polyoxyalkylenes, biological studies  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(human growth hormone conjugates; growth hormone receptor antagonist-COX-2 inhibitor combination with antihypertension agents for use in treatment of patients with acromegaly)
- IT Drug delivery systems  
(prodrugs; growth hormone receptor antagonist-COX-2 inhibitor combination with antihypertension agents for use in treatment of patients with acromegaly)
- IT **Adrenoceptor antagonists**  
( $\beta$  -, as anti-hypertensive agents; growth hormone receptor antagonist-COX-2 inhibitor combination with antihypertension agents for use in treatment of patients with acromegaly)
- IT 83150-76-9, Octreotide  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(conversion to pegvisomant; growth hormone receptor antagonist-COX-2 inhibitor combination with antihypertension agents for use in treatment of patients with acromegaly)
- IT 9002-72-6D, Somatotropin, variants and pegylated forms 25322-68-3D, Polyethylene glycol, human growth hormone conjugates 107724-20-9, **Eplerenone** 218620-50-9, Pegvisomant  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(growth hormone receptor antagonist-COX-2 inhibitor combination with antihypertension agents for use in treatment of patients with acromegaly)
- IT 9015-94-5, Renin, biological studies  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(hypertension comprising low levels of; growth hormone receptor antagonist-COX-2 inhibitor combination with antihypertension agents for use in treatment of patients with acromegaly)
- IT 9015-82-1  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(inhibitors, as anti-hypertensive agents; growth hormone receptor antagonist-COX-2 inhibitor combination with antihypertension agents for use in treatment of patients with acromegaly)
- RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
- RE
- (1) Coats, A; INTERNATIONAL JOURNAL OF CARDIOLOGY, CAPLUS 2001:495110 2001, V80(1), P1 MEDLINE
- (2) Goffin, V; CURRENT OPINION IN INVESTIGATIONAL DRUGS 2002, V3(5), P752 HCAPLUS
- (3) McMahon, E; CURRENT OPINION IN PHARMACOLOGY 2001, V1(2), P190 HCAPLUS
- (4) Zillich, A; ANNALS OF PHARMACOTHERAPY 2002, V36(10), P1567 HCAPLUS
- IT 107724-20-9, **Eplerenone**  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(growth hormone receptor antagonist-COX-2 inhibitor combination with antihypertension agents for use in treatment of patients with acromegaly)
- RN 107724-20-9 HCAPLUS
- CN Pregn-4-ene-7,21-dicarboxylic acid, 9,11-epoxy-17-hydroxy-3-oxo-,  $\gamma$ -lactone, methyl ester, (7 $\alpha$ ,11 $\alpha$ ,17 $\alpha$ )- (9CI) (CA



anti-obesity agent is described for treatment of circulatory disorders, including cardiovascular disorders such as hypertension, congestive heart failure, cirrhosis and ascites. Preferred anti-obesity agents are those compds. having high potency and bioavailability. Preferred aldosterone receptor antagonists are 20-spiroxane steroidal compds. characterized by the presence of a 9 $\alpha$ ,11 $\alpha$ -substituted epoxy moiety.

- ST aldosterone receptor antagonist antiobesity agent cardiovascular disorders treatment
- IT 5-HT antagonists  
(5-HT<sub>2C</sub>; combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)
- IT Transport proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(ASBT (apical sodium-dependent bile acid transporter), inhibitors; combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)
- IT Cholecystokinin receptors  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(CCKA, agonists; combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)
- IT Neuropeptide Y receptors  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(Y<sub>1</sub>, antagonists; combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)
- IT Neuropeptide Y receptors  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(Y<sub>5</sub>, antagonists; combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)
- IT Cytokines  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(adiponectin; combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)
- IT Angiotensin receptor antagonists  
(angiotensin I; combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)
- IT Angiotensin receptor antagonists  
(angiotensin II; combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)
- IT Endothelin receptors  
Glucocorticoid receptors  
Glucocorticoids  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(antagonists; combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)
- IT Antiarteriosclerotics  
(antiatherosclerotics; combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)
- IT Heart, disease  
(arrhythmia; combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)
- IT Liver, disease

- (ascites and congestion; combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)
- IT Ion channel blockers  
(calcium; combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)
- IT Brain, disease  
(cerebrovascular; combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)
- IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(cholesterol ester-exchanging, inhibitors; combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)
- IT 5-HT reuptake inhibitors  
Anti-ischemic agents  
Antiarrhythmics  
Antidiabetic agents  
Antihypertensives  
Antiobesity agents  
Antioxidants  
Appetite depressants  
Atherosclerosis  
Blood vessel, disease  
Cardiovascular agents  
Cardiovascular system, disease  
Combination chemotherapy  
Diuretics  
Drug interactions  
Edema  
Human  
Hyperglycemia  
Hypertension  
Ischemia  
Kidney, disease  
Liver, disease  
Obesity  
Thrombosis  
Vasodilators  
(combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)
- IT Cannabinoid receptors  
Mineralocorticoid receptors  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)
- IT Ciliary neurotrophic factor  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)
- IT Spleen, disease  
(congestion; combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)
- IT Artery, disease  
(coronary; combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and

- combination with third agent)
- IT Kidney, disease  
(diabetic nephropathy; combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)
- IT Circulation  
(disorder; combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)
- IT Baroreceptors  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(dysfunction; combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)
- IT Blood vessel, disease  
(endothelium; combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)
- IT Kidney, disease  
(failure, chronic; combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)
- IT Heart, disease  
(failure; combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)
- IT Blood vessel, disease  
Heart, disease  
Kidney, disease  
(fibrosis; combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)
- IT Kidney, disease  
(glomerulosclerosis; combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)
- IT Receptors  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(glp-1, agonists; combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)
- IT Heart, disease  
(hypertrophic cardiomyopathy; combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)
- IT Heart, disease  
(infarction; combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)
- IT Gastric emptying  
(inhibitors; combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)
- IT Blood vessel, disease  
(injury; combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)
- IT Diabetes mellitus  
(insulin-dependent; combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)
- IT Kidney, disease  
(ischemia; combination of an aldosterone receptor antagonist and an

anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)

IT Heart, disease  
(left ventricle, hypertrophy; combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)

IT Ascites  
(liver; combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)

IT Pituitary hormone receptors  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(melanocortin receptor 4, agonists; combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)

IT Disease, animal  
(metabolic syndrome X; combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)

IT Albumins, biological studies  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(microalbuminuria; combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)

IT Kidney, disease  
(nephrosclerosis, malignant; combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)

IT Nerve, disease  
(neuropathy; combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)

IT Diabetes mellitus  
(non-insulin-dependent; combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)

IT Nervous system agents  
(noradrenaline reuptake inhibitors; combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)

IT Artery, disease  
(proliferative arteriopathy; combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(proteinuria; combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)

IT Eye, disease  
(retinopathy; combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)

IT Appetite  
(satiety, increase of; combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)

IT Bile acids  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(sequestrants; combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)

IT Brain, disease

(stroke; combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)

## IT Death

(sudden death, cardiac; combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)

## IT Kidney, disease

(thrombotic lesions; combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)

## IT Endothelium

(vascular, disease; combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)

## IT Adrenoceptor antagonists

( $\alpha$ -; combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)

## IT Integrins

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
( $\alpha$ IIb $\beta$ 3, antagonists; combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)

## IT Thyroid hormone receptors

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
( $\beta$ , agonists; combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)

## IT Adrenoceptor antagonists

( $\beta$  -; combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)

## IT 57-88-5, Cholesterol, biological studies

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(absorption inhibitors; combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)

## IT 62571-86-2, Captopril 75847-73-3, Enalapril 76547-98-3, Lisinopril 82834-16-0, Perindopril 85441-61-8, Quinapril 86541-75-5, Benazepril 87333-19-5, Ramipril 87679-37-6, Trandolapril 88768-40-5, Cilazapril 98048-97-6, Fosinopril

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(angiotensin converting enzyme inhibitor; combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)

## IT 9041-90-1, Angiotensin I 82785-45-3, Neuropeptide Y

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(antagonists; combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)

## IT 657-24-9, Metformin

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(antidiabetic; combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)


## IT 138238-81-0, Endothelin converting enzyme 1 766549-20-6, Endothelin converting enzyme 2

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with

- third agent)
- IT 52-01-7, Spironolactone 59-67-6, Niacin, biological studies 1406-18-4, Vitamin E 9002-72-6D, Somatotropin, fragments 23288-49-5, Probucol 89750-14-1, GLP-1 95716-76-0 95716-78-2 95716-94-2 95716-98-6 95716-99-7 95717-01-4 95717-02-5 96829-58-2, Orlistat 106650-56-0, Sibutramine 107724-20-9 141732-76-5, Exendin 4 149820-74-6, Xenilofiban 163250-90-6, Orbofiban 168273-06-1, SR-141716 395665-58-4 416839-88-8, Axokine 430433-43-5, CP 644673 782479-58-7 782479-59-8 782482-03-5, HMR 1426 782482-04-6, GI 181771 782482-05-7, BVT 933  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)
- IT 60-27-5, Creatinine  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(decreased clearance; combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)
- IT 943-45-3, Fibrin acid  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(derivs.; combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)
- IT 9001-62-1, Lipase  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(gastrointestinal, inhibitors; combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)
- IT 9004-10-8, Insulin, biological studies  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(hyperinsulinemia and resistance; combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)
- IT 9028-35-7  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(inhibitors, statins; combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)
- IT 9015-82-1 9015-94-5, Renin, biological studies 9023-93-2, Acetyl CoA carboxylase 9041-46-7, 11 $\beta$ -Hydroxysteroid dehydrogenase 1 9045-77-6, Fatty acid synthase 54249-88-6, DPP-IV 300865-11-6, PTP-1B 329900-75-6, Cyclooxygenase-2  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(inhibitors; combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)
- IT 107724-20-9  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)
- RN 107724-20-9 HCAPLUS
- CN Pregn-4-ene-7,21-dicarboxylic acid, 9,11-epoxy-17-hydroxy-3-oxo-,  $\gamma$ -lactone, methyl ester, (7 $\alpha$ ,11 $\alpha$ ,17 $\alpha$ )-(9CI) (CA INDEX NAME)

Absolute stereochemistry.





L78 ANSWER 3 OF 5 HCAPLUS COPYRIGHT 2005 ACS on STN  
 AN 2004:802700 HCAPLUS  
 DN 141:289096  
 ED Entered STN: 01 Oct 2004  
 TI Combination of an aldosterone receptor antagonist and a neutral  
 endopeptidase inhibitor  
 IN McMahon, Ellen G.; Rudolph, Amy E.  
 PA Pharmacia Corporation, USA  
 SO PCT Int. Appl., 172 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 IC ICM A61K  
 CC 1-12 (Pharmacology)  
 Section cross-reference(s): 2, 63

## FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004082636	A2	20040930	WO 2004-US8220	20040318
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004192584	A1	20040930	US 2004-803317	20040318
PRAI US 2003-455738P	P	20030318		

## CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2004082636	ICM	A61K
WO 2004082636	ECLA	A61K031/56+M; A61K045/06
US 2004192584	ECLA	A61K031/56+M; A61K045/06

AB Combinations, compns., and therapeutic methods of treatment and/or prophylaxis of a hypertension, cardiovascular disease, renal dysfunction, edema, cerebrovascular disease, or insulinopathy pathol. condition in a subject are described. Methods for prophylaxis or treatment of a pathol. condition comprise the administration of (i) a combination of one or more aldosterone receptor antagonists and one or more neutral endopeptidase

(NEP) inhibitors, (iii) a combination of one or more aldosterone receptor antagonists, one or more NEP inhibitors, and one or more ACE inhibitors, (iii) or a combination of one or more aldosterone receptor antagonists and one or more vasopeptidase inhibitors selected from a specific group of compds. described herein. The aldosterone receptor antagonist is administered in a daily dose ranging from about 0.1 to 2000 mg, the NEP inhibitor is administered in a daily dose ranging from about 0.1 to 1000 mg, and the ACE inhibitor is administered in a daily dose ranging from about 0.1 to 1000 mg. A kit is also described containing a first amount of an aldosterone receptor antagonist and a second amount of an inhibitor selected from the group consisting of (1) a vasopeptidase inhibitor, wherein the first amount of the aldosterone receptor antagonist exhibits a release profile, determined using a suitable release profile test, in which more than about 20% by weight of the aldosterone receptor antagonist is released within about 4 h after initiation of the test, (2) a vasopeptidase inhibitor other than omapatrilat, and (3) a neutral endopeptidase inhibitor. Clin. therapy protocols for combination therapy are outlined.

- ST aldosterone receptor antagonist neutral endopeptidase vasopeptidase inhibitor therapy
- IT Endothelin receptors
  - Mineralocorticoid receptors
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (antagonists; combination therapy with aldosterone receptor antagonist and neutral endopeptidase inhibitor)
- IT Transport proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (bile acid-sodium-cotransporter, inhibitors; combination therapy with aldosterone receptor antagonist and neutral endopeptidase inhibitor)
- IT Sequestering agents
  - (bile; combination therapy with aldosterone receptor antagonist and neutral endopeptidase inhibitor)
- IT Ion channel blockers
  - (calcium; combination therapy with aldosterone receptor antagonist and neutral endopeptidase inhibitor)
- IT Brain, disease
  - (cerebrovascular; combination therapy with aldosterone receptor antagonist and neutral endopeptidase inhibitor)
- IT Transport proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (cholesteryl ester-transporting, inhibitors; combination therapy with aldosterone receptor antagonist and neutral endopeptidase inhibitor)
- IT Antioxidants
  - Blood vessel, disease
  - Cardiovascular system, disease
  - Combination chemotherapy
  - Diuretics
  - Edema
  - Human
  - Hypertension
  - Kidney, disease
  - Liver, disease
  - Vasodilators
    - (combination therapy with aldosterone receptor antagonist and neutral endopeptidase inhibitor)
- IT Baroreceptors
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (dysfunction; combination therapy with aldosterone receptor antagonist and neutral endopeptidase inhibitor)
- IT Blood vessel, disease
  - (endothelium, dysfunction; combination therapy with aldosterone receptor antagonist and neutral endopeptidase inhibitor)
- IT Drug delivery systems
  - (kits; combination therapy with aldosterone receptor antagonist and

neutral endopeptidase inhibitor)

IT Nerve, disease  
(neuropathy; combination therapy with aldosterone receptor antagonist and neutral endopeptidase inhibitor)

IT Eye, disease  
(retinopathy; combination therapy with aldosterone receptor antagonist and neutral endopeptidase inhibitor)

IT Adrenoceptor antagonists  
( $\alpha$ -; combination therapy with aldosterone receptor antagonist and neutral endopeptidase inhibitor)

IT Integrins  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
( $\alpha$ IIb $\beta$ 3, antagonists; combination therapy with aldosterone receptor antagonist and neutral endopeptidase inhibitor)

IT **Adrenoceptor antagonists**  
( $\beta$  -; combination therapy with aldosterone receptor antagonist and neutral endopeptidase inhibitor)

IT 57-88-5, Cholesterol, biological studies  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(absorption inhibitors; combination therapy with aldosterone receptor antagonist and neutral endopeptidase inhibitor)

IT 9041-90-1, Angiotensin I 11128-99-7, Angiotensin II  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(antagonists; combination therapy with aldosterone receptor antagonist and neutral endopeptidase inhibitor)

IT 59-67-6, Niacin, biological studies 1406-18-4, Vitamin E 23288-49-5, Probuco1 36357-77-4, Phosphoramidon 62571-86-2, Captopril 75847-73-3, Enalapril 76547-98-3, Lisinopril 81110-73-8, Racecadotril 82586-55-8, Quinopril 82834-16-0, Perindopril 86541-75-5, Benazepril 87333-19-5, Ramipril 87679-37-6, Trandolapril 88768-40-5, Cilazapril 95716-76-0 95716-78-2 95716-94-2 95716-95-3 95716-96-4 95716-97-5 98048-97-6, Fosinopril 107724-20-9, **Eplerenone** 112573-73-6, Ecadotril 123122-54-3, Candoxatrilat 123122-55-4, Candoxatril 129981-36-8, Sampatrilat 135038-57-2, Fasidotril 138238-81-0, Endothelin-converting enzyme 142695-08-7, M100240 160135-92-2, Gemopatrilat 167305-00-2, Omapatrilat 763102-14-3 763102-15-4 763102-16-5 763102-17-6 763102-18-7 763139-71-5, GW 660511  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(combination therapy with aldosterone receptor antagonist and neutral endopeptidase inhibitor)

IT 9028-35-7, Hydroxymethylglutaryl-CoA reductase  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(inhibitors, statins; combination therapy with aldosterone receptor antagonist and neutral endopeptidase inhibitor)

IT 9015-82-1, Vasoepitidase 9015-94-5, Renin, biological studies 82707-54-8, Neutral endopeptidase 329900-75-6, Cyclooxygenase-2  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(inhibitors; combination therapy with aldosterone receptor antagonist and neutral endopeptidase inhibitor)


IT 9004-10-8, Insulin, biological studies  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(insulinopathy; combination therapy with aldosterone receptor antagonist and neutral endopeptidase inhibitor)

IT 107724-20-9, **Eplerenone**  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(combination therapy with aldosterone receptor antagonist and neutral endopeptidase inhibitor)

RN 107724-20-9 HCAPLUS

CN Pregn-4-ene-7,21-dicarboxylic acid, 9,11-epoxy-17-hydroxy-3-oxo-,  $\gamma$ -lactone, methyl ester, (7 $\alpha$ ,11 $\alpha$ ,17 $\alpha$ )- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L78 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2005 ACS on STN  
 AN 2004:780354 HCAPLUS  
 DN 141:289052  
 ED Entered STN: 24 Sep 2004  
 TI Combination of an aldosterone receptor antagonist and an endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for the treatment of cardiovascular and other conditions  
 IN McMahon, Ellen G.; Rudolph, Amy E.  
 PA **Pharmacia Corporation, USA**  
 SO U.S. Pat. Appl. Publ., 42 pp.  
 CODEN: USXXCO  
 DT Patent  
 LA English  
 IC ICM A61K031-56  
 NCL 514171000  
 CC 1-8 (Pharmacology)  
 Section cross-reference(s): 63

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004186083	A1	20040923	US 2004-803818	20040318
	WO 2004082637	A2	20040930	WO 2004-US8250	20040318
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRAI US 2003-455580P P 20030318

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 2004186083	ICM	A61K031-56
	NCL	514171000
US 2004186083	ECLA	A61K031/56+M; A61K045/06
WO 2004082637	ECLA	A61K031/56+M; A61K045/06

AB The invention describes combinations, compns., and therapeutic methods of treatment and/or prophylaxis of hypertension, cardiovascular disease,

renal dysfunction, edema, cerebrovascular disease, or insulinopathy pathol. conditions in a subject, wherein the methods comprise the administration of a combination of one or more aldosterone receptor antagonists and one or more endothelin receptor antagonist and/or ECE inhibitors.

- ST endothelin aldosterone receptor antagonist combination therapeutic; aldosterone receptor endothelin converting enzyme inhibitor combination therapeutic; cardiovascular cerebrovascular renal therapeutic endothelin aldosterone receptor antagonist combination; edema insulinopathy endothelin aldosterone receptor antagonist combination
- IT Angiotensin receptors
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (angiotensin I antagonists; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)
- IT Angiotensin receptor antagonists
  - (angiotensin II; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)
- IT Antiarteriosclerotics
  - (antiatherosclerotics; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)
- IT Bile acids
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (apical sodium bile acid transport inhibitors; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)
- IT Heart, disease
  - (arrhythmia; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)
- IT Liver
  - (ascites; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)
- IT Sequestering agents
  - (bile acid; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)
- IT Ion channel blockers
  - (calcium; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)
- IT Heart, disease
  - (cardiac lesions; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)
- IT Brain, disease
  - (cerebrovascular; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (cholesterol ester-exchanging, inhibitors; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)
- IT Anti-ischemic agents
  - Antiarrhythmics
  - Anticoagulants

Antidiabetic agents  
 Antihypertensives  
 Antioxidants  
 Atherosclerosis  
 Blood vessel, disease  
 Cardiovascular agents  
 Cardiovascular system, disease  
 Cirrhosis  
 Combination chemotherapy  
 Cytotoxic agents  
 Diuretics  
 Drug delivery systems  
 Edema  
 Human  
 Hypertension  
 Ischemia  
 Kidney, disease  
 Liver, disease  
 Nervous system agents  
 Thrombosis  
 Vasodilators

(combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)

IT Endothelin receptors

Mineralocorticoid receptors

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)

IT Lung, disease

Respiratory tract, disease

(congestion; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)

IT Artery

(coronary, fibrinoid necrosis; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)

IT Blood vessel

(damage; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)

IT Heart, disease

(decreased ejection fraction; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)

IT Blood vessel, disease

(decreased vascular compliance; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)

IT Kidney, disease

(diabetic nephropathy; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)

IT Blood pressure

(diastolic, diastolic dysfunction; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)

- IT Baroreceptors  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(dysfunction; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)
- IT Endothelium  
(endothelial dysfunction and thickening; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)
- IT Steroids, biological studies  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(epoxysteroids; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)
- IT Kidney, disease  
(failure, chronic; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)
- IT Heart, disease  
(failure; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)
- IT Heart, disease  
(fibrosis; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)
- IT Capillary vessel  
(focal thrombosis of glomerular capillaries; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)
- IT Necrosis  
(global fibrinoid; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)
- IT Kidney, disease  
(glomerulosclerosis; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)
- IT Kidney  
(glomerulus, glomerular filtration; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)
- IT Liver, disease  
(hepatic congestion; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)
- IT Heart, disease  
(hypertrophic cardiomyopathy; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)
- IT Artery, disease  
(impaired arterial compliance; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)
- IT Heart, disease  
(infarction; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme

- inhibitor for treatment of cardiovascular and other conditions)
- IT Diabetes mellitus  
(insulin-dependent; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)
- IT Disease, animal  
(insulinopathy; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)
- IT Kidney, disease  
(ischemia; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)
- IT Heart, disease  
(left ventricle, hypertrophy; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)
- IT Ascites  
(liver; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)
- IT Kidney  
(mesangium, reticulated mesangial matrix expansion; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)
- IT Disease, animal  
(metabolic syndrome X; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)
- IT Albumins, biological studies  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(microalbuminuria; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)
- IT Heart, disease  
(myocardial necrotic lesions; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)
- IT Kidney, disease  
(nephrosclerosis, malignant; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)
- IT Nerve, disease  
(neuropathy; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)
- IT Diabetes mellitus  
(non-insulin-dependent; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)
- IT Animal tissue  
(peripheral tissue edema; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)
- IT Disease, animal  
(pre-diabetic; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)



- IT Drug delivery systems  
(prodrugs; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)
- IT Artery, disease  
(proliferative arteriopathy; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)
- IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(proteinuria; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)
- IT Kidney, disease  
(reduced blood flow; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)
- IT Artery  
(renal, renal arteriopathy; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)
- IT Eye, disease  
(retinopathy; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)
- IT Spleen  
(splenic congestion; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)
- IT Brain, disease  
(stroke; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)
- IT Heart, disease  
(sudden cardiac death; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)
- IT Blood pressure  
(systolic, systolic dysfunction; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)
- IT Liver  
(toxicity, ascites; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)
- IT Drug delivery systems  
(unit doses; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)
- IT Blood vessel, disease  
(vascular fibrosis; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)
- IT Blood vessel, disease  
(vascular wall hypertrophy; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)
- IT Adrenoceptor antagonists  
( $\alpha$ -; combination of aldosterone receptor antagonist and

endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)

IT Integrins

RL: BSU (Biological study, unclassified); BIOL (Biological study) ( $\alpha$ IIB $\beta$ 3, antagonists; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)

IT Adrenoceptor antagonists

( $\beta$  -, combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)

IT 174767-80-7, Sch 54470

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (Sch 54470; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)

IT 245660-81-5, TMC 66

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (TMC 66; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)

IT 57-88-5, Cholesterol, biological studies

RL: BSU (Biological study, unclassified); BIOL (Biological study) (cholesterol absorption inhibitors; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)

IT 52-01-7, Spironolactone. 59-67-6, Niacin, biological studies

943-45-3D, Fibrin acid, derivs. 1406-18-4, Vitamin E 23288-49-5, Probucol 36357-77-4, Phosphoramidon 107724-20-9, Eplerenone 147536-97-8, Bosentan 154116-31-1, CGS 26303 162990-71-8, FR901533 167256-08-8, Enrasentan 169319-62-4, CGS-30440 171714-84-4, Darusentan 173937-91-2, Atrasentan 177036-94-1, Ambrisentan 180384-57-0, Tezosentan 182821-27-8, SLV-306 184036-34-8, Sitaxsentan 186366-61-0, CGS-26670 194542-56-8, SM-19712 208765-45-1, CGS 31447 395665-48-2 395665-50-6 395665-56-2 395665-58-4 395665-60-8 395665-62-0 395665-64-2 395665-66-4 395665-68-6 396068-70-5 761406-93-3 762262-08-8, KC 12615 762262-10-2, KC 90095-1AC

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)

IT 60-27-5, Creatinine

RL: BSU (Biological study, unclassified); BIOL (Biological study) (decreased clearance; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)

IT 9028-35-7

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (inhibitors, statins; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)

IT 9015-82-1, Angiotensin converting enzyme 9015-94-5, Renin, biological studies 138238-81-0, Endothelin converting enzyme 329900-75-6, Cyclooxygenase-2

RL: BSU (Biological study, unclassified); BIOL (Biological study) (inhibitors; combination of aldosterone receptor antagonist and

endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)

IT 50-99-7, D-Glucose, biological studies 9004-10-8, Insulin, biological studies

RL: BSU (Biological study, unclassified); BIOL (Biological study) (resistance; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)


IT 107724-20-9, **Eplerenone 395665-48-2**

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)

RN 107724-20-9 HCAPLUS

CN Pregn-4-ene-7,21-dicarboxylic acid, 9,11-epoxy-17-hydroxy-3-oxo-,  $\gamma$ -lactone, methyl ester, (7 $\alpha$ ,11 $\alpha$ ,17 $\alpha$ )- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 395665-48-2 HCAPLUS

CN Pregn-4-ene-7,21-dicarboxylic acid, 9,11-epoxy-17-hydroxy-3-oxo-,  $\gamma$ -lactone, methyl ester, (7 $\alpha$ ,11 $\alpha$ )- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L78 ANSWER 5 OF 5 HCAPLUS COPYRIGHT 2005 ACS on STN  
 AN 2003:610248 HCAPLUS  
 DN 139:169328  
 ED Entered STN: 08 Aug 2003  
 TI Aldosterone receptor antagonist and alpha-adrenergic modulating agent  
 combination therapy for prevention or treatment of pathogenic conditions  
 IN McMahon, Ellen G.; Rudolph, Amy E.  
 PA Pharmacia Corporation, USA  
 SO PCT Int. Appl., 75 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 IC ICM A61K031-00  
 CC 63-6 (Pharmaceuticals)  
 Section cross-reference(s): 2

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003063846	A2	20030807	WO 2003-US2723	20030130
	WO 2003063846	A3	20031204		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	US 2003199483	A1	20031023	US 2003-354653	20030130
	EP 1469862	A2	20041027	EP 2003-710786	20030130
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
	BR 2003007336	A	20041207	BR 2003-7336	20030130
PRAI	US 2002-353801P	P	20020130		
	WO 2003-US2723	W	20030130		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2003063846	ICM	A61K031-00

AB A combination therapy comprising a therapeutically-effective amount of an aldosterone receptor antagonist and a amount of an  $\alpha$ -adrenergic modulating agent is described for treatment of circulatory disorders, including cardiovascular disorders such as hypertension, congestive heart failure, cirrhosis and ascites. Preferred  $\alpha$ -adrenergic modulating agents are those compds. having high potency and bioavailability. Preferred aldosterone receptor antagonists are 20-spiroxane steroidal compds. characterized by the presence of a 9,11-substituted epoxy moiety. A preferred combination therapy includes an  $\alpha$ 1-adrenergic antagonist or an  $\alpha$ 2-adrenergic agonist and the aldosterone receptor antagonist **epoxymexrenone**. Thus, a solution contains 0.5% dapiprazole and **eplerenone**.

ST aldosterone receptor antagonist adrenergic pathogenic

IT Antihypertensives

Ascites

Cardiovascular system, disease

Cirrhosis

Dissolution

Human

Hypertension

Inotropics

(aldosterone receptor antagonist and  $\alpha$ -adrenergic modulators)

- combination therapy for prevention or treatment of pathogenic conditions)
- IT Mineralocorticoid receptors  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(aldosterone receptor antagonist and  $\alpha$ -adrenergic modulators combination therapy for prevention or treatment of pathogenic conditions)
- IT Drug delivery systems  
(capsules; aldosterone receptor antagonist and  $\alpha$ -adrenergic modulators combination therapy for prevention or treatment of pathogenic conditions)
- IT Steroids, biological studies  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(epoxy-containing; aldosterone receptor antagonist and  $\alpha$ -adrenergic modulators combination therapy for prevention or treatment of pathogenic conditions)
- IT Heart, disease  
Heart, disease  
(failure; aldosterone receptor antagonist and  $\alpha$ -adrenergic modulators combination therapy for prevention or treatment of pathogenic conditions)
- IT Drug delivery systems  
(injections; aldosterone receptor antagonist and  $\alpha$ -adrenergic modulators combination therapy for prevention or treatment of pathogenic conditions)
- IT Drug delivery systems  
(solns.; aldosterone receptor antagonist and  $\alpha$ -adrenergic modulators combination therapy for prevention or treatment of pathogenic conditions)
- IT Drug delivery systems  
(tablets; aldosterone receptor antagonist and  $\alpha$ -adrenergic modulators combination therapy for prevention or treatment of pathogenic conditions)
- IT Adrenoceptor antagonists  
( $\alpha$ -; aldosterone receptor antagonist and  $\alpha$ -adrenergic modulators combination therapy for prevention or treatment of pathogenic conditions)
- IT Adrenoceptor antagonists  
( $\alpha_1$ -; aldosterone receptor antagonist and  $\alpha$ -adrenergic modulators combination therapy for prevention or treatment of pathogenic conditions)
- IT Adrenoceptor antagonists  
( $\alpha_2$ -; aldosterone receptor antagonist and  $\alpha$ -adrenergic modulators combination therapy for prevention or treatment of pathogenic conditions)
- IT 50-60-2, Phentolamine 52-01-7, Spironolactone 59-96-1, Phenoxybenzamine 59-98-3, Tolazoline 146-48-5, Yohimbine 151-21-3, SDS, biological studies 4205-90-7, Clonidine 5051-62-7, Guanabenz 5053-06-5, Fenspiride 19216-56-9, Prazosin 26844-12-2, Indoramin 27848-84-6, Nicergoline 29110-47-2, Guanfacine 34661-75-1, Urapidil 35795-16-5, Trimazosin **36894-69-6**, **Labetalol** 54187-04-1, Rilmenidine 57149-07-2, Naftopidil 63590-64-7, Terazosin 66711-21-5, Apraclonidine 68377-92-4, Arotinolol 72822-12-9, Dapiprazole 74050-98-9, Ketanserin 74191-85-8, Doxazosin 75438-57-2, Moxonidine 77606-94-1, SUN 9221 80755-51-7, Bunazosin 81403-80-7, Alfuzosin 85320-68-9, Amosulalol 95716-76-0 95716-78-2 95716-94-2 95716-95-3 95716-96-4 95716-97-5 95716-98-6 95716-99-7 95717-02-5 103377-41-9, Monatepil 106133-20-4, Tamsulosin **107724-20-9**, **Eplerenone** 149882-25-7 150284-32-5, S 2150
- RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(aldosterone receptor antagonist and  $\alpha$ -adrenergic modulators combination therapy for prevention or treatment of pathogenic

conditions)


IT 36894-69-6, Labetalol 107724-20-9,

Eplerenone

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (aldosterone receptor antagonist and  $\alpha$ -adrenergic modulators  
 combination therapy for prevention or treatment of pathogenic  
 conditions)

RN 36894-69-6 HCAPLUS


CN Benzamide, 2-hydroxy-5-[1-hydroxy-2-[(1-methyl-3-phenylpropyl)amino]ethyl]-  
 (9CI) (CA INDEX NAME)



RN 107724-20-9 HCAPLUS

CN Pregn-4-ene-7,21-dicarboxylic acid, 9,11-epoxy-17-hydroxy-3-oxo-,  
 $\gamma$ -lactone, methyl ester, (7 $\alpha$ ,11 $\alpha$ ,17 $\alpha$ )- (9CI) (CA  
 INDEX NAME)

Absolute stereochemistry.



=&gt;